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Background and main aims  
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. The 
hallmark is a chronic inflammation affecting the joints and in some cases in the uvea of the 
eyes.2 Prognostication of the disease course is challenging due to the heterogeneity of JIA. It 
is still of great importance since early aggressive treatment in children with poor prognosis 
may modify and improve the disease course.3-5 In paper I, we aimed to develop clinically 
applicable tools for prediction of unfavorable disease outcomes to guide early treatment 
decisions in JIA. Our second objective was to validate the prediction models in an 
independent cohort to verify the general predictive ability. In collaboration with the Canadian 
ReACCh-Out investigators, we aimed to validate their Canadian prediction model to see how 
well it predicted severe disease course among the Nordic children with JIA (paper II). We 
further hypothesized that the Nordic prediction model for non-achievement of remission off 
medication would perform well when externally validated in the independent Canadian 
ReACCh-Out cohort (paper III). The models’ predictive abilities were also tested on the 
outcome that they originally were not designed for (paper II and III). The overall goal of 
papers I-III was to obtain validated prediction models for use in clinical practice. 
 
Uveitis is the most common extra-articular manifestation in JIA. There are sparse long-term 
prospective studies on the consequences of having JIA-associated uveitis. We aimed to assess 
and describe the long-term outcomes of uveitis in a Nordic JIA-cohort. The aim of paper IV 
was further to gather clinical information relevant for the screening and treatment strategies in 
JIA-associated uveitis, and identify predictors and targets for the prediction of unfavorable 
outcomes in JIA-associated uveitis. 
 
Methods  
In the Nordic prospective, population-based, multicenter, JIA cohort, we constructed four 
multivariate logistic regression models. The primary outcome to predict was non-achievement 
of remission, and the secondary outcomes were functional disability and articular damage, 
eight years after disease onset (paper I). External validation of the Nordic prediction models 
was performed in the Canadian ReACCh-Out cohort with 513 children and a 3-year follow-
up. In parallel, the Canadian model was externally validated in the Nordic JIA cohort with 
440 children and an 8-year follow up. The models were evaluated as published and then 
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evaluated after repeated fine-tuning of the logistic regression coefficients in training cohorts 
before testing in disjoint validation cohorts. Predictive ability was assessed with the area 
under (AUC) the receiver operating characteristic (ROC) curve and C-indices, considering C-
index or AUC values >0.7 to be helpful for prediction (paper I, II and III). 
 
In the Nordic JIA cohort 18 years after the onset of JIA, a total of 434 patients were assessed. 
Data on clinical characteristics, disease activity, ocular complications, and visual outcome 
were collected and analyzed. Long-term outcome and predictors associated with uveitis 
complications were identified (paper IV). 
 
Main results 
The model for prediction of the primary outcome non-achievement of remission comprised of 
eight clinical variables: the cumulative active joint count, ESR mm/h, CRP >10 mg/l, 
morning stiffness >15 minutes, physician´s GA, presence of ANA, presence of HLA-B27 and 
ankle joint arthritis. The model performed well with AUC equal to 0.78 (IQR 0.72–0.82) in 
internal validation (paper I). The Canadian prediction model had excellent predictive ability 
for severe disease course in external validation in the Nordic JIA cohort, yielding a C-index 
0.85 (0.80–0.89). The Canadian model could not predict non-achievement of remission with 
an acceptable C-index level (paper II). The Nordic model for predicting non-achievement of 
remission performed acceptable with a C-index of 0.73 (0.66-0.80), and after fine-tuning with 
a C-index of 0.76 (0.69-0.83). For prediction of severe disease course, the Nordic model 
achieved a C-index of 0.79 (0.68–0.91) in the Canadian JIA cohort (paper III). 
 
We found a high cumulative incidence of uveitis (96 of 434 (22%) patients) in the Nordic JIA 
cohort. Complications were present in 38.8% of the young adults with JIA-associated uveitis. 
Predictors associated with the development of ocular complications were short duration 
between the onset of JIA, and the diagnosis of uveitis, a diagnosis of uveitis before the onset 
of JIA, and presence of ANA (paper IV). 
 
Main conclusions 
A well-performing prediction model can help assess the risk of ongoing severe disease and 
guide early therapeutic decisions. We concluded that it is possible to develop prediction 
models with acceptable predictive ability for long-term unfavorable outcome in the 
heterogenous disease of JIA. External validation of the Nordic and Canadian models yielded a 
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good predictive ability for severe disease course confirming their applicability for this 
outcome. In all tests the C-indices for prediction of severe disease course were higher than for 
non-achievement of remission. The results imply that a prediction model's performance also 
largely depends on which outcome you aim to predict. Prediction of a severe disease course 
was more precise than prediction of non-achievement remission (paper I-III). 
 
In the Nordic JIA cohort, more than 1 in 5 children developed uveitis. Long-term follow-up of 
JIA-associated uveitis shows that a considerable proportion of patients develop sight-
threatening complications in early adulthood. Our findings emphasize the need for 
interdisciplinary care, with timely systemic immunosuppressive treatment in high-risk 
patients to minimize the risk of visual damage and reduced quality of life in young adults with 
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1 Introduction  
The work in this thesis is based on data from the Nordic JIA cohort, which consist of children 
with JIA included between 1997-2000. The children were followed prospectively until the last 
follow-up 18-years after disease onset. The Nordic Study Group of Pediatric Rheumatology 
(NoSPeR) conducted the study from each respective pediatric and ophthalmology center in 
the participating countries. Regular meetings in the NoSPeR group were held twice a year 
while planning the study and during data collection and the analysis phase.  
 
We use data from the baseline study visit, the 8-year follow-up, and the 18-year follow-up in 
this thesis. I collected data for the participants in Northern Norway at the 18-year follow-up, 
and wrote the research papers, and the thesis, while in a 50% PhD-position from September 
2015 to December 2020. I combined the research work with clinical work at the Department 
of Pediatrics at the University Hospital of North Norway and completed my pediatrics 
specialization in August 2020. 
 
In paper I, we used data from the Nordic JIA cohort to build models for predicting long-term 
unfavorable outcomes in JIA based on clinical characteristics early in the disease course. We 
tested the model’s predictive ability using internal cross-validation, i.e., applying the model in 
a subset of the Nordic JIA cohort different from the subset used to develop this model. The 
next step after internal validation was to test the model's predictive ability in another 
independent cohort. A collaboration with the Canadian ReAACh-out investigators, a research 
group that had also developed a prediction model for prediction of severe disease course, 
provided the possibility of external validation. In paper II, we externally validated the 
Canadian JIA model in the Nordic JIA cohort. In paper III, we externally validated the Nordic 
JIA prediction model in the Canadian ReAACh-out JIA cohort. 
 
Uveitis is the most common manifestation of JIA outside the joints. Uveitis is an 
inflammation of the uvea in the eye which may result in sight-threatening complications. In 
paper IV, we present the long-term outcomes for the children with JIA that developed uveitis. 
We identified demographic, clinical, and laboratory predictors for developing uveitis-related 
complications in the Nordic JIA population. 
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2 Juvenile idiopathic arthritis 
Juvenile idiopathic arthritis (JIA) encompasses arthritis of unknown origin that develops 
before age 16 years, with a duration over six weeks. JIA is not one disease but rather a group 
of chronic rheumatic diseases characterized by arthritis where infections and other reasons for 
arthritis are excluded.2, 6 Arthritis is an inflammation of the joint defined clinically by a 
swollen joint or a joint with limitation of movement, accompanied by joint pain or 
tenderness.1 Children with JIA have a diverse genetic background, pathophysiology, clinical 
presentation, disease severity, and prognosis.6 The course and outcome in JIA may vary 
considerably, with disease severity spanning from inflammation in one joint of limited 
duration to unremitting widespread disabling arthritis.1 Extra-articular manifestations such as 
serositis and inflammation of the uveal tract of the eye (uveitis) may also present.2  
 
2.1 Epidemiology  
The reported incidence of JIA is between 2-22 children per 100 000 per year. The prevalence 
also varies greatly in different parts of the world, from 15 to 150 per 100 000.7 Even higher 
prevalence has been reported from a population-based study in Australia.8 There are 
numerous reasons for the variation in reported incidence and prevalence. Changing 
classification criteria used through the years, different study designs, different follow-up 
times, genetic factors, and ethnicity may all contribute to the differences reported in 
epidemiologic studies.9  
 
There are also geographic differences in the distribution of children belonging to each JIA 
category (Table 1). For instance, oligoarthritis is the most common category in the northern 
countries, while systemic JIA is rare. In contrast, systemic JIA is more common in Asia and 
Africa, where oligoarthritis is infrequent. This suggests a genetic disposition for different 
phenotypes of JIA.9 Overall, reports on the incidence of JIA in the Nordic countries are in the 
higher ranges. In our Nordic population-based study, the incidence was 15 per 100 000 <16 
years per year.10 A retrospective study from Northern Norway found a cumulative incidence 
of 22%.11 A recent study from Sweden reported an incidence of 12.8 per 100 000 children 
<16 years per year, confirming similar incidence in the Nordic countries.12  
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2.2 Classification criteria 
In order to group the children with JIA into more homogeneous disease groups, JIA has been 
divided into seven categories based on clinical characteristics and laboratory findings, 
including; the number of joints involved, family history, presence or absence of extraarticular 
manifestations, presence or absence of rheumatoid factor (RF) and human leucocyte antigen 
B27 (HLA-B27) during the first six months after the onset of JIA.1 The partition in categories 
is used for defining homogeneous groups both in research and for establishing prognosis and 
treatment strategies in clinical practice. Further modifications of the category definitions are 
recently suggested and under validation in order to define even more similar groups of 
children with JIA.13 
 
The currently used classification criteria are the International League of Association for 
Rheumatology (ILAR) classification criteria (Table 1).1 The ILAR criteria defines JIA as 
arthritis that begins before the age of sixteen, with a duration of at least six weeks where the 













2.3 Etiology and pathogenesis  
In general, JIA is considered to be an autoimmune disease with disruption of the immune 
system mechanisms to establish and keep tolerance to self.14  Both the innate and the adaptive 
immune systems contribute to an erroneous immune response against self-antigens driving a 
chronic inflammation process.14 The etiology is largely unknown, but the disease is thought to 
arise in a genetically predisposed child after exposure to one or several environmental 
triggers. 2, 15, 16 Studies on environmental triggers in JIA, such as smoking, viruses, bacteria 
and vaccination are inconsistent in both the direction and magnitude of the effects and have 
yet to be confirmed.2, 17, 18  
 
Table 1. The different JIA categories according to the ILAR classification criteria1 
Arthritis in	one or	more	joints	with or	preceded by	fever of at	least 2	weeks’	duration that is	documented to	be	daily for	at	






Arthritis affecting 1	to	4	joints	during	the first	6	months of disease.	Two subcategories are recognized:
1.	Persistent	oligoarthritis:	Affecting not	more	than 4	joints	throughout the disease course.	
2.	Extended	oligoarthritis:	Affecting a	total	of more	than 4	joints	after the first	6	months of disease.	
Oligoarthritis
Arthritis affecting 5	or	more	joints	during	the first	6	months of disease;	a	test	for	RF	is	negative.	
Polyarthritis RF	negative	
Arthritis affecting 5	or	more	joints	during	the first	6	months of disease;	2	or	more	tests	for	RF	at	least 3	months apart
during	the first	6	months of disease are positive.	
Polyarthritis RF	positive	





Arthritis and	enthesitis,	or	arthritis or	enthesitis with at	least 2	of the following:
1.	Presence of or	a	history of sacroiliac joint	tenderness and/or	inflammatory lumbosacral pain.
2.	The	presence of HLA-B27	antigen.
3.	Onset of arthritis in	a	male	over	6	years of age.
4.	Acute (symptomatic)	anterior uveitis.
5.	History of ankylosing spondylitis,	enthesitis- related arthritis,	sacroiliitis with inflammatory bowel disease,	Reiter’s
syndrome,	or	acute anterior uveitis in	a	first-degree relative.
Enthesitis-related arthritis







































The common pathophysiological feature in the different JIA categories is the joint 
inflammation, characterized by infiltration of neutrophils, plasma cells, and activated T cells, 
macrophages, and dendritic cells.19 The Th1 CD4+ cells seem to drive the inflammation, 
causing production of cytokines. The sustaining inflammatory process results in hypertrophy 
of the synovium and new vascularization. Furthermore, it may lead to the formation of pannus 
together with damage of cartilage and/or bone tissue.20 
 
JIA mostly occurs sporadic, but the relative risk of developing JIA has been reported to be in 
the range of 15-30 among siblings.21 Studies of monozygotic twins show a concordant rate of 
20-40%. This higher risk of developing JIA, suggest that genetic factors plays a part in 
predisposing for the disease, but do not explain fully the etiology.21, 22 Interestingly, studies 
have shown that siblings with JIA often have a similar disease course and disease onset 
time.21, 23  
 
Both human leukocyte antigen (HLA), which plays a role in the antigen presentation to 
autoreactive T cells, and non-HLA susceptibility loci are found in JIA patients.15, 16, 24, 25 
There are associations between HLA polymorphisms and JIA categories, although the 
findings vary between studies. 15, 16, 24 The oligoarticular category is associated with the 
following human leucocyte antigens; HLA DRB1:11, HLA DRB1:08, HLA DPB1:02.25 An 
association is also found between the antinuclear antibody (ANA) against intracellular nuclear 
antigens, and early onset oligoarthritis.26 RF-negative polyarticular JIA is associated with 
HLA DRB1:11, HLA DRB1:08 and HLA DRB1:13.25 Oligoarthritis and RF-negative 
polyarthritis share common HLA-associations, and these categories may be more similar than 
previously thought.25 RF-positive polyarticular JIA is associated with HLA DRB1:01 and 
HLA DRB1:04. The children in the RF-positive category may also have anti-citrullinated 
protein antibodies (anti-CCP) against the modified amino-acid citrulline. Anti-CCP is 
associated with a more severe prognosis and a disease course similar to adult rheumatoid 
arthritis.25, 27, 28 Enthesitis-related arthritis is associated with HLA B27 and HLA DRB1:01.29 
 
There are also associations between JIA and non-HLA genes resulting in dysregulation of   
cytokines such as TNF-α, interleukine-6 (IL-6), interleukine-8 (IL-8), interleukine-1 (IL-1) 




There are no known autoantibodies associated with systemic JIA, but there is an association 
with HLA DRB1:11, which is considered a risk factor for systemic JIA.31 The main feature of 
the pathogenesis in systemic JIA is a highly activated innate immune system with an 
imbalance in cytokine regulation driving the inflammation.32 The pro-inflammatory cytokines 
IL-6, IL-1, and IL-18 play an essential role in the inflammatory process of systemic JIA. 
Treatment strategies with anti-IL-6-antibody and anti-IL-1-antagonist have been proven 
effective in systemic JIA, confirming the role of these interleukins in the pathogenesis of 
systemic JIA.33 
 
Genetic information may possibly be used to group JIA patients into more homogenous 
categories,1, 25 and used as predictors in prediction tools, perhaps improving prognostication. 
 
2.4 Current treatment strategies 
The primary treatment goal in JIA is clinical remission or inactive disease. If the primary 
treatment goal is not achievable the alternative option is minimal disease activity.34  
There is increasing evidence that early aggressive treatment with synthetic and biologic 
disease-modifying anti-rheumatic drugs (DMARDs) may modify the disease course and 
improves outcome in selected JIA categories. The discovery of the prompt treatment benefit 
led to the concept of starting treatment early during the "window of opportunity”3-5, 35  
 
A treat-to-target treatment strategy has emerged in JIA. The strategy was first introduced in 
adult rheumatology for rheumatoid arthritis (RA) and has shown to be superior to standard 
clinical care.36-38 The focus in treat-to-target strategy is prompt control of inflammation by 
stepping up treatment aiming for inactive disease. During this period, the disease activity is 
frequently assessed, and if progress is not made, treatment is adjusted.34, 39 Prompt initiation 
of appropriate therapy is important in order to prevent joint damage and improving the long-
term outcomes.3-5 The combination of early diagnosis, an increasingly number of available 
efficient drugs, early aggressive treatment and treat-to-target strategy pose a challenge for 
physicians who need to decide whether and how to start initial treatment, and when to step-up 
systemic treatment. 
 
The American College of Rheumatology (ACR) has published treatment guidelines in JIA.40-
43 The commonly used drugs in JIA are non-steroidal anti-inflammatory drugs (NSAIDs), 
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intraarticular and systemic glucocorticoids, synthetic and biologic DMARDs. Synthetic and 
biologic DMARDs are indicated to achieve the treatment goals in children with moderate to 
high disease activity.  
 
The most commonly used synthetic DMARD is methotrexate, a chemotherapeutic agent that 
in modest doses suppresses the immune system.44, 45 When methotrexate is not enough, or not 
tolerated, biologic DMARDs is an increasingly used treatment option. In JIA, this has become 
the cornerstone in the combined “early aggressive-treatment and treat-to-target strategy.” 
These drugs function by modulating specific immune systems pathways, such as TNF-α, IL-1, 
and IL-6 signaling or lymphocyte activation or function. Biologics agents became available 
around two decades ago. Their introduction and increased availability have improved patient 
outcomes tremendously. The proportion of children entering adulthood without joint damage 
or complications from JIA-associated uveitis has increased compared with the pre-biologic 
era.46, 47 The most commonly prescribed biologics agents are the TNF-inhibitors: etanercept, 
adalimumab, and infliximab. Other targeted biologic drugs are abatacept (a T-cell co-
stimulatory modulator), anakinra (an IL-1 receptor antagonist), canakinumab (an IL-1β 
inhibitor), and tocilizumab (an anti-IL-6 pathway inhibitor). The interleukin inhibitors are 
considered first-line biologic therapy for systemic JIA.43 A recent study estimate that 
approximately 20% of the children with JIA start biologic DMARDs within the first three 
years after diagnosis. Among these one in five later switch to a second biologic.48, 49  
However, studies reporting treatment failure before the current treat-to-target approach, may 
have a higher proportion of non-responders.  
 
Intraarticular glucocorticoid injections combined with NSAIDs may be sufficient in treating 
active arthritis in patients with e.g., oligoarthritis or as a bridging therapy while waiting for 
the full effect of DMARDs. Systemic glucocorticoid use has decreased after the introduction 
of biologic agents but may still have a place as bridging therapy, and in the treatment in 
systemic JIA.40, 50 
 
2.5 Disease outcomes  
Due the heterogeneous nature of JIA, there is no single outcome measure comprising the 
overall disease outcome. Several measures of disease activity and remission, functional 
ability, and damage are developed and validated for JIA. These are mostly based on 
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combinations of clinical findings, laboratory tests and patient-reported outcomes (PROMs). 
Among the PROMs questionnaires, there are both generic tools developed to assess general 
child and adolescent health and disease specific tools designed for JIA. 
 
 Measures of remission and disease activity 
JIA researchers and patients are generally interested in outcomes assessing disease activity, 
remission, functional ability, quality of life, joint damage, pain, extraarticular complications, 
and treatment response. In JIA, the ultimate goal of treatment and the outcome to strive for, is 
disease remission over time. Remission is defined as clinical remission on medication when 
there is an inactive disease on medication for six successive months, and clinical remission 
off medication when inactive disease for at least 12 consecutive months without 
medication.51, 52 According to the 2004 Wallace preliminary criteria,51 inactive disease is 
defined as 1) No joints with active arthritis meaning no swelling or no movement limitation 
with pain or tenderness. 2) Absence of systemic features such as serositis, splenomegaly, 
generalized lymphadenopathy, fever, or rash. 3) No active uveitis. 4) Normal erythrocyte 
sedimentation rate (ESR) or C-reactive protein (CRP). 5) Physician´s GA of disease activity 
assessed as no disease activity present.  
 
As new therapeutic alternatives emerged over the last decades, it became clear that we need 
explicit and objective criteria to describe disease status.53-56  The 2004 Wallace's preliminary 
criteria were developed by a consensus formation approach. This was a collaboration between 
The Childhood Arthritis and Rheumatology Research Alliance (CARRA), The Pediatric 
Rheumatology International Trials Organization (PRINTO), and The Pediatric Rheumatology 
Collaborative Study Group (PRCSG). The criteria were applicable for the oligoarticular, 
polyarticular, and systemic JIA categories. However, in clinical practice and research, the 
Wallace criteria are also used to evaluate disease activity for patients with ERA, psoriatic 
arthritis, and undifferentiated arthritis. The Wallace preliminary criteria were validated in 
2011.52 The revised version is known as the American College of Rheumatology (ACR) 2011 
provisional criteria. There were three main changes in the revision: 1) The definition of 
abnormal ESR and CRP. The new definition does not take elevated ESR and CRP into 
account if it is not attributable to JIA. 2) The definition of uveitis according to the SUN 
working group.57 3) Morning stiffness less than 15 minutes duration was added as a criterion 




Recent studies have shown that studies using different criteria for defining clinical inactive 
disease cannot be compared directly. Even if the different definitions use mostly the same 
variables they may capture different patients.58 Clinical inactive disease within the first year 
after onset of JIA has been reported to be between 25-45% in recent years.58, 59 Long-term 
studies report remission-off-medication rates in the range of 35-60%,60, 61 with considerable 
variation between the different JIA categories. Glerup et al. found that 33% of the patients 
with JIA were in clinical remission off medication for at least 12 months, and that 46% had 
active disease according to the ACR 2011 provisional criteria 18 years after disease onset.61 
Another long-term prospective study, carried out before the biologic era reported that 59% 
were in clinical remission and 34% had active disease at the 30-year follow-up.60 
 
For assessing JIA disease activity in everyday practice, the composite Juvenile Arthritis 
Disease Activity Scores (JADAS) is easier to use.62 JADAS is the main composite measure of 
disease activity currently used. Composite measures have been found to be more robust than 
individual variables for assessment of disease activity.62, 63  Indeed, the heterogeneity of JIA 
favors a composite assessment of disease activity. By grouping together information on 
different aspects of the disease, such as the number of active joints, patient's/parent's GA, 
physician's GA of disease activity and acute phase reactants (ESR or CRP) a score is 
obtained. Several versions of JADAS have been developed. The main difference between the 
versions is the number of active joints evaluated (10, 27 or 71 joints), and whether blood tests 
are included or not. There are different JADAS cut-off thresholds for defining inactive 
disease, minimal and severe disease activity.62, 64, 65 Both the ACR 2011 and the JADAS 
criteria include the core variables active joint count and physician global assessment. Other 
variables, such as patient-reported outcome, acute phase reactants, systemic clinical features, 
uveitis, and morning stiffness, are included in some JADAS scores. Clinical JADAS 
(cJADAS) does not include acute phase reactants but captures disease activity just as well as 
JADAS. 
 
There is evidence that the Wallace criteria and the JADAS are inconsistent with respect to 
identification of clinically inactive disease. This inconsistency may be due to some of the 
variables included, especially the patient/parent GA of well-being, which is included in 
JADAS but not in the Wallace criteria, and also the physician GA of disease activity. The 
physicians tend not to mark zero on the physician GA of disease activity, even if the child is 
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in remission. The child will then be evaluated as having an active disease. This effect is 
smaller by using JADAS with cut-off values for defining disease activity status.66 
 
 Measures of physical and psychosocial function and damage 
The Childhood Health Assessment Questionnaire (CHAQ) is a standard and validated 
disease-specific instrument for measuring functional disability in JIA. CHAQ gives a 
comprehensive evaluation of functional ability in different activities of everyday life.67 
CHAQ is completed by children of age >9 years, or otherwise by their parents. In adults >18 
years, the corresponding Health Assessment Questionnaires (HAQ) is used. The scores range 
from zero to three, where zero is no functional disability, and three worst possible.67 The 
CHAQ is a JIA-specific and frequently used patient-reported outcome measurement. 
 
The Child Health Questionnaire (CHQ) is also used to assess functional disability, but in 
contrast to CHAQ, it is a generic patient-reported measurement tool that is also used for 
children with other chronic conditions such as asthma and attention deficit disorder. In 
addition to scoring the physical function, it also assesses psychosocial functioning to achieve 
a broader evaluation of daily functioning. The CHQ-PF50 (parents form) consists of 50 items 
and 12 domains, yielding a physical summary score (PhS) and a psychological summary score 
(PsS). The scores range from 0 to 100, with a higher score indicating better function.67, 68 
 
The Juvenile Arthritis Damage Index (JADI) is a validated disease-specific tool for measuring 
articular and extraarticular permanent damage due to JIA. Physicians fill in a standardized 
form to assess accumulated damage. Articular damage (JADI-A) is scored from 0 (indicating 
no damage) to a maximum of 72, where 36 joints or joint groups are scored 0 for no damage, 
1 for partial damage, or 2 for severe damage. Extraarticular damage (JADI-E) is scored from 
0 to 17.69 
 
2.6 Prediction of disease outcome  
A prognosis is a prediction of the course of disease following its onset. Prediction of disease 
outcome in JIA is challenging due to the heterogeneous nature of the disease, even within the 
same JIA category. To enable physicians to answer parents' and children's questions regarding 
long-term prognosis, physicians have had information on prognosis available only on a group 
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level, not individually. Moreover, early prediction of disease course for the individual child 
can facilitate tailored personalized treatment. Hence, JIA researchers are increasingly 
interested in methods for determining whether a child will respond well to therapy, grow up 
with an active or inactive disease and achieve remission or not.3, 70-73 Several studies have 
presented predictors in terms of clinical features associated with an unfavorable outcome at 
the group level, but few studies have demonstrated individual predictors.74-76 More recent 
studies have aimed to identify predictors that can be used to predict outcomes for 
individuals.77-81 
 
2.7 Clinical predictors  
To guide early treatment decisions, predictions of disease outcomes have to make optimal use 
of information that is collected early in the disease. Variables suitable for prediction of 
disease outcomes may be patient and disease characteristics, imaging results, laboratory tests 
and other relevant variables. Identifying variables that have an association with the outcome 
is, however, only the first step towards a model that can guide treatment. The second step is to 
understand how the combination of predictors as a whole, can determine the most likely 
disease course. This second step is of particular importance in JIA, since there is increasing 
evidence that early aggressive treatment modifies disease course.4, 5  
 
In 2005 Adib et al.71, 82 reviewed outcomes and predictors used at the time. They found that 
patients with an oligoarticular JIA had the best prognosis. The worst prognosis was seen in 
systemic and polyarticular JIA. Female gender, symmetric joint involvement, elevated 
inflammatory markers, and RF positivity were also predictors of an unfavorable outcome. 
However, the reviewed studies were frequently inconsistent with large variability in the data. 
The authors also pointed out the large variability of outcomes used and called for unified 
remission criteria.  
 
A more recent systematic review article by Van Dijkhuizen et al.72 evaluated early 
characteristics predicting validated outcomes of disease activity, joint damage, functional 
ability, and quality of life. Most of the reviewed studies were retrospective, assessing mainly 
clinical and laboratory variables. The polyarticular and systemic categories were associated 
with the worst outcomes, consistent with Adib et al. Van Dijkhuizen et al. also found that a 
delay in JIA diagnosis was associated with an unfavorable outcome.74, 75 A polyarticular onset 
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of JIA had the worst prognosis regarding joint damage, and patterns of symmetric joint 
involvement and higher disease activity parameters were predictors of a worse functional 
ability.74, 76, 83 The results were difficult to generalize since different methods for determining 
disease activity were used, as well as different study designs, and a large variation in the 
variables assessed. 
 
Recent studies confirm what is previously reported. The polyarticular and enthesitis-related 
arthritis (ERA) categories have poorer outcomes than children with oligoarthritis.61, 84-86 
Interestingly, the children with systemic JIA seem to have a better long-term prognosis than 
previously reported,87 possibly because of the specific treatment with interleukin antagonists 
and inhibitors that are now available. Symmetric joint arthritis and arthritis in specific joints 
such as the ankle, wrist, fingers, and the cervical spine are reported to have a worse prognosis. 
This may, however, mainly reflect that many cumulative active joints are affected, and a 
polyarticular course, more than the specific joint involvement.79, 81, 86, 88, 89  The predictive 
value is not straightforward to establish since these variables correlate with other disease 
activity measures, and sometimes also with the JIA category. The effect of confounding 
factors must be kept in mind when developing prediction tools. The different variables 
assessing disease activity cannot be pooled together in prediction models before considering 
their correlation and their individual predictive capability.  
 
Inconsistencies in reported predictors over time may be explained by the absence of 
standardized classification systems, outcome definitions, evolving therapeutic approaches, 
and statistical methods. Prospective evaluation using validated outcome measures is required 
to generate robust disease outcomes and prediction models. 
 
2.8 Prediction models in JIA  
Recent prediction-model studies are presented in Table 2. The predictive performance of a 
prediction model is often reported as AUC of the ROC, or as a C-index. The AUC of the ROC 
is the same as concordance probability (C-index) for binary outcomes. In the following 
section, the two terminologies are used.  
 
Bulatovic et al.80 developed a prediction model that included clinical and genetic variables to 
identify patients with JIA that do not respond to methotrexate treatment. The AUC of the 
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ROC curve was 0.65. The model classified 72% of patients correctly in the development 
cohort, but only 65% in the validation cohort. In 2017 Guzman et al.77 developed a clinical 
prediction model for predicting severe disease course, an outcome constructed from data to 
identify the most severely affected children with JIA. The model performed excellently in 
both development and validation cohorts. However, the model was complex, and the outcome 
was not an established and validated outcome measure. Van Dijkhuizen et al. published in 
2015, a model for predicting methotrexate intolerance. The authors showed that this model 
had a moderate predictive ability, and suggested further validation in an independent cohort. 
They also proposed updating the model with new predictors before it could be recommended 
as a clinical tool.90 In 2018, Van Dijkhuizen et al.81 published models to predict inactive 
disease within two years of diagnosis. The model combined clinical characteristics, Luminex 
technology to identify biomarkers and microbiota data. The AUC statistic of the model was 
only 0.65 for the whole cohort, but the model performed better in selected subgroups. Mo et 
al.91 used machine learning methods for prediction of treatment response within three months 
after starting methotrexate. The two models (Table 2) used both clinical and laboratory 
variables, and performed excellently. Guzman et al.86 published in 2019, a model that used 
clinical and laboratory features to predict early remission on treatment within one year of 
diagnosis. The model did not achieve AUC >0.70, which is usually considered the threshold 
for acceptable for prediction. The Table 2 in this thesis is adapted from Table 3 in the review 
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et al 2012,  
The 
Netherlands 
Retrospective JIA cohort. 
N=183 patients for model 
development. 
Prospective JIA cohort. 





ESR and gene SNPs (MDR-
1/ABCB, MRP-1/ABCC1, 
PCFT) involved in the 





the ACR ped. 
70 criteria 




(95% CI:0.63-0.81).  
In internal validation:  
AUC=0.65  
(95% CI:0.54-0.77).  
Prediction model 
transformed into risk 
score (range 0-11).  











Prospective JIA cohort. 
Total N=152 patients. 
Multivariable logistic 
regression model.  
 
JIA category, ANA, 
parent/patient assessment of 
pain, JADAS-27, 
thrombocytes, ALT, 
creatinine and SNPs 
determined at MTX start. 
Prediction of 
MTX 
intolerance at 6 
or 12 months 
after MTX start. 
C-index=0.78.  
In internal validation:  
C-index=0.67. 
Prediction model 
transformed into a 
risk score  
(range 0-17).  






et al 2017, 
Canada  
Prospective JIA cohort. 
Total N=1087 patients. 
Four distinct courses were 
identified in 609 patients. 
75% of cohort for model 
development.  





Active joint count, psoriatic 
arthritis, oligoarthritis, RF-
negative polyarthritis, upper 
limb joint involvement, 
symmetric joint 
involvement, RF-positive, 
subtalar joint involvement, 
finger joint involvement, 
cervical spine involvement, 
ankle joint involvement, hip 
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In internal validation: 
Mean C-index=0.85. 
91% of children in 
the highest decile of 
risk experienced a 
severe disease course, 
and 5% in the lowest 
decile of risk 









Prospective JIA cohort.  
Total N=152 patients. 
75% of cohort for model 
development. 





Oligoarthritis: JADAS at 
baseline, mogibacteriaceae 
in stool, time since baseline. 
ANA positive patients: 
shorter time with morning 
stiffness, higher hemoglobin, 
treatment with biologics, 
time since baseline. 
Polyarthritis: RF-neg., 
shorter time with morning 
stiffness, higher hemoglobin, 







the first 2 years. 












et al 2019, 
China 
Retrospective JIA cohort.  
N=362 patients. 
Extreme gradient boosting 
(XGBoost), support vector 
machine, random forest, 
and logistic regression 
machine learning 
algorithms. 
80% of cohort for model 
development. 
20% of cohort for model 
validation.  
The XGBoost established 
the best models.  
Pre-MTX administration 
prediction model: CRP, 
CD3+Abs, RF-IgG, tender 
joint count, total bilirubin, 
indirect bilirubin, APTT, PT, 
TT, and fibrinogen. 
Mix-variables model 
(collected within 3 months, 
before and after MTX 
administration): CRP, 
CD3+CD4+, CD3+CD8, 
RF-IgG, total bilirubin, and 
fibrinogen near 3 months 
after administration. 
Prediction of the 
response to 





baseline to 3 
months after 
starting MTX. 
For the pre-MTX 
administration 












et al 2019, 
Canada 
Prospective JIA cohort.  
Total N=1087 patients. 
75% of the cohort for 
development. 
25% of cohort for model 
validation.  
Best performing model: 
cox-logistic regression 
model. 
Physician GA, time onset to 
diagnosis, RF-pos. 
polyarthritis, sJIA, wrist 
involvement, subtalar joint 
involvement, symmetric 
joint involvement, upper 
limb involvement, lower 
limb involvement, enthesitis, 
number of enthesitis sites, 
pain VAS, parent´s GA, 
French ethnicity, history of 
joint swelling, HLA B27, 
ANA, RF. 
Inactive disease 
for ≥ 6 months 
within 1 year of 
diagnosis in 
patients who did 









*The predictive performance of a prediction model is often reported as AUC of the ROC or as C-index. The AUC of the 
ROC is the same as concordance probability (C-index) for binary outcomes. ESR, Erythrocyte sedimentation rate; MDR-
1/ABCB1, methionine synthase reductase, multidrug resistance 1; MRP-1/ABCC1, multidrug resistance protein 1; 
PCFT, proton-coupled folate transporter; MTX, methotrexate; SNPs, single nucleotide polymorphisms; PPV, positive 
predictive value; NPV, negative predictive value; ALT, alanine aminotransferase; TMJ, temporomandibular joint; GA, 
global assessment; CXCL-9, Chemokine C-X-C motif ligand 9; APTT, Active partial thrombin time; PT, Prothrombin 
time; TT, Thrombin time; ACR, American College of Rheumatology; ANA, antinuclear antibody; AUC, area under the 
Receiver Operating Characteristic Curve; C-index, concordance index; CI, confidence interval; JADAS, Juvenile 
Arthritis Disease Activity Score; sJIA, systemic JIA; VAS, Visual Analogue Scale.  
The table is adapted from the review of Guzman et al 2019, Predicting disease severity and remission in juvenile 
idiopathic arthritis: are we getting closer? 
 
 Modeling studies in medicine 
Prediction-model building is a relatively new branch of JIA research.77-81, 90, 92 In other fields 
of medicine there are several well-known prediction rules applied in clinical practice, such as 
the Framingham Risk Score used to estimate cardiovascular risk of an individual,93, 94 and the 
FRAX model for osteoporosis risk.95 There are also examples in pediatrics,96 such as the 
recently published prediction rule for identification of febrile infants at low risk of serious 
bacterial infections.97  
 
Prediction models in medicine should be accurate for the outcome in question for each 
patient. Besides accuracy, a clinically relevant prediction model needs to be simple. 
Simplicity may be challenging to achieve since more complex models, that make use of more 
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information, may perform better. A simple model may be easier to construct for homogenous 
outcomes, but in JIA disease heterogeneity presents a challenge. In JIA, disease heterogeneity 
presents a challenge. Therefore, very simplified prediction models may not be realistic. An 
alternative approach may be to develop separate models for different JIA categories. 
 
 Development and validation of prediction models 
The optimal design for prognostic research is a longitudinal cohort study. The guideline 
“Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or 
Diagnosis (TRIPOD)” present norms for developing and validating prediction models.98-100 
Prediction models, also called prediction rules, combine several predictors and the 
contribution of each predictor is weighted. From the weighted rule, a risk score for the 
assessed outcome is obtained.101 The outcome is often binary, i.e., the prediction model gives 
the probability of a given outcome or not.  
 
In developing a prediction model, different procedures for selecting predictors may be used. 
Logistic regression or Cox regression models are the most commonly used in medicine.100, 102 
In multivariable logistic regression model-building, one approach is to remove predictors 
based on p-values or their regression coefficients. Alternatively, clinical judgment or a 
literature review can be used to decide if specific variables should be used in the model. One 
can also give preference to variables with few missing data. It is also common to avoid 
variables that significantly overlap or correlate with variables that are already included. 
Selecting predictor variables is not an easy task; for instance, with many potential predictors, 
there is an increased risk of choosing uninformative variables and, in this way, overfitting the 
model. Overfitting is a modeling error that may improve the model's performance in the 
training cohort, but decreases its predictive ability in the test cohort. Overfitting is common if 
the number of predictor variables is high compared to how often the predicted outcome 
occurs. This is a particular concern when the sample size is small. Underfitting occurs if 
essential and informative variables are not included in the model.103 
 
For a realistic evaluation of a model's predictive ability, it is not enough to quantify the 
predictive ability in the total cohort used for building the model. This approach will result in 
an overestimation of predictive power, and is not recommended.98 Every prediction model 
should at least undergo internal validation, which may be done by resampling, e.g., 
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bootstrapping or cross-validation, to evaluate the model's performance more realistically. 
Another option is to randomly split the data into two parts: one for development often called a 
training set, and another for model performance evaluation. The latter is often called the 
validation set. The data set may also be evaluated at different time points. In this case the data 
is split by time or location into one part for development and the other for testing of the 
model. In this way, one tests the model in a set of patients whose information has not been 
used to develop the model. This will be the case when the model is applied to future patients. 
When testing is done in the same cohort, it is called internal validation. The splitting of the 
cohort in training and testing cohort needs to be done several times to obtain confidence 
intervals for the model's predictive ability.98 If the model's predictive ability is not tested, and 
the presented accuracy of the model is the one for the whole cohort, the predictive ability will 
most likely be over-optimistic.  
 
Before prediction models can be recommended for general use in clinical practice, the 
predictive performance, reliability, and accuracy across different populations need to be 
assessed to avoid overestimating the model's predictive performance. External validation 
refers to testing a prediction model in a cohort separate to the one used to build the model, or 
to evaluation of an already published model on separate data. 
 
If a model predicts a given outcome, what is the probability that this prediction becomes true? 
This question is answered by the C-index (equal to the AUC). In a logistic regression model, 
the C-statistic measures the goodness of fit: the probability that a randomly selected patient 
who experienced the outcome had a higher risk score than a patient who did not experience 
the predicted outcome. The value ranges from 0.5 to 1.0. An AUC value of 1.0 is equal to 
perfect prediction; the model can separate the patients experiencing the outcome perfectly 
from those who do not experience the outcome. In general, a value above 0.7 is considered 
helpful for prediction. In contrast, a value of 0.5 is equal to chance alone, while a model with 
a predictive performance above 0.8 has excellent predictive ability.104 
 
Clinical prediction models may improve outcomes. For the patients where predictions are 
carried out, measures can be implemented to improve the predicted outcome. One example is 
initiation of early potent treatment in JIA. The ultimate test of a prediction model's usefulness 
would be a randomized controlled trial using a prediction model to guide treatment decisions 
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as a part of clinical care versus standard clinical care. Only then, we will know whether 
outcomes can be significantly improved. 
 
 From modelling to clinical applicable prediction tools  
A clinical prediction tool (a risk calculator) allows physicians to feed models with the 
required information, e.g., clinical features and laboratory findings. In this way, physicians 
can receive objective probability-based risk scores for a given outcome. For a patient in the 
early stages of the disease course, the required input can be entered into a software tool that 
may be implemented as an online calculator or a mobile app. If the prediction model is a 
multivariable logistic regression model, the different variables are multiplied by their 
respective coefficients and summed up. The output obtained is a prediction score, which can 
be translated into the probability of an unfavorable outcome. Figure 1 shows a mobile app 








3 Uveitis in JIA 
3.1 General aspects and epidemiology 
Although the main feature of JIA is arthritis, several extraarticular manifestations may arise 
with potentially higher morbidity than the joint disease. Uveitis is the most common 
extraarticular manifestation. It is characterized by an inflammation of the uvea in the eye, 
affecting the iris, ciliary body, and the choroid.2 In the majority of studies, the cumulative 
incidence of juvenile idiopathic arthritis-associated uveitis (JIA-U) is found to be between 4-
24%, but both lower and higher rates have also been reported.105-111 Differences in study 
design, patient accrual, and geographic and ethnic variations are likely reasons for the 
variation in reported uveitis rates.105, 111 Reports have shown clear differences in uveitis rates 
across different parts of the world. JIA-U is more common in Northern Europe than in Asia 
and South America, and it has been suggested that children of European descent, especially 
with Nordic descent, have higher risk of JIA-U.105, 106, 112, 113 
 
In contrast to intraocular inflammation in adults, children with JIA-U are often asymptomatic 
and therefore dependent on physicians’ awareness and vigilance of the disease to be 
discovered. Chronic anterior uveitis is the most frequent type of uveitis associated with JIA, 
affecting both eyes in the majority of children. This type of uveitis onset goes unnoticed by 
the children or parents in more than 85% of the cases.111, 114 Approximately 80-90% are 
diagnosed with uveitis within four years of JIA onset. However, there are children who 
develop uveitis before JIA and later on in life, with the risk of delayed diagnosis.106, 114, 115 
Since chronic anterior uveitis often is asymptomatic until ocular complications occur, children 
with JIA should undergo ophthalmologic screening regularly. Early identification and 
treatment of uveitis is necessary to prevent complications that may lead to visual impairment. 
Effective screening by slit lamp examination is necessary.116, 117  
 
Acute anterior uveitis is another type of uveitis associated with JIA. This type is associated 
with human leukocyte antigen B27 (HLA-B27), and is more common among children with 
ERA and psoriatic arthritis. Acute anterior uveitis is usually symptomatic, unilateral, and is 
often more episodic. Children with acute uveitis often present with a painful red eye. They are 
promptly examined and treated by the ophthalmologist. Consequently, they have a lower risk 
of developing ocular complications.41, 118 
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All children with suspected or confirmed JIA need to be examined by an ophthalmologist at 
regular intervals according to their risk profile. Different screening programs have been 
suggested.114, 116 According to the recent 2019 ACR recommendations regarding screening in 
JIA-U the following children with JIA are considered to be at high risk of uveitis: Those with 
oligoarthritis, RF negative polyarthritis, psoriatic arthritis, and undifferentiated arthritis who 
are ANA positive, younger than seven years at JIA onset, and have a duration of their uveitis 
of four years or less. These children should be screened every three months.41 Children with 
low to moderate risk of JIA-U should be screened every 6-12 months. These are children that 
are ANA negative but in the high-risk JIA categories, and who develop JIA after the age of 
seven, or have had JIA for more than four years. The low to moderate risk group also include 
the RF positive polyarthritis, systemic JIA and ERA not mentioned in the high-risk group.41 
 
3.2 Classification of JIA-associated uveitis 
The International Standardization of Uveitis Nomenclature (SUN) working group57 developed 
standardized classification criteria for uveitis. Uveitis in children can be idiopathic or 
associated with other diseases than JIA such as e.g., reactive arthritis, inflammatory bowel 
disease, Behcet´s disease and vasculitis. The SUN-criteria categorizes uveitis according to the 
anatomic localization of inflammation.57 In addition uveitis is classified according to the onset 
type, duration and clinical course of uveitis. In JIA-U, the most typically finding is an anterior 
localization, with a chronic or recurrent course.105 The SUN working group also established 
criteria for assessing the degree of inflammation in the eye, and the occurrence of ocular 
complications.57 The ACR 2011 criteria for inactive JIA disease include the assessment of 
uveitis activity. In order to have inactive JIA disease,52 no active uveitis defined as <1 cell in 
field sizes of 1x1mm slit beam should be found.57 The SUN working group also defined 
criteria for assessing the degree of improvement of inflammation. Uveitis is registered as 
inactive if no cells are found in the anterior chamber, in remission if inactive disease is 
present for three months or more, after stopping uveitis treatment. Worsening is defined as a 
two-step increase in the level of inflammation or increase in grade from 3+ to 4+. Improved 
uveitis activity is present if there is a two-step decrease in the level of inflammation, or 
decrease to inactive uveitis.57 
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3.3 Etiology and pathogenesis of JIA-associated uveitis 
The cause of uveitis in JIA is still unknown. As in JIA, uveitis is thought to be an autoimmune 
disorder.119 The pathogenesis of JIA-U is probably similar to the pathogenesis in JIA, 
influenced by both environmental and genetic factors.119 The adaptive immune system with 
both T cells, mostly CD4+ cells, and B lymphocytes, plays a role in the response towards 
ocular self-antigens, producing cytokines and driving the ocular inflammation.119 Recent 
studies have found an association between HLA-DRB1*11 and HLA-DRB1*13, and an 
increased risk of JIA-U.120 
 
Hep2-ANA positivity is reported to be more frequent among the JIA-U patients than in JIA 
patients without uveitis, raising the question of whether this antibody plays a role in the 
pathophysiology of uveitis.107, 112, 121 Although antibody binding to ocular components have 
been found in children with JIA-U, no antigen as the target for ANA has been found.122 
 
3.4 Current treatment strategies in JIA-associated uveitis 
The goal in treatment of JIA-U is inactive disease. The treatment strategy of uveitis is similar 
to the stepping-up treatment strategies for arthritis.41, 123A combination of regularly 
ophthalmological screening and prompt treatment, with repeated assessments of treatment 
results and continuous evaluation of the need for early systemic treatment is crucial in order 
to gain control of the uveitis. The aim is quiescence of inflammation in order to avoid 
complications endangering vision. The care of patients with JIA-U should be 
interdisciplinary, involving both ophthalmologists and pediatric rheumatologists. Local 
treatment with topical glucocorticoid eye drops is the first choice if active uveitis is present. 
The decision to step up treatment depends on the degree of inflammation, the local 
glucocorticoid dose, flare-ups despite local treatment, development of complications, or not 
achieving inactive disease. Synthetic or biologic DMARDs should be considered if local 
treatment cannot be stepped down within three months.41, 123 Methotrexate is often the first 
choice of systemic treatment. If severe inflammation is present, both methotrexate and an 
TNF inhibitor such as adalimumab may be needed.124, 125 Etanercept was not found effective 
in the treatment of uveitis in an RCT, and should be avoided in JIA if the indication for 
starting biologics is mainly or partly due to uveitis.126 Topical glucocorticoids have an adverse 
potential for causing glaucoma and cataract, and is therefore recommended only for shorter 
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periods.41, 127  If the child is in need of topical glucocorticoids despite systemic therapy, the 
treatment should be intensified  or switched to another TNF inhibitor. Alternative biologic 
DMARDs for JIA-U are abatacept or tocilizumab, or synthetic DMARDs such as 
mycophenolate or leflunomide.128, 129 After the treatment goal is achieved, the 
recommendation is to continue systemic treatment for a minimum of two years before 
tapering. As for treatment of arthritis in JIA, systemic glucocorticoids are not recommended, 
other than as a possible bridging therapy awaiting the effect of DMARDs.41, 50 
 
3.5 Ocular complications in JIA-associated uveitis 
The frequency of ocular complications due to longstanding chronic anterior uveitis in JIA has 
decreased in the last decade. Two or more decades ago, up to 90% of the patients with JIA-U 
developed ocular complications.130-132 The most severe consequence of ocular complications 
is impaired vison and in worst case blindness. Cataract and glaucoma are the most common 
ocular complications threatening the sight in children with JIA-U.117, 133, 134 Cataract is a 
clouding of the normally clear lens of the eye, and glaucoma is when damage of the optic 
nerve is caused by high pressure in the eye. The reported cataract rate in JIA-U is 20-80%, 
and for glaucoma 10-40%.135-137 These numbers vary greatly depending on the time period, 
study design, and the cohort composition in the studies. In JIA-U, the percentage with ocular 
complications have decreased the past years. This decrease is most likely a result of tight 
screening programs and earlier initiation of synthetic and biologic DMARDs in JIA.138, 139 
More restrictive use of local glucocorticoids may also be beneficial, since they are known to 
have an adverse effect of inducing glaucoma and cataract as mentioned above.41 Other sight 
threatening complications are synechiae which often develops as the result of severe 
inflammation resulting in adherence between the lens and iris. Band keratopathy, macular 
edema, and phthisis bulbi may also occur.114, 135, 140 Figure 2 shows the eye of a young boy 





Figure 2. Slit lamp photo from a patient with JIA-associated uveitis. A grayish area with band keratopathy is 
seen to the left from the slit light on the cornea. Posterior synechiae are visible at the pupillary border. The lens 
does not seem to be completely clear as seen with incipient cataract of the lens. Photo by Terje Christioffersen 
 
3.6 Predictors of uveitis and uveitis-related complications 
Young age at the onset of JIA, as well as belonging to the oligoarthritis and RF- negative 
polyarthritis categories, are considered to be predictors associated with an increased risk of 
developing uveitis.107, 114, 117 Presence of ANA and HLA-B27 are associated with chronic and 
acute uveitis, respectively.108, 111 In contrast, uveitis is rarely seen in the systemic JIA and RF 
positive polyarthritis categories.105, 111 
 
Predictors associated with the occurrence of ocular complication are: the presence of ocular 
complications at baseline, severe inflammation in the uvea, the onset of uveitis before 
arthritis, and a short interval between the onset of JIA and the onset of uveitis.117, 133, 138, 141 
Even though males are underrepresented among patients with JIA-U, males are reported to be 
more prone to develop ocular complications.142 Some studies have shown that female gender, 
persistent oligoarthritis, and presence of ANA are significant predictors of ocular 
complications.133, 143 However, there are discrepancies between studies, and most reports find 
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no significant associations between ocular complications and JIA subtype, ANA nor female 
gender. 
 
In Table 3, selected studies from 2007-2020 reporting on predictors of ocular complications 
and the rates of complications in JIA-U. The JIA onsets in these studies span from the 1980s 
to the present.84, 108, 113-115, 133, 137-139, 141, 142, 144-147  The proportion of JIA-U patients that 
developed ocular complications range from approximately 20% to 60%. A recent study from 
a large German inception cohort reported a rate of complications in the lower end of this 
range.138 In a Finish study, the rate of complications decreased from 35% for patients enrolled 
in the year 1990, to 21% for patients enrolled in the year 2000.139 Before the year 2000, few 
patients with JIA were treated with biologics agents, compared to today. Biologic treatment 
targets specific parts of the immune system involved in inflammation. The treatment can be 
highly effective when uveitis is refractory to local steroids or synthetic DMARDs.41 A 
German study on JIA-U reported that 29% had complications of their uveitis. This rate is 
lower than the complication rates reported from the pre-biologic era.138 Another reason for the 
lower rate of ocular complications in the recent years may be the increased use of 
standardized uveitis screening guidelines.116 A known risk factor for developing ocular 
complications is the onset of uveitis before arthritis, and most uveitis develops in the first few 
years after JIA diagnosis. Therefore, early and regular eye screening at a short intervals in the 
beginning of the disease course is essential to avoid long-term ocular complications.115 The 
studies presented in Table 3 originate from Europe and North America, and only one study 
analyzed predictors associated with complications for different ethnicities.108 The largest 




























loss and uveitis activity 
% 
Heiligenhaus 
et al 2007, 
Germany 





Mean follow-up  
5.6 years. 
Complications  




56% of JIA-U patients. 
Woreta  
et al 2007, 
USA 
75 JIA-U. 75 Retrospective. 
Cross-sectional. 
Patients evaluated 
between the years 
1984-2005. 





between the diagnosis 
of arthritis and 
uveitis. 
Complications: 
64% of JIA-U patients. 
67% of eyes of JIA-U. 
VA in affected eyes: 
20/50 or worse: 36%. 
20/200 or worse: 24%. 
Thorne  
et al 2007, 
USA 
75 JIA-U. 75 Retrospective. 
Median follow-up  
3-years. 
Patients evaluated 
between the years 
1984-2005. 
Presence of posterior 
synechiae. 
Presence of anterior 




Any ocular complication: 
0.33/EY. 
VA: 
11% VA loss. 
20/50 or worse: 10/EY.  




et al 2007, 
Canada 
1081 JIA. 142  
(13%) 
Inception cohort. 
Tertiary center.  
Mean follow-up  
6.9 years. 
Ophthalmologists' 




with abnormal vision. 
Complications: 
37.3% of JIA-U patients. 
4.9% of total JIA cohort. 
Reininga  
et al 2008, 
The 
Netherlands 








Not reported. Complications: 
48% of JIA-U patients. 
VA: 
21 of 25 patients had  
VA ≥0.1.  
4 patients had VA <0.05.  
Sabri  









6.9 years.  
To be included: 
minimum of 1-
year follow-up. 
Short time from 
diagnosis of JIA to 
uveitis. 
Higher use of oral 
prednisone. 
Ocular surgery.  
Complications: 
37.3% of JIA-U patients. 
32.5% of eyes of JIA-U. 
Impaired VA in 6 eyes: 
3.4%.  
Blindness in 10 eyes: 
5.7%.  
Skarin  







Examined at 7 
and 24 years after 
onset of JIA-U. 
Tertiary center. 
Not reported. Complications: 
58% of JIA-U patients. 
7 years after JIA-U 
onset: Cataract 42%, 
Glaucoma 5%. 
24 years after JIA-U 
onset: Cataract 51%, 
Glaucoma 22%.  




et al 2012, 
The 
Netherlands 
62 JIA-U. 62 Retrospective.  
2-years follow-up. 
Female gender, but 













Not reported. Not reported. 
Gregory  













increased risk of 
vision loss. 
Complications: 
60.2% eyes of JIA-U. 
Incidence of developing 
at least 1 new ocular 
complication over 
follow-up was 0.15/EY. 
VA at presentation:  
20/50 or worse: 240 eyes 
(40.3%).  
20/200 or worse: 144 
eyes (24.2%). 
Kotaniemi  

















by 10 years. 
Not reported. Complications: 
1990-1993:  
35% of JIA-U patients. 
2000-2003:  
21% of JIA-U patients.  
Paroli  
et al 2015, 
Italy 






flare >1.  
Complications: 
30% of eyes of JIA-U. 
At baseline:  
Post. synechiae: 52%. 
Band keratopathy: 38%. 
Cataract:12%. 
VA: 
20/50 or worse: 0.04/EY.  
20/200 or worse: 
0.02/EY. 
Tappeiner  














Not reported. Complications: 
33.6% of JIA-U patients 
in 2002.  
23.9% of JIA-U patients 
in 2013. 
Uveitis activity:  
69.4% in 2002. 
34.7% in 2013. 
Haasnoot  
et al 2016, 
The 
Netherlands 
67 JIA-U. 67 Retrospective.  
Assessed during 
18th, 22nd and 




54% of JIA-U patients. 
Uveitis activity 18th life 
year: 54%.  
Visual impairment or 





et al 2017, 
Greece 







Not reported. Complications: 
46% of JIA-U patients. 
Papadopoulou 
et al 2017, 
Sweden 




Not reported. Complications: 
47% of JIA-U patients.  





The ultimate treatment goal in JIA and JIA-U is inactive disease, with no signs of arthritis or 
active uveitis. The treatment strategies are in general costly and come with potential serious 
side effects. Identifying the patients at high risk of high disease activity and need for early 


















et al 2019, 
Germany 




At first uveitis: 
Older age at JIA 
onset. 
Short duration 
between JIA and 
uveitis onset. 
Higher anterior 
chamber cell grades. 




At first uveitis: 29.8%. 
1-year follow-up: 30.7%. 
2-year follow-up: 32.8%. 
 
Uveitis activity: 
1-year follow-up: 18.2%. 
2-year follow-up: 20%. 
JIA, Juvenile idiopathic arthritis; JIA-U, JIA-associated uveitis; ANA, anti-nuclear antibody; VA, visual acuity; 
IOP, intraocular pressure; EY, eyes per year. 
 
 36 
4 Aims of the study 
The overall aim was to develop clinically useful prediction tools relevant for guiding early 
treatment decisions in JIA. Further, to provide new insight in long-term outcome of JIA-
associated uveitis, and to assess predictors of ocular complications.   
 
Specific aims are listed below.  
 
4.1 Paper I: 
• Develop a prediction model based on baseline clinical characteristics in the Nordic 
JIA cohort to assess the probability of the main outcome non-achievement of 
remission off medication for each child with JIA.  
 
• Develop a prediction model based on baseline clinical characteristics in the Nordic 
JIA cohort to assess the probability of functional disability in different activities of 
everyday life, and the probability of joint damage for each child with JIA using the 
following validated outcome measures: CHAQ, CHQ-PF50 (PhS) and JADI-A.    
 
• Develop a clinical tool to assist in decision-making for early treatment strategies in 
JIA as software for mobile devices (iOS) and online applications to ensure 
convenience for use in clinical practice. 
 
• Test the predictive ability of the Canadian prediction model developed in the Canadian 
ReACCh-Out cohort77 for the following outcomes: non-achievement of remission off 
medication, functional disability, and joint damage in the Nordic JIA cohort. 
 
4.2 Paper II and Paper III: 
We aimed to validate each prediction model in a different cohort than the one used for 
building the model.   
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 Paper II: Part 1 – External validation of the Canadian prediction model in 
the Nordic JIA cohort 
• Test the Canadian prediction model's ability to predict the outcome it was constructed 
to predict, severe disease course (Canadian outcome) in Nordic patients with JIA. 
 
• Test the Canadian prediction model's ability to predict non-achievement of remission 
off medication (the Nordic outcome) in Nordic patients with JIA. 
 
• Test the Nordic prediction model's ability (developed in paper I) to predict severe 
disease course (Canadian outcome) in Nordic patients with JIA. 
 
 Paper III: Part 2 – External validation of the Nordic prediction models in 
the ReACCh-Out cohort 
• Test the Nordic prediction model's ability to predict the outcome it was constructed to 
predict, non-achievement of remission off medication and functional disability (Nordic 
outcomes) in Canadian patients with JIA. 
 
• Test the Nordic prediction model's ability to predict severe disease course (Canadian 
outcome) in Canadian patients with JIA. 
 
4.3 Paper IV:  
• Assess the long-term outcome of uveitis in JIA in terms of cumulative incidence, 
clinical characteristics, disease activity, ocular complications, and visual outcome.  
 
• Identify predictors for development of uveitis-related complications that may further 
be used in individual prognostication. 
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5 Materials and methods 
5.1 Study design and population 
 The Nordic JIA cohort 
The population-based, longitudinal, prospective, multicenter study on JIA in the Nordic 
countries was initiated and run by The Nordic Study Group of Pediatric Rheumatology 
(NoSPeR). The central part of the thesis is based on data from the Nordic JIA cohort.  
We studied consecutive new JIA cases included from January 1997 to June 2000 from 12 
participating centers from defined geographical areas of Denmark, Finland, Norway, and 
Sweden. The Nordic countries' health care system is mostly free of charge for children under 
16 years of age, making it feasible to conduct a population-based study. During the inclusion 
period, letters were repeatedly sent to primary health care providers, child health centers, 
orthopedic, pediatric, and rheumatology specialists in the catchment areas to ensure all 
eligible patients' referral to collect a population-based cohort.148 
 
The included patients were followed prospectively for 18 years. The first visit was the 
baseline study visit with 500 patients, approximately six months after onset of JIA. Besides 
the baseline visit, there were two other major visits, the 8-year visit with 440 patients and the 
18-year visit with 434 patients (Figure 3). 
 
The children were followed at regular intervals, with two visits in the first year, and after that, 
1-to-3-year intervals up to the 8-year visit.148 During this observation period, the children 
were also screened for uveitis by an ophthalmologist at each center. In the first two years, the 
ophthalmologic examinations were scheduled every 2-3 months; after that, longer intervals 
depending on the time since onset of JIA and the JIA category.  
 
 The ReACCh-Out cohort 
We used the Canadian ReACCh-Out cohort for the validation of the Nordic JIA prediction 
model. The Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh-
Out) cohort is a prospective and multicenter cohort. Initially 1497 children with JIA were 
included from 16 pediatric rheumatology centers across Canada between January 2005 and 
December 2010. The first visit occurred as soon as possible after diagnosis, but could be up to 
 
 39 
one year after diagnosis. Follow-up visits were scheduled every six months during the first 
two years, and then yearly up to 5 years, or until May 2012.59, 74 
 
5.2 Inclusion criteria 
For the studies based on the Nordic JIA cohort, the inclusion occurred between January 1st, 
1997, and June 30th, 2000. Children or adolescents <16 years of age with newly diagnosed 
JIA according to the ILAR criteria were included in the study.1 To continue in the study a 
minimum of two study visits was required, one of them being the baseline visit. 
 
For the study based on the Canadian ReACCh-Out cohort, the inclusion period was from 
January 2005 to December 2010. Children or adolescents <16 years of age with newly 
diagnosed JIA according to the ILAR criteria were included in the study. 
In the Nordic prediction model development study (paper I) 423 of 500 (85%) children in the 
Nordic JIA cohort met the inclusion criteria of having a baseline study visit, an 8-year-follow-
up visit, and not belonging to the systemic JIA category.79 In the validation study of the 
Canadian prediction model (paper II), all children in the cohort with 8-year follow-up were 
included. These were 440 of 500 (88%), including those with systemic JIA (Figure 3).149  
 
For the validation of the Nordic prediction model in the Canadian ReACCh-Out cohort (paper 
III), Canadian children recruited within three months of diagnosis who had enough 
information at the 3-year visit to ascertain the outcomes were included. Data from 513 
children attending the 3-year visit in the ReACCh-Out cohort study were used.150  
 
The inclusion criteria for the study on JIA-associated uveitis (paper IV) were all children in 
the Nordic JIA cohort with a baseline visit and an 18-year follow-up visit. In all, 434 of 500 
(86.8%) patients were followed for 18 years. Among these, 329 of 434 (75.8%) attended the 
study visit at the department of pediatrics, and 273 of 329 (83.0%) attended the study visit at 
the department of ophthalmology. The remaining 105 (24.2%) patients participated in the 18-





Figure 3. Flow chart of the Nordic JIA cohort from baseline to the 18-year follow-up. The number of patients 
that physically attended the study visit at the pediatric rheumatologist and ophthalmologist at the 18-year follow-
up is presented. a10 of 77 excluded patients fulfilled the inclusion criteria after re-evaluation. 
 
5.3 Data collection 
A thorough registration of medical and family history, symptoms, and clinical findings 
including complete joint counts, patient/parent-completed health assessment measures, and 
laboratory parameters. This was performed every six months during the first year. Then new 
visits were performed every 1-3 years during the first eight years after disease onset, at the 8-
year follow-up and finally at the 18-year follow-up. Information from all study visits was 
prospectively registered in a specifically designed database (4th Dimension) at all centers. 
Local biobanks of serum and full blood specimens were sampled at baseline, 8-years, and 18-
years. At the 18-year follow-up, the patients were also examined by an ophthalmologist and 
comprehensive clinical information on uveitis was collected. The data from the 18-year visit 
was stored in a new database (SurveyXact). The core variables from baseline and 8-year were 
merged with the latest data set in SurveyXact. 
 
Data registered at baseline (approximately six months after disease onset)  
• Demographics including age, date of onset of JIA, family history, medication, and 
information about progress in school and physical education 
• General physical examination including joint assessment 
Excluded due to not fulfilled 
inclusion criteria, n=77a




















Included after re-evaluation 
of inclusion criteria, n=10
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• Uveitis-related clinical data 
• Assessment of disease activity measures and disease course  
• Classification according to ILAR and EULAR criteria 
• Serum and EDTA whole blood sampled and stored 
• Registration of results of laboratory tests such as ANA, rheumatoid factor, HLA-B27, 
and the inflammatory parameters CRP and ESR 
• Patient/parent-reported questionnaires: CHAQ  
 
Data registered at the 1-3-year interval after disease onset 
• General physical examination including joint assessment 
• Uveitis-related clinical data 
• Assessment of disease activity measures and disease course  
• Classification according to ILAR and EULAR criteria 
• Routine blood samples  
• Patient/parent reported questionnaires: CHAQ 
 
Data registered at the 8-year follow-up  
• Update on demographics and family history, medication, and information about 
education/employment 
• General physical examination including joint assessment 
• Serum and EDTA whole blood sampled and stored  
• Registration of results of ANA, rheumatoid factor, HLA-B27, and the inflammatory 
parameters CRP and ESR 
• Extended information on uveitis-related clinical data 
• Assessment of disease activity measures and disease course: JADAS 
• Assessment of joint damage: JADI-A and JADI-E 
• Patient/parent-reported questionnaires: CHAQ, HAQ, CHQ-PF50, SF-36 
 
Data registered at the 18-year follow-up 
• Update on demographics and family history, medication, and information on 
education/employment 




• Ophthalmology visit for eye status and registration of uveitis-related clinical data 
• Dental visit for temporomandibular joint status and oral examination data, including a 
full-face cone-beam computed tomography (CBCT) 
• Serum and EDTA whole blood sampled and stored 
• Assessment of disease activity measures and disease course: JADAS and DAS 
• Assessment of joint damage: JADI-A and JADI-E 
• Patient-reported questionnaires: HAQ, SF-36, FSS 
 
5.4 Predictor variables and outcomes assessed 
In paper I, several clinical variables were screened as potential predictor variables. Five 
clinical variables were included a priori in the four prediction models. These variables were 
the cumulative active joint count, erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP), morning stiffness, and physician’s global assessment of disease activity (Physician’s 
GA). According to the provisional Wallace 2004 criteria, these four variables are assessed 
when evaluating if the patient is in remission.51 We considered to include whether the patient 
had active uveitis or not, but since the patients with uveitis were a subgroup of the total 
cohort, this variable was not included in the prediction model. Other key variables were 
included by the model-building procedure described in the statistics section. As a result of this 
procedure, the set of included variables were different for each of the four outcomes. 
 
The primary outcome assessed in paper I was non-achievement of remission off medication; 
this included active disease, inactive disease of fewer than 12 months of duration, and clinical 
remission on medication according to the preliminary Wallace criteria.51 The secondary 
outcomes were functional disability assessed by CHAQ and CHQ-PF50 (only PhS was 
assessed), and joint damage assessed by JADI-A. In the model for prediction of non-
achievement of remission off medication, ANA, HLA-B27, and ankle joint arthritis entered 
the model as predictors in addition to the five a priori variables. Figure 4 shows the resulting 
multivariable logistic regression model for prediction of non-achievement of remission off 
medication. In the model for predicting functional disability assessed by CHAQ, finger joint 
arthritis and pain VAS were added by the modeling building procedure. For the prediction of 
functional disability assessed by PhS, pain reports on a VAS were entered as an additional 
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variable in the model. Finger joint arthritis and older age at disease onset were the extra 
predictor variables in the model predicting joint damage assessed by JADI-A. 
 
In paper II, we evaluated the Canadians’ prediction model’s validity. The Canadian model 
uses 16 predictor variables (active joint count at baseline, psoriatic arthritis, oligoarthritis, RF 
negative polyarthritis, upper limb joint involvement, symmetric joint involvement, RF 
positivity, subtalar joint involvement, finger joint involvement, cervical spine involvement, 
ankle joint involvement, presence of morning stiffness, hip involvement, temporal mandibular 
joint involvement, mid-foot involvement, and presence of enthesitis). The multivariable 
logistic regression prediction model is shown in Figure 4. The model was tested in the Nordic 
cohort using the outcomes non-achievement of remission off medication (Nordic outcome) 
and severe disease course (Canadian outcome). In the Nordic cohort, the severe disease 
course outcome was constructed on the basis of the variables cumulative active joint count, 
remission status, CHAQ and the PhS derived from CHQ-PF50 form. We also constructed an 
alternative version including pain reports on VAS at the 8-year visit. The outcome 
construction is described in detail in the section on statistical methods. 
 
In paper III, the Nordic prediction model developed in paper I was tested in the ReACCh-Out 
cohort. For Canadian children, we used the eight variables in the model for prediction of non-
achievement of remission off medication (stated above) to predict the outcomes severe disease 
course and non-achievement of remission off medication at the 3-year visit. The exact same 
definition of the non-achievement of remission used in the original Nordic study, was not 
possible to use in the ReACCh-Out cohort due to differences in the frequency of visits and 
other differences between the two cohorts. The outcome severe disease course was originally 
constructed in the ReACCh-Out cohort with a cluster procedure based on changes in pain, 
health related quality of life, number of active joints, medication requirements, and 




Figure 4. Illustration of the Canadian and Nordic multivariable logistic regression models. The yellow boxes 
present the included predictor variables and coefficients. C-indices in internal validation were 0.85 for the 
Canadian model and 0.78 for the Nordic model. 
 
In paper IV, we identified the following predictors associated with the outcome ocular 
complications: short time interval between the onset of JIA and uveitis, onset of uveitis before 
JIA, and positive ANA test. Other variables explored as possible predictors of developing 
ocular complications were: gender, young age at diagnosis of uveitis, young age at diagnosis 
of JIA, oligoarthritis and RF negative polyarthritis categories, and HLA-B 27. These are 
variables previously reported to be associated with increased risk of uveitis. An association 
with uveitis-related ocular complications was, however, not found.105, 107, 112 
 
5.5 Statistical methods 
The analyses were performed using the software packages STATA version 14, and Wolfram 
Mathematica version 11.1.1.0, and R software. Conventional descriptive statistics such as 
absolute numbers, median, interquartile range (IQR; 1st and 3rd quartile), and percentages 
were used to describe demographics and clinical characteristics in paper I-IV. In the following 
sections the methods used for developing models, validation of models, and construction of 
clusters and heat-maps will be presented in more detail. 
 
 Prediction model building 
In paper I, we performed univariate logistic regression as a screening procedure to assess 
baseline variables as potential predictors for the four outcomes. Variables with a p <0.05 in 
the univariate analysis were considered candidates for a prediction model. The variables' 
Canadian prediction model
Nordic prediction model
A= – 2.92 + 0.18 * (active joint count) – 1.23 * (psoriatic
arthritis) – 1.14 * (oligoarthritis) – 0.49 * (RF negative
polyarthritis) + 0.75 * (upper limb joint arthritis) – 0.88
* (symmetric joint arthritis) + 1.31 * (RF positivity) –
1.42 * (subtalar joint arthritis) – 0.31 * (finger joint
arthritis) + 0.84 * (cervical spine arthritis) + 0.48 *
(ankle joint arthritis) + 0.56 * (morning stiffness) + 0.06
* (hip joint arthritis) + 1.50 * (TMJ arthritis) + 0.54 *
(mid foot arthritis) + 0.86 * (enthesitis)
A= – 1.58 + 0.04 * (cumulative active joint count) + 0.03
* (ESR mm/h) – 0.07 * (CRP >10 mg/l) + 1.16 * (morning
stiffness >15 min) + 0.16 * (physician´s GA VAS) + 1.25 *
(ANA positive) + 1.37 (HLA-B27 positive) + 1.10 * (ankle
joint arthritis)
Methods
Multivariable logistic regression models: ! = !!"#!" with # = $$ + $!&! +⋯+ $%&%
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dependencies were assessed by Spearman correlation, and if two variables had strong 
correlations, only one was included. Models were constructed based on the predefined 
variables selected a priori, and the additional variables selected using a forward stepwise 
method where the criterion for inclusion was that a variable contributed to the multivariable 
model with p <0.05, when included. For each predictor variable, the model coefficients were 
estimated by multivariable logistic regression. The probability of the predicted outcome is 
computed according to the formula  
 
! = 1/(1 + '!"), with ) = *# + *$+$ +⋯+ *%+% , (1) 
 
where *$, … , *% are the model coefficients for each predictor variable +&.  
 
 Validation of prediction models 
In paper I, internal cross-validation was performed by randomly dividing the cohort 100 times 
in a training cohort and a validation cohort. Prediction models were constructed in the training 
cohort to find variables and estimate model coefficients in each realization. In the validation 
cohort, the multivariable logistic regression model provided a probability of each of the 
patients' outcome. The receiver operating characteristic (ROC) curve was computed by 
comparing the predicted probability of unfavorable outcome with the actual outcome at the 8-
year visit, and the area under the curve (AUC) estimated. 
 
In paper II, we needed to construct a version of the severe disease course (Canadian outcome) 
in the Nordic JIA cohort. The K-medoids clustering algorithm was used to divide patients into 
mild, moderate, severe controlled, and severe persistent disease courses, in this way, grouping 
patients with similar characteristics together. The union of the two worst groups constituted 
the severe disease course outcome. The identified patients in the Nordic cohort were 
compared to the patients identified in the ReACCh-Out cohort. The percentage of patients 
with severe disease course, and their clinical characteristics were similar in both cohorts. 
External validation of the Canadian model was first done without fine-tuning, meaning that 
we tested the model exactly as it was published, and afterwards with fine-tuning. The fine-
tuning was done by re-estimating coefficients in 500 repeated random splits. For each random 
split, we used 75% of the cohort for training and 25% of the cohort for testing the model. 
Internal validation of the Nordic model for prediction of severe disease course was also 
 
 46 
performed. Uncertainty was measured by bootstrapping (resampling) and reported as the IQR. 
The results were presented with C-indices, equivalent to the area under the Receiver 
Operating Characteristic curve (AUC).  
 
In paper III, we performed validation of the Nordic model in the ReACCh-Out cohort. 
Missing information on baseline predictor variables were imputed by multiple imputation by 
chained equations (MICE) in 20 data sets.151 The Nordic prediction model (exactly as 
published in paper I) was applied to 100% of the data within each of 20 imputed datasets. The 
C-index and the standard error (SE) of the C-index were computed from each data set. The 
fine-tuned Nordic model, with re-estimated coefficients and intercept, was tested by multiple 
splits of the ReACCh-Out cohort. For a given imputed dataset, the average C-index was 
estimated using the Leave-One-Out Cross-Validation (LOOCV) error method. Standard errors 
were estimated by nested cross-validation bootstrapping with 25 bootstrap samples, with a 
total of 500 fits. The C-index and standard deviation (SD) of all predicted values were 
computed. 
 
 Cluster analysis  
We had to construct a version of severe disease course in the Nordic cohort. To do this we 
used four variables collected at the 8-year follow-up. These variables were the cumulative 
active joint count, the remission status, the Childhood Health Assessment Questionnaire 
disability index (CHAQ), and the Physical Summary Score (PhS) derived from the Child 
Health Questionnaire Parent form (CHQ-PF50). We used multiple imputation of missing data 
using a principal component algorithm. On the imputed and normalized data, we used the K-
means clustering algorithm to group patients. The K-means method groups observations, in 
this case, patients, so that each one belongs to the cluster whose mean is closest. This analysis 
was carried out in Wolfram Mathematica version 11.3.0.0.  
 
We decided to group the cohort into four clusters, the same number of clusters chosen by 
Guzman et al.77 The clinical characteristics of each of the four groups were analyzed using 
standard descriptive statistics. The result of this investigation clearly showed that two of the 
clusters were associated with more serious disease, which combined made up 22% of the 
cohort. We also considered an alternative construction of severe disease course that included 
pain VAS as a fifth variable. To make the relative size of this version correspond to those 
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found in the Canadian study, we used the K-medoids algorithm. This algorithm is similar to 
the K-means method except for the use of real observations (medoids) instead of means to 
represent the center of clusters.   
 
 Hierarchical clustering and heat-maps  
In paper IV, we used hierarchical clustering to make two heat maps to analyze uveitis in the 
Nordic JIA cohort. One heat map was to illustrate the association between predictors and 
complications. The other heat map to illustrate how complications are distributed between the 
different uveitis characteristics.  
 
The heat map for predictors and uveitis complications was constructed starting from a matrix 
where the horizontal position represented patients with uveitis. The vertical positions 
represented complications (glaucoma, cataract, synechiae, epiretinal membrane, hypotony, 
phthisis, macular edema, and band keratopathy). An entry in the matrix was assigned the 
value 0 if the given patient did not have the given complication. The value was 0.5 if the 
patient had the complication in one eye, and the value was 1 if the patient had the 
complication in both eyes. The agglomerative clustering algorithm was applied to patients and 
complications, and the rows and columns were reordered according to the hierarchical 
clustering. After the reordering, patients with similar complications were placed next to each 
other, and complications that were distributed similarly in the cohort were placed next to each 
other. The heat map was annotated with predictors.  
 
The second heat map was constructed in the same way. The aim was to illustrate uveitis 
characteristics according to SUN criteria, and we therefor clustered eyes instead of patients. 
Vertical positions represented different uveitis characteristics. The characteristics were 0 or 1 
variables, except for one variable which took three values (acute=1, recurrent=0.5, and 
chronic=0). After hierarchical clustering and reordering, the heat map was annotated with 
uveitis complications.    
 
5.6 Ethical approval 
Approvals from medical research ethics committees and data protection authorities were 
granted according to each participating country's regulations and in accordance with the 
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Declaration of Helsinki. Sweden; Dnr 2014/413-31, Denmark; 1-10-72-280-13, Norway; 
REK 2012/2051, and Finland; 174/13/03/03/2014. Written informed consent was obtained 
from parents of children aged <16 years and from the children themselves if aged ≥16 years 
of age.  
 
6 Summary of main results 
The main results from the four papers constituting the thesis are presented in this section. For 
further details see the published papers attached. 
 
6.1 Paper I 
Predicting unfavorable long-term outcome in juvenile idiopathic arthritis: results from the 
Nordic cohort study 
 
Study cohort 
• In the Nordic JIA cohort 423 patients were included after 17 patients with systemic 
JIA were excluded. The outcome was assessed eight years after disease onset. 
 
• Among the included patients, we had data for 410 of 423 (96.9%) for assessment of 
remission status, 340 of 423 (80.4%) for CHAQ scores, 199 of 423 (47.0%) for CHQ-
PF50 (PhS) scores, and 216 of 423 (51.1%) for JADI-A data at the 8-year follow-up. 
 
Predictor variables  
• We found moderate to strong correlations (Spearman correlation coefficients ≥ 0.50) 
between the cumulative active joint count, joint-specific variables, and polyarthritis 
RF-negative category. Moderate to strong correlations was also found between 
physician’s GA and PROMs. 
 
• Predictor variables significantly associated with non-achievement of remission off 
medication in univariate logistic regression were: higher cumulative active joint count, 
higher physician’s GA, polyarthrits RF-negative category, ankle joint arthritis, tarsal 
joint arthritis, subtalar joint arthritis, wrist joint arthritis, finger joint arthritis, upper 
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limb joint arthritis, symmetric ankle joint arthritis, symmetric finger joints arthritis, 
higher patients/parents GA, higher CHAQ-score, higher pain VAS, morning stiffness 
>15 min, higher ESR, CRP >10, and positive HLA B27. 
 
• The five selected a priori variables were: cumulative joint count within six months of 
JIA onset, ESR, CRP, morning stiffness and physician GA. 
 
Prediction of the main outcome non-achievement of remission off medication 
• 244 of 410 (59.5%) patients did not achieve remission off medication at the 8-year 
follow-up visit. 
 
• The multivariable logistic regression prediction model for prediction of non-
achievement of remission off medication eight years after JIA onset was given by 
Equation (1), with:  
A= −1.58 + 0.04 × (cumulative joint count within 6 months of onset) + 0.03 × (ESR 
mm/h) −0.07 × (CRP>10mg/L) + 1.16 × (morning stiffness >15 min) + 0.16 × 
(physician GA) + 1.25 × (ANA positive) + 1.37 × (HLA B27 positive) + 1.10 × (ankle 
joint arthritis) 
 
• The model predictive ability presented with AUC was 0.84 for the total cohort. In 
internal validation the AUC was 0.78 (IQR 0.72–0.82) for the model including 
laboratory parameters (ESR, CRP, ANA, and HLA B27). When we excluded the 
laboratory parameters, we achieved an AUC of 0.76 (IQR 0.72–0.80). 
 
Prediction of the functional disability and joint damage  
• 111 of 340 (32.7%) patients had functional disability defined as a CHAQ >0, and 40 
of 199 (20.1%) had functional disability defined as a PhS <40, at the 8-year follow-up 
visit. 
 




• The multivariable logistic regression model for prediction of CHAQ >0 included the 
following two variables in addition to the five a priori variables: finger joint arthritis 
(β6=1.21) and pain VAS (β7=0.77).  
 
• The model for predicting CHAQ >0 achieved an AUC of 0.79 for the total cohort. In 
internal validation the AUC was 0.73 (IQR 0.67–0.76). 
 
• The multivariable logistic regression model for prediction of PhS <40 included pain 
VAS (β6=1.30) in addition to the five a priori variables.  
 
• The model for predicting PhS <40 achieved an AUC of 0.90 for the total cohort. In 
internal validation the AUC was 0.74 (IQR 0.65–0.80). 
 
• The multivariable logistic regression model for prediction of JADI-A >0 included the 
following two variables in addition to the five a priori variables: finger joint arthritis 
(β6=1.84) and older age at disease onset (years) (β7=0.16). 
 
• The model for predicting JADI-A >0 achieved an AUC of 0.84 for the total cohort. In 
internal validation the AUC was 0.73 (IQR 0.63–0.76). 
 
Testing the Canadian prediction model on the Nordic outcomes 
• The Canadian model was applied directly as published77 on the children in the Nordic 
JIA cohort, and yielded an AUC of 0.69 to predict non-achievement of remission off 
medication. The AUCs were 0.68 for CHAQ >0, 0.69 for PhS <40, and 0.71 for JADI- 
A >0. 
 
6.2 Paper II 
Validation of prediction models of severe disease course and non-achievement of remission 







• In the Nordic JIA cohort 440 patients were included, also the patients with systemic 
JIA. The outcome was assessed eight years after the onset of JIA. 
 
• Our cluster analysis identified 98 of 440 (22%) as having a severe disease course in 
the Nordic validation cohort, compared to 125 of 609 (21%) identified by the cluster 
analysis in the ReACCh-Out development cohort. 
 
• 246 of 427 (58%) patients did not achieve remission off medication at the 8-year visit. 
 
• The patients identified to have a severe disease course had similar disease 
characteristics in the ReACCh-Out development cohort and the Nordic validation 
cohort. In general, the severe disease course in the Nordic cohort and the severe 
disease course in the ReACCh-Out cohort had the following similar characteristics: 
The patients were older at JIA onset, longer time from disease onset to diagnosis, they 
had higher cumulative affected joint count with the neck, finger joints, and ankle 
joints frequently affected, higher reports on pain and CHAQ scores, and a higher 
percentage used synthetic DMARDs at baseline in the severe disease course groups. 
 
Prediction model validation 
• External validation of the Canadian model (without fine-tuning) for predicting severe 
disease course (the Canadian outcome, constructed in the Nordic cohort) yielded an 
excellent predictive performance with a C-index of 0.85 (IQR 0.83-0.87).  
 
• When the model was fine-tuned to the Nordic patients by re-estimation of parameters, 
the predictive performance remained at the same level as without fine-tuning (C-index 
of 0.85 (IQR 0.81-0.89)). 
 
• The Canadian model did not achieve acceptable predictive performance when applied 
to predict non-achievement of remission off medication (the Nordic outcome) with a 
C-index of 0.66 (IQR 0.63-0.68). When the model was fine-tuned to the Nordic 




• The Nordic model (developed in paper I) performed excellently when applied to 
predict severe disease course (the Canadian outcome), which was not the outcome it 
was constructed to predict. The result was a C-index of 0.90 (IQR 0.86-0.92) in the 
Nordic cohort. 
 
6.3 Paper III  
Validation of prediction models of severe disease course and non-achievement of remission 
in juvenile idiopathic arthritis part 2: results of the Nordic model in the Canadian cohort 
 
Study cohort 
• In the ReACCh-Out cohort 513 patients were included, and the outcome was assessed 
at a mean of 3.75 years (3-year follow-up visit) after the onset of JIA. 
 
• 408 of 506 (81%) patients with data to assess remission status did not achieve 
remission off medication at the 3-year follow-up in the ReACCh-Out cohort. 
 
• 53 of 354 (15%) were identified to have a severe disease course at the 3-year follow-
up in the ReACCh-Out cohort. 
 
• 137 of 361 (38%) reported functional disability with a CHAQ >0 at the 3-year follow-
up in the ReACCh-Out cohort. 
 
• The patients who did not achieve remission off medication had similar characteristics 
in the Nordic development cohort and the ReACCh-Out validation cohort. The 
following characteristics were similar: Younger age at disease onset, both had the 
highest percentage from the RF-polyarthritis category, the active joint count was 
higher, ankle and finger joints frequently affected, the scores in PROMs and physician 







Prediction model validation 
• External validation of the Nordic model (without fine-tuning) for prediction of non-
achievement of remission off medication (the Nordic outcome, in the ReACCh-Out 
cohort) resulted in a lower C-index than in internal validation in the Nordic 
development cohort. In the external validation we found the C-index to be 0.68 (95% 
CI 0.62-0.74). Excluding patients with systemic JIA, as done in the Nordic 
development cohort, improved the predictive performance to a C-index of 0.73 (0.66-
0.80) i.e., an acceptable predictive ability. 
 
• When the Nordic model was fine-tuned to the Canadian patients, with re-estimation of 
coefficients, the predictive performance for non-achievement of remission off 
medication improved to a C-index of 0.74 (0.67-0.80), and 0.76 (0.69-0.83) if 
systemic JIA patients were excluded. The fine-tuned version with no laboratory 
parameters had a C-index of 0.74 (CI 0.67–0.81), which is the same predictive 
performance as with the laboratory parameters. This model has the advantage of being 
simpler. 
 
• The Nordic model applied to predict severe disease course (the Canadian outcome) 
yielded a C-index of 0.69 (CI 0.61-0.78) when applied directly, a C-index of 0.79 
(0.68-0.91) after fine-tuning, and a C-index of 0.79 (CI 0.69-0.89) without laboratory 
parameters. The fine-tuned Nordic model predicted well severe disease course, an 
outcome it originally was not developed to predict. 
 
• The Nordic prediction model for functional disability (CHAQ >0) did not achieve a C-
index >0.7 when tested in the ReACCh-Out cohort. 
 
6.4 Paper IV 
Uveitis in Juvenile Idiopathic Arthritis – 18-Year Outcome in the Population-based Nordic 
Cohort Study 
 
Study cohort, disease activity and treatment  
• In the Nordic JIA cohort, 434 patients with JIA were followed for 18 years. Of these, 
96 patients developed JIA-U. 
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• We found the cumulative incidence of uveitis to be 22.1%, and 2.8% developed 
uveitis late (between the 8-year and the 18-year follow-up). 
 
• The majority of patients with JIA-U had bilateral and anterior uveitis. Patients with 
JIA-U were significantly younger at JIA onset than the patients without uveitis. The 
median time from onset of JIA to the uveitis diagnosis was 1.6 years (IQR 0.4-5.0 
years). 
 
• At the 18-year follow-up visit, active uveitis was found in 24.4%. Active JIA disease 
was significantly higher among patients with JIA-U than those without uveitis. The 
percentage of patients in medication-free remission was lower among those with JIA-
U. 
 
• There was a significantly higher use of synthetic and biologic DMARDs among the 
patients with JIA-U over the 18-years period compared to the patients without uveitis. 
This difference was also present at the 18-year follow-up visit. At the visit, a 
significantly higher percentage of patients with JIA-U used synthetic and biologic 
DMARDs compared to the patients without uveitis. 
 
Ocular complications  
• One or more ocular complications was found in 31 of 80 (38.8%) examined patients 
with uveitis at the 18-year follow-up visit. The most frequent ocular complications 
were cataract and glaucoma. Among the 31 patients who developed complications, the 
majority did so during the first 8-years after uveitis onset.  
 
• Although the rate of ocular complications was relatively high, the visual acuity was 
good with binocular best-corrected visual acuity (BCVA) <6/12 in only 5.0% of the 
patients with JIA-U. 
 
Predictor variables associated with ocular complications 
• Onset of uveitis before JIA, a short interval between the onset of JIA and the diagnosis 
of uveitis, and the presence of ANA positivity are significant predictors associated 
with the development of ocular complications. The eight children diagnosed with 
 
 55 
uveitis before JIA developed cataract, and seven also glaucoma. These results 
emphasize the need for tight screening of uveitis and stepping up treatment early until 
inactive uveitis is achieved. 
 
7 Discussion 
The studies presented in this thesis provide new insight into the prediction of disease outcome 
in JIA, the challenges regarding disease outcome measures, and summarizes the long-term 
outcome in JIA-associated uveitis.  
 
Our Nordic prediction model uses easily available clinical variables and performed well in 
predicting non-achievement of remission off medication in both internal and external 
validation. We discovered that the model performed equally well without laboratory 
variables. This makes it possible to simplify the model even more, enabling it for clinical use. 
We externally validated the Canadian prediction model, yielding an excellent performance for 
predicting severe disease course outcome in the Nordic JIA cohort. We learned that the 
choice of outcome strongly influences the predictive ability of a model. Our simplified Nordic 
prediction model had an excellent predictive performance for the Canadian severe disease 
course outcome. In contrast, the Canadian model did not achieve acceptable predictive 
performance for non-achievement of remission. Hence, it is essential to define optimal, 
clinically relevant prediction outcomes, validated across different JIA cohorts, before 
individualized prediction can be generally recommended.  
 
Our uveitis study is, to our knowledge, the only population-based study following JIA-U 
patients prospectively for almost two decades. We found a high cumulative incidence of 
uveitis and ocular complications almost two decades after JIA onset. Our findings support 
most previous conclusions, especially that children who develop uveitis before JIA or near 
after, are at high risk of ocular complications. We also found that uveitis may develop several 
years after JIA onset. This finding raises important questions about how many years after 
disease onset regular eye screening is beneficial. The predictors associated with ocular 
complications in uveitis may serve as key variables in further efforts to develop prediction 
models for unfavorable outcome in JIA-associated uveitis. 
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7.1 General strengths and limitations  
The Nordic JIA cohort study is unique in JIA research because of the multicenter 
longitudinal, prospective population-based study design. The long follow-up time makes it 
suitable for assessment of long-term outcomes. The study has collected a broad range of 
demographic, clinical and patient-reported information throughout the study period. Validated 
outcome measures are used, and despite the long-follow up time, we had a low rate (15%) of 
patients lost to follow-up.51, 52, 60, 62, 69 
 
In addition to the study design and conductance, the model development study's main 
strengths in the Nordic cohort (paper I) are the use of validated outcome measures, the 
simplicity of the models, and the strict internal cross-validations. A strength of the two 
validation papers (paper II and III) is the use of the strict TRIPOD100 guidelines for 
performing external validations and critical evaluations of the models before 
recommendation. These studies are the first external validations published on prediction 
models in JIA. The uveitis paper (paper IV) is the only long-term prospective population-
based study on JIA-U, as far as we are aware of. However, differences in health care systems, 
socioeconomic conditions, and differences in the JIA cohorts, genetics, and ethnicity need to 
be kept in mind when generalizing the results. We have reliable ophthalmologic data for 83% 
of the patients with uveitis after almost two decades, and this represents a major strength of 
our study. The study was conducted using established criteria for the classification of JIA1, 
validated outcome measures and classification of uveitis according to the SUN criteria. This 
makes it possible to compare results with other cohorts.57 
 
One of several study limitations is that the baseline study visit took place six months after 
disease onset and was not necessarily the first clinical visit. Most likely many children with 
high disease activity had therefore already started treatment. When predictor variables were 
assessed at the study visit at approximately six months, the disease activity was most likely 
milder than at the first clinical visit. Also, the treatment at baseline and during the disease 
course may have altered the disease outcome. Treatment strategies have evolved rapidly. 
There is now earlier and more aggressive treatment strategies than in the beginning of the 
Nordic JIA study. Hence, it is not straightforward to make assumptions about the effects of 
treatment.4, 40, 43, 53 
 
 57 
For the uveitis paper (paper IV), a limitation is that we do not have information on the precise 
timepoints when patients started topical corticosteroids. We could therefore not assess the 
association between the use of topical steroids and uveitis-related complications. The exact 
time point for start of systemic treatment and whether this was treatment primary for uveitis 
or arthritis is also unknown. The study started at the beginning of the biologic era when early 
aggressive treatment strategies were not established. Compared to other studies, this may have 
caused a higher incidence of uveitis and accompanying complications.139, 146 Emerging 
research shows a significant reduction in uveitis occurrence coinciding with the increased use 
of synthetic and biologic DMARDs.146, 152 During the 18-year follow-up in our cohort, we 
saw a significant increase in the use of these drugs. At approximately 12 months after onset of 
JIA, 36.7% of the cohort used synthetic DMARDs, while only 1.8% used biologic DMARDs. 
During the total period of 18 years, 60% had used synthetic DMARDs, and 30% had used 
biologics at some point.61 
 
The primary outcome in paper I, non-achievement of remission off medication, is defined as 
inactive disease for more than 12 months and does not necessarily reflect the disease course 
during the whole study period. Between the eight and the 18-year follow-up we have ten years 
without study data. For instance, the exact time points for development of uveitis-associated 
complications and alterations in treatment are not reported. Another issue is the chosen cut-off 
thresholds used for the secondary outcomes in paper I (CHAQ >0, PhS <40 and JADI-E >0). 
Results may have been different if we used a higher cut-off for significant functional 
disability and joint damage. It is also possible that this would have given better predictive 
abilities. Missing information was another limitation of the secondary outcomes, with 
possible implications for predictive performance.  
 
There were few patients with systemic JIA, RF-positive polyarthritis and psoriatic arthritis. 
This was one of the reasons why we excluded the systemic JIA patients from the model 
development study (paper I). Another reason is the very different clinical features of this 
category. By removing the systemic JIA, we were trying to make the cohort more 
homogenous. There is still considerable diversity among the other categories, and perhaps 
different models are needed for different categories. Such a study will be difficult to perform 
because of the need for a very large cohort. Otherwise, the sample size when assessing 
subgroups of JIA will be too small. We have also previously shown in the Nordic JIA cohort 
that categories may change during disease course for individual patients.148 The small number 
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of patients with RF positive polyarthritis may have caused this category not to enter the model 
as a predictor variable through the model-building procedure. On the other hand, with 
increased sample size, the category would most likely correlate strongly with the cumulative 
active joint count and would have been removed regardless. In the validation studies (paper II 
and III), the distribution of categories within the severe disease course cluster differed 
somewhat between the Canadian and Nordic constructions. Compared to the Canadian cohort, 
the Nordic cohort had fewer with RF-positive polyarthritis and systemic JIA. 
 
7.2 Methodological considerations 
 Study design and the population-based approach  
The NoSPeR researchers decided to conduct a population-based, prospective longitudinal JIA 
cohort study. This design was chosen with the purpose of collecting the whole range of 
disease severity and explore the characteristics of the disease course. The Nordic JIA cohort 
provides a unique possibility to identify associations between baseline predictors and 
outcomes in JIA, and assess the long term-outcomes from child to adulthood. 
 
Population-based studies capture the full disease spectrum, from mild oligoarthritis cases to 
severe polyarticular or systemic JIA. The feasibility of conducting a population-based study is 
rare in most parts of the world. In the Nordic countries, all health care systems for children 
are free of charge, and a broad range of measures was taken to strive for a population-based 
study. During the inclusion period, letters were repeatedly sent to primary healthcare 
providers, child health centers, orthopedic, pediatric, and rheumatology specialists in the 
catchment areas to ensure all eligible patients' referral.148 Nevertheless, there is a risk of 
missing children with JIA due to undiagnosed or misdiagnosed patients, not referring eligible 
patients, referral to other than the participating centers’ and children/parent’s own decision 
not to participate. In the way the Nordic health care system is organized, most children with a 
longstanding arthritis will be referred from the primary health care to the pediatric 
rheumatologist. The study centers also had the primary responsibility for diagnosing and 
treating all children with suspected rheumatic diseases in their catchment area. Only three 
individuals declined to participate in the study, and only 12 did not want to participate further 
at some point in the follow-up study.  
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The advantage of a population-based study is the possibility of generalization of results. The 
estimated incidences and prevalence of the disease are thought to be representative for the 
region. When the study population is followed longitudinally, it is suitable for assessment of 
the relationship between exposure or predictors and the postulated outcome.153, 154  
 
Several studies on JIA are registry-based or tertiary center studies. Most prospective studies in 
JIA have few years of follow-up time. Tertiary-center-based studies and cross-sectional 
assessments may underreport the milder forms of JIA, while the more severely affected 
patients may be overrepresented. This may not give a realistic picture of the distribution of 
JIA categories and disease course in the population. 
 
Different study designs and follow-up times may make the comparison of results across 
different studies challenging, or even wrong. The use of different outcomes can also affect the 
possibility of comparison. Direct comparison across studies is hampered when validated 
outcome measures are not used.  
 
 Lost to follow-up and follow-up by telephone interview 
During the observation period of 18 years, 15% of the participants were lost to follow-up. The 
loss to follow-up in our long-term study is low compared to others.60, 155 After such a long 
follow-up time, those who did not attend the visit may be the ones that have been in remission 
for a long time. We found no significant differences in age at onset, gender, JIA category, and 
number of active joints among the patients lost to follow-up and the patients still included. 
Five patients with uveitis were lost to follow-up between the 8-year and the 18-year visit.  
 
Some of the patients included in the study participated only through a telephone interview. 
This rate was 14.5% at the 8-year follow-up and 24.2% at the 18-year follow-up. Among the 
patients who participated through a telephone interview at the 18-year follow-up we had 
access to medical records for 91%. The medical records were used to check unclear issues or 
missing responses. At the 18-year follow-up, 10 of 96 patients with JIA-U participated 
through the telephone interview. Data collected per telephone are not as robust as the data 
collected at clinical visits. For the results on JIA and uveitis disease activity, only patients 
attending a visit at the pediatric rheumatologist and ophthalmologist were included. 
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 Data quality and handling 
In the Nordic JIA cohort, the collected data were plotted into the data bases 4th dimension up 
to the 8-year visit, and SurveyXact for the 18-year visit. In case of missing data or any 
inconsistencies, we cross-checked by asking the physician that examined the patients. We also 
had the possibility of cross-checking the medical records in the vast majority of cases. Data 
were then exported via Excel to the researchers’ preferred statistical package. 
 
 Considerations concerning prediction model development  
Due to past evidence of poor quality of reporting in prediction model studies in medicine, the 
TRIPOD initiative developed a recommendations for studies developing, validating, and 
updating prediction models.100 We have followed these recommendations.  
 
In the model-building part there is a sequence of choices to be made. In paper I we decided to 
include five predefined key variables (the cumulative active joint count, ESR, CRP, 
physician's GA, and morning stiffness) before entering additional predictor variables. This 
choice was based on clinical judgment and criteria for defining inactive disease and clinical 
remission.51, 52 Studies have shown that the same child can be classified as either having 
active disease or inactive disease depending on which set of criteria is used.58 At the moment 
there are no recommendations for optimal treat-to-target strategies, and therefore no 
established outcome for assessing this strategy. 52, 58, 66, 156 Besides the a priori variables 
mentioned above, additional variables were included by the model-building procedure. For 
the main outcome, non-achievement of remission, the additional predictor variables were 
ankle joint arthritis, HLA B27, and ANA. 
 
In the process of building a logistic regression model, several clinical variables are usually 
screened as potential predictor variables. In this process, there is a risk of selecting 
uninformative predictors and overfitting the model. One measure to avoid overfitting a model 
is performing internal cross-validation by randomly splitting the cohort into a development 
cohort and a validation cohort. This was done for both the Nordic and the Canadian models in 
their respective development cohorts. Both models performed well in internal cross-
validations. This approach may be problematic if there is a small sample size or limited data, 
in which case one risks a lack of power in each set.157-159 An alternative method is to split the 
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data into time-periods so that development and testing of the model can be done for different 
time points. This strategy could be a more robust way of evaluating model performance when 
sample sizes are limited and the same cohort is used.160, 161  
 
It is not easy to compare our modelling results in JIA with other studies because there are 
sparse reports on this topic in JIA research. Most of the prediction-modeling studies in JIA 
have focused on response/non-response to methotrexate treatment.80, 86, 90 The most relevant 
comparison is with the model of Guzman et al. which performed excellently for severe 
disease course in internal and external validation.77 The Canadian prediction model contains 
16 predictor variables. The combination of a specific data-driven constructed outcome 
together with many predictor variables may have caused overestimation of the predictive 
ability in internal validation.77, 79, 86 The performance was lower for the other unfavorable 
outcomes; non-achievement of remission off medication, CHAQ >0, PhS <40, and JADI-A >0 
(paper I and paper II). In contrast, the Nordic model performed well when applied to the 
Canadian outcome severe disease course (paper II and III) but had a lower predictive ability 
for non-achievement of remission in external validation. This lower predictive ability may be 
due to the distribution of this outcome, which is almost half and half (favorable versus 
unfavorable outcome). The proportion of Nordic children that did not obtain remission off 
medication was 59.5% at the 8-year follow-up visit. Non-remission is more difficult to predict 
compared to the outcome severe disease course which identifies a more distinct group, 
namely the 20% of patients with the most severe illness.  
 
 Construction of the severe disease course outcome 
One of the methodological challenges in paper II was to define an outcome in the Nordic 
cohort that corresponded to what Guzman et al. had termed severe disease course. This 
outcome is not based on distinct predefined criteria, and it was not obvious how to decide 
which children in the Nordic cohort should be included in this group. One approach could 
have been to specify a set of objective criteria to apply in the Nordic cohort. These criteria 
would have had to be tuned so that the clinical characteristics were consistent with the 
Canadian cohort's severe disease course group. We used the alternative approach of a data-




In the Canadian cohort, Guzman et al. formed four different disease courses using a clustering 
algorithm based on the following variables: participant-defined quality of life and pain reports 
(both assessed on a 10-cm VAS), active joint count, medication requirements, and medication 
side effects. The severe disease course was the union of the two worst groups, severe 
controlled course and severe persistent course.77 We decided to construct clusters of patients 
based on four variables collected at the 8-year follow-up in the Nordic cohort. The four 
variables used were the cumulative active joint count, remission status, CHAQ, and the PhS 
derived from the CHQ- PF50. The reason for choosing different variables for cluster analysis 
was that we did not have Nordic data on the same variables used in the Canadian cohort. 
Different clinical characteristics may, however, identify the same group of patients, those 
with the highest disease burden. In the Nordic cohort, 22% were identified as having a severe 
disease course. This percentage was 21% in the Canadian cohort. We analyzed 440 patients, 
and after imputation, we had 1760 data points. The Canadian study used five variables with 
values from at least 6 of 8 visits for 609 patients, which gave 24 360 data points. The main 
difference in the construction was that Guzman et al. used data collected from at least six 
visits and we used only the 8-year visit. The Canadian construction may better identify 
temporal structure in the disease trajectories, but this has not been seen in the results. Missing 
data were imputed for the outcome variables. The results were the same with and without 
imputation suggesting that imputation was not a source of bias. 
 
Guzman et al. compared several different clustering algorithms (K-Means, K-Medoids, 
Agglomerative Clustering, and Divisive clustering) to consider the different choices for the 
number of clusters to construct. The constructions were compared with silhouette values and 
R2. They also carried out a stability analysis for their clusters. In the Nordic cohort, this 
analysis was not relevant since our aim was not to demonstrate the existence of clusters but 
rather to replicate the severe disease course group found in the Canadian cohort in order to 
test prediction models for this outcome. We deliberately made a series of choices to achieve 




7.3 Clinical implications of the results 
 Prediction of unfavorable disease outcome in JIA  
Previous assumptions that JIA is a disease that the child would outgrow are not accurate. The 
course of JIA is often chronic with fluctuating disease activity.76, 162, 163 In the Nordic cohort 
at the 8-year follow-up 40.5% were in remission without the use of medication, and at the 18-
year follow-up remission off medication was seen in 32.8% of the patients.61, 148 Since the 
clinical heterogeneity is considerable, predicting disease course and outcome is challenging.78 
 
In recent years, the implementation of prediction models in medicine has been of great 
interest with the goals of cost-effective treatment strategies, informed decision-making, and 
improved patient outcomes.164, 165 Currently, there are no clinical established used statistical 
prediction models in JIA. As a result of the treat-to-target treatment strategy and the concept 
of “window of opportunity” there is an increased interest in prediction models to identify 
children with a high probability of an unfavorable outcome.3, 5, 36-39 Prediction of the long-
term outcome based on early clinical characteristics and robust disease activity measures 
would be especially beneficial in JIA. By feeding models with early clinical characteristics, 
physicians may receive objective probability-based assessments to aid treatment decisions. 
The aim was therefore to develop rules to predict long-term unfavorable outcomes to guide 
early treatment decisions in children with JIA onset. In the Nordic cohort we developed four 
prediction models (paper I). The four models all achieved AUCs >0.7, which is considered 
helpful in prediction.104  
 
To generalize the use of prediction models, we need to validate the model in an independent 
cohort and report details on the development and validation so that other research groups can 
replicate and verify the results.157 External validation of the Canadian model applied precisely 
as published in the Nordic cohort (paper II), yielded a C-index of 0.85 (IQR 0.83–0.87) for 
prediction of severe disease course and a C-index of 0.66 (0.63–0.68) for prediction of non-
achievement of remission. The performance was slightly better for prediction of non-
achievement of remission after fine-tuning, with a median C-index of 0.69 (0.65–0.73. The 
Nordic model performed excellently with a median C-index of 0.90 (0.86–0.92) for severe 




The purpose of paper III was to externally validate the Nordic prediction models in Canadian 
patients with JIA to predict the main outcome non-achievement of remission, severe disease 
course, and CHAQ >0. The Nordic models were evaluated as published and after fine-tuning 
of coefficients. The fine-tuned Nordic model without the blood tests (active joint count, 
physician global assessment of disease activity, morning stiffness, and ankle involvement) 
predicted well non-achievement of remission and severe disease course in Canadian patients 
with C-indices of 0.74 (0.67–0.80) and 0.79 (0.68–0.91), respectively. A possible reason for 
this effect was the shorter follow-up time in the Canadian cohort. The last study visit was 
approximately three years after inclusion in order to have sufficient outcome data, which is 
significantly earlier than the eight years follow-up in the Nordic cohort. Fewer patients have 
probably achieved remission off medication at three years than at eight years after onset. In 
time, the percentage of patients achieving remission off medication tend to increase, 
compared to early in the disease course where fluctuating disease activity is more common.61, 
163 60, 166 This may have contributed to the Nordic prediction model's reduced predictive 
performance for non-remission off medication in Canadian patients.  
 
Surprisingly, the Nordic model performed better in predicting the Canadian outcome severe 
disease course. This result is consistent with our findings in paper II and further highlights 
the importance of the outcome in prediction studies. Which outcome one aims to predict will 
likely influence the overall accuracy and the predictive performance.149, 150 It is possible to 
construct a data-driven outcome for which we can obtain excellent prediction performance. 
Still, if this outcome is difficult to replicate in other JIA populations, the purpose of the model 
vanishes, and the research becomes technical and non-applicable in clinical practice. Hence, 
the outcome needs to be standardized and easy to replicate across studies and populations.  
 
In assessing disease activity and remission status, it may be better to predict an overall course 
of JIA, at least for an estimated period, rather than the outcome at a single point in time. We 
should be cautious in screening too many predictor variables, and we should carefully assess 
the dependency among them. For instance, the dependence among clinical characteristics of 
disease activity, such as the number of active joints, the physician’s GA, the parent/patient 
GA, CHAQ score, and joint involvement patterns may lead to confounding bias. Involvement 
of specific joints may also have a relationship with the outcome, e.g., finger joints are more 
frequently affected in the polyarticular categories, which is known to be associated with a 




A good prediction model should be simple and have sufficient predictive accuracy for clinical 
purposes.100 The exclusion of ESR, CRP, ANA, and HLA B27 had a negligible impact on the 
Nordic model accuracy both in internal validation (paper II) and external validation (paper 
III). This result is very interesting and comparable to results on clinical JADAS, where 
removing acute phase reactants in JADAS (clinical JADAS) did not reduce the accuracy in 
identifying patients with similar disease activity.167, 168  
 
Our findings indicate that the Nordic prediction model without blood tests and the data-driven 
outcome severe disease course outcome could be an optimal combination obtaining an 
excellent predictive performance while keeping the model simple to use. The challenge 
remains to identify a proxy for severe disease course based on already established validated 
outcome measures in JIA to facilitate comparison and validation across different cohorts. 
 
 Long-term outcome in uveitis - what have we learned? 
The current prevalence of uveitis, ocular complications and visual impairment seems to have 
decreased compared to earlier reports.111, 139, 146, 152 This may be due to a combination of tight 
screening programs, and more aggressive early treat-to-target strategies in JIA. Early stepping 
up treatment to synthetic and biologic DMARDs seems to prevent development of uveitis and 
complications.145-147, 169  
 
In paper IV we found a high cumulative incidence of uveitis and uveitis-related complications 
18-years after onset of JIA.115 One possible reason for this finding is the study design, with 
prospective long-term follow-up capturing more uveitis cases and development of ocular 
complications. Another reason for the higher prevalence of uveitis in the Nordic countries 
may be the genetic background. Through the years, studies in the Nordic countries have 
reported a higher incidence of uveitis compared to other populations. Inherent genetic risk for 
developing uveitis may contribute to the higher incidences in these countries.11, 105, 106, 108, 112, 
113, 132 Another factor is the that the study began very early in the biologic era. In our study, 
26% of the children with uveitis were treated with synthetic DMARDs approximately six 
months after onset of JIA. This rate increased to 53% up to the 1-year visit, and 75% up to the 
8-year visit. None of the patients with JIA-U used biologic DMARDs at the six months visit. 
Eight were treated with biologic DMARDs at the 1-year visit, of whom three were diagnosed 
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with uveitis before JIA.41 Timely start of systemic treatment may reduce the risk of 
complications. In a recent German study with two years follow-up, they found a significant 
reduced risk of developing uveitis in 1 year among children with JIA that were treated with 
methotrexate, or TNF inhibitors, or a combination of both.152 Tappeiner et al. also showed in 
another large German study a reduction in uveitis point prevalence between 2002 and 2013. 
The majority of children develop their uveitis within the first 4 years after onset of JIA.107 In 
our study we found that children developing uveitis before or near after the onset of JIA had 
increased risk of ocular complications.115, 135, 137 These results emphasize the need for early 
treatment strategies. 
 
After the year 2000 the reported proportion of uveitis related complications have been in the 
range 25-50%.133, 145, 170 In our study, we found that 38.8% of the patients had ocular 
complications 18 years after the onset of JIA. This is in the higher end of the range of what 
has been previously reported. The findings may have severe implications for the young adults 
in our study (median age at visit of 22 years). Since JIA-U is mostly asymptomatic and the 
start of early treatment may prevent complications, early and frequent ophthalmologic 
screening is important. Several screening guidelines have been published and modified 
throughout the years.114, 116, 123, 171 In 2019, The ACR foundation published recommendations 
for screening of children with JIA and management and treatment of established uveitis in 
JIA.41 Both the uveitis inflammation and corticosteroid treatment can lead to ocular 
complications, and the consequence may be visual impairment. The rate of visual impairment 
in JIA-U varies but is often reported between 10-20%.133, 170 In our cohort, 5% had BCVA 
<6/12, which is comparable to the study by Carvounis et al.111 who found a bilateral VA 
<20/40 in 9% of the patients with JIA-U. Skarin et al. performed a retrospective 24-year study 
in the pre-biologic era. In their JIA cohort, 16% developed uveitis. Among the JIA-U patients, 
51% had cataract, and 22% glaucoma after 24 years.135 In our prospective study, 31% 
developed cataract and 28% glaucoma after 18 years of follow-up. Cataract, glaucoma, and 
synechiae were the most common ocular complications. This result is in line with other 
studies.135 
 
How do we know which children are at high risk of uveitis, and when should these children 
start synthetic DMARDs? We have previously published a study on predictors for the 
development of uveitis,112 and in line with several other studies, we found that young age at 
JIA onset, and the presence of Hep2-ANA were predictors of chronic uveitis.107, 114 In the 
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current study we analyzed predictors for developing ocular complications in children with 
uveitis. We found that short duration between the onset of JIA and the diagnosis of uveitis 
was a predictor for developing ocular complications, together with a diagnosis of uveitis 
before the onset of JIA. Presence of Hep2-ANA was also associated with developing one or 
more complications. In 2019, Heiligenhaus et al. found that older age at JIA onset, short 
interval between JIA and the onset of uveitis, higher anterior chamber cell grades, poor visual 
acuity, and the use of topical corticosteroid at first documentation of uveitis were associated 
with uveitis-related complications. In contrast, JIA onset after the age of five years, no use of 
topical corticosteroids, and adalimumab treatment were associated with inactive uveitis for at 
least 6 months.138 A recent study presenting a multivariable prediction model for estimating 
the probability of developing uveitis in children with JIA. The model achieved a median AUC 
of 0.75 after internal validation. The prediction model used the following predictor variables: 
age at JIA onset, JIA category and ANA positivity.172 Haasnoot et al published in 2019 a 
review regarding biomarkers measured at JIA-onset. The purpose was to identify biomarkers 
with potential for prediction of uveitis in order to develop clinical prediction tools for 
improving early diagnosis of uveitis and aid treatment decisions. Among the possible 
biomarkers were: ESR, S100A12 protein, HLA-DRB1-YST-motif, and ANA. The predictive 
ability to identify children with high risk of uveitis should be tested with both internal and 
external validation.92 This may be done in long-term prospective studies. We are not aware of 
studies reporting on prediction models for uveitis-related ocular complications. 
 
8 Concluding remarks 
This thesis provides new knowledge on prediction modeling in JIA, and new insight into the 
long-term consequences of uveitis in JIA. 
 
• We have demonstrated that it is possible to develop models for prediction of long-term 
unfavorable outcome in JIA based on early clinical predictors. The prediction models 
have acceptable performance and require only easily available baseline variables. The 
models are easy to use as online calculators or a mobile device (iOS), and may be 
valuable tools to aid early treatment decisions after validation in other JIA cohorts. 
 
• Based on clinical characteristics from the baseline visit, approximately six months 
after JIA onset we can calculate a probability of not achieving remission off 
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medication eight years ahead in time. This probability score can support decisions of 
when to start or step-up treatment. 
 
• Outcomes and predictors need to be carefully assessed in model construction. The 
work presented in this thesis suggests that we should aim for simple models and 
validated outcomes. 
 
• We found an excellent predictive performance of the Canadian model (median C-
index of 0.85) for severe disease course when externally validated in the Nordic JIA 
cohort. The Nordic model also achieved an excellent performance in predicting severe 
disease course, with a C-index of 0.90 in internal validation. 
 
• The Nordic model performed well in predicting non-achievement of remission off 
medication (median C-index of 0.73) when externally validated in the Canadian cohort 
(excluding systemic JIA). 
 
• The fine-tuned Nordic model predicted well non-achievement of remission off 
medication (median C-index 0.76) and severe disease course (median C-index 0.79) 
when externally validated in Canadian patients with JIA (excluding systemic JIA). 
The simple model, without laboratory parameters, combining active joint count, 
physician´s GA, morning stiffness and ankle involvement, preformed just as well as 
the model with laboratory parameters. 
 
• In all tests the C-indices for prediction of severe disease course were higher than for 
non-achievement of remission off medication. This shows that prediction of long-term 
remission is more challenging than prediction of severe disease course. 
  
• We identified some key points after performing the validation studies:  
 
1. The choice of outcome to be predicted is essential for predictive performance, 
and perhaps more important than model design. It is easier to predict a severe 




2. Data-driven outcomes may be highly valuable. However, remission according 
to the 2004 Wallace criteria, and the revised 2011 ACR criteria, for inactive 
disease are validated outcome measures, and hence more accessible for use and 
evaluation in other cohorts. 
 
3. In prediction studies the outcome needs to be practical for clinical use. 
Therefore, identifying a clinical useful validated prediction outcome is an 
important future task. 
 
4. Prediction models based on a few key variables may have similar predictive 
ability as more complex models. Carefully evaluating the predictors is 
necessary for satisfactory model development. 
 
• We found a high cumulative incidence of uveitis in the Nordic JIA cohort. A 
considerable proportion of patients with JIA-U that develop sight-threatening 
complications in young adulthood. Close interdisciplinary collaborations between 
pediatric rheumatologists and ophthalmologist are necessary in order to start early 
synthetic and or biologic DMARDs in patients with high risk of complications. 
 
• Predictors associated with the development of uveitis-related ocular complications are: 
onset of uveitis before JIA or closely after the onset of JIA, and ANA positivity.  
 
• Our study underlines the importance of immediate and frequent screening by an 
ophthalmologist if JIA is suspected or confirmed. In addition, we recommend 
increased awareness in young adults with JIA based on our finding of asymptomatic 
late-onset uveitis. 
 
9 Futures perspectives 
• Future studies should focus on determining improved clinical disease-outcome 
definitions in JIA to facilitate more accurate validation across cohorts. A treat-to-
target strategy requires validated outcome measures. These outcomes should 
preferably not be data-driven, but if data-driven outcomes are necessary, they must be 




• Future work will aim to further simplify prediction models making them easier to use 
in clinical practice.  
 
• We need to identify an objective clinical definition of a severe disease course. In that 
context, explore whether JADAS scores early in the disease are a robust measure to 
identify patients with a high probability of severe disease course. 
 
• Once improved outcomes and models are in place, we can test models in a third and 
independent cohort. The ultimate step in assessing of whether prediction models 
improve outcome in JIA or not is a randomized controlled trial.  
 
• Our future work will also aim to develop prediction models for severe uveitis. This 
will enable targeted screening and treatment strategies adapted to high-risk subgroups. 
 
• We also plan to describe predictors associated with active uveitis and early 
development of ocular complications in a recent Norwegian 2-year prospective 
follow-up cohort. We will compare incidence of uveitis in this cohort with our long-
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Abstract
Background: The aim was to develop prediction rules that may guide early treatment decisions based on baseline
clinical predictors of long-term unfavorable outcome in juvenile idiopathic arthritis (JIA).
Methods: In the Nordic JIA cohort, we assessed baseline disease characteristics as predictors of the following outcomes
8 years after disease onset. Non-achievement of remission off medication according to the preliminary Wallace criteria,
functional disability assessed by Childhood Health Assessment Questionnaire (CHAQ) and Physical Summary Score (PhS)
of the Child Health Questionnaire, and articular damage assessed by the Juvenile Arthritis Damage Index-Articular (JADI-
A). Multivariable models were constructed, and cross-validations were performed by repeated partitioning of the cohort
into training sets for developing prediction models and validation sets to test predictive ability.
Results: The total cohort constituted 423 children. Remission status was available in 410 children: 244 (59.5%) of these did
not achieve remission off medication at the final study visit. Functional disability was present in 111/340 (32.7%) children
assessed by CHAQ and 40/199 (20.1%) by PhS, and joint damage was found in 29/216 (13.4%). Model performance was
acceptable for making predictions of long-term outcome. In validation sets, the area under the curves (AUCs) in the
receiver operating characteristic (ROC) curves were 0.78 (IQR 0.72–0.82) for non-achievement of remission off medication,
0.73 (IQR 0.67–0.76) for functional disability assessed by CHAQ, 0.74 (IQR 0.65–0.80) for functional disability assessed by
PhS, and 0.73 (IQR 0.63–0.76) for joint damage using JADI-A.
Conclusion: The feasibility of making long-term predictions of JIA outcome based on early clinical assessment is
demonstrated. The prediction models have acceptable precision and require only readily available baseline variables.
Further testing in other cohorts is warranted.
Keywords: Juvenile idiopathic arthritis, Disease activity, Prediction, Outcome research
Background
Juvenile idiopathic arthritis (JIA) is a heterogeneous child-
hood disease, with chronic joint inflammation as the com-
mon feature. The JIA categories differ by the number of
joints affected, and the presence of extra-articular involve-
ment [1]. Disease course and prognosis differ between JIA
categories, but there is also large variability within each
category [2, 3]. Therefore, efforts have been made to discern
baseline clinical prognostic factors that can predict the se-
verity, course, and long-term outcome of the disease [4, 5].
The primary goal of JIA treatment is to achieve remission
[6]. Early prediction of the disease course for the individual
child can facilitate tailored treatment. There is increasing
evidence for the concept of “the window of therapeutic op-
portunity” in JIA, where early aggressive treatment with bio-
logic agents and/or other disease-modifying anti-rheumatic
drugs (DMARDs) may modify the disease course and im-
prove long-term prognosis [7–9]. On the other hand, it is
* Correspondence: veronika.rypdal@unn.no
1Department of Pediatrics, University Hospital of North Norway, Tromsø,
Norway
2Department of Clinical Medicine, UIT the Arctic University of Norway,
Tromsø, Norway
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rypdal et al. Arthritis Research & Therapy  (2018) 20:91 
https://doi.org/10.1186/s13075-018-1571-6
also essential to avoid unnecessary, costly, and potentially
toxic treatment in children with a favorable prognosis.
Guzman et al. have recently presented a model for
prediction of severe disease course, with outcomes de-
veloped specifically for their study [10]. In a systematic
literature review, Dijkhuizen and Wulffraat state the
need for prospective longitudinal studies of baseline
clinical predictors using standardized validated outcome
measures [4]. In the Nordic JIA cohort, we studied pre-
diction of four established and validated outcomes, and
aimed to construct prediction models that may aid deci-
sion on early aggressive treatment.
Methods
Study population
The initial prospective longitudinal multicenter Nordic
JIA cohort consisted of consecutive children with inci-
dent JIA from 12 participating centers in defined geo-
graphical areas of Denmark, Finland, Norway and
Sweden. All children in these areas with newly diag-
nosed JIA and disease onset in the study periods be-
tween 1 January 1997 and 30 June 2000 were included.
The study was designed to be as close to population-
based as possible, as previously reported [11].
In the current study, 440 children met the criteria of
having a baseline study visit and a final study visit 8 years
after disease onset. Out of these, 17 patients with sys-
temic JIA were excluded, because systemic JIA is consid-
ered to have autoinflammatory rather than autoimmune
disease mechanisms, and the clinical characteristics of
predominantly fever, rash and serositis differs from other
JIA-categories [12].
The baseline study visit was planned 6 months after dis-
ease onset. At this visit, disease activity variables, complete
joint count, physician’s global assessment of disease activ-
ity (physician’s GA) on a 10-cm visual analogue scale
(VAS), patient’s/parent’s global assessment (GA), medica-
tion and blood tests were registered [13]. Disease onset
was defined as the time of presentation of symptoms of
active arthritis, and the JIA categories were determined ac-
cording to the International League of Associations for
Rheumatology (ILAR) criteria [14].
Outcomes
At follow up, we evaluated 4 outcomes: (1) the main
outcome was non-achievement of remission off medica-
tion, chosen as the best available validated measure of
an adverse disease state over time. This included active
disease, inactive disease of less than 12 months of dur-
ation, and clinical remission on medication (according
to the preliminary Wallace criteria) [15, 16]. For the re-
mainder of the paper, not in remission or non-
achievement of remission refers to non-achievement of
remission off medication unless otherwise specified; (2)
and (3) functional disability was evaluated using the
Childhood Health Assessment Questionnaire (CHAQ),
and the Child Health Questionnaire Parent form (CHQ-
PF50), aiming to achieve a broad evaluation of functional
disability using both the JIA-specific CHAQ and the
generic CHQ-PF50 instruments. CHAQ addresses func-
tional ability in different activities of everyday life [17].
The CHAQ was completed by children of age >9 years,
and otherwise by their parents, and the corresponding
Health Assessment Questionnaire (HAQ) by participants
> 18 years of age. From this point on in the text, CHAQ
will refer to both the CHAQ and HAQ scores. The
CHQ-PF50 consists of 50 items and 12 domains asses-
sing health-related quality of life, yielding a physical
summary score (PhS) and a psychological summary
score (PsS) [17]. PhS ranges from 0 to 100, with a higher
score indicating better functional ability; and (4) joint
damage was assessed using the Juvenile Arthritis Dam-
age Index of articular damage (JADI-A) ranging from 0
to a maximum of 72, where 36 joints, or joint groups,
are scored 0 for no damage, 1 for partial damage, or 2
for severe damage [18]. All 4 outcomes were dichoto-
mized; remission was dichotomized into clinical remis-
sion (those achieving remission without medication),
and non-achievement of remission off medication (those
not achieving remission or achieving remission on medi-
cation), CHAQ and JADI-A into score = 0, indicating no
functional disability or no joint damage, and positive
score >0, PhS into good functional ability, defined as
score ≥40, and functional disability <40. This latter cut-
off level is based on a reference score of 40 being one
standard deviation below the mean score of healthy chil-
dren in the USA [19].
Laboratory tests
Antinuclear antibodies (ANA) and rheumatoid factor
(RF) were tested at least twice with a minimum of 3
months apart. ANA was analyzed by immunofluores-
cence on Hep-2 cells. Tests were interpreted accord-
ing to cutoff values of the local immunological
laboratories. HLA-B27 was analyzed using standard-
ized methods [20]. C-reactive protein (CRP) was mea-
sured with immunoassays, with values <10 mg/L
considered normal.
Statistics
Conventional descriptive statistics (absolute numbers,
median, 1st and 3rd quartile, and percentage) were
used to describe demographics and clinical character-
istics. Univariate logistic regression was performed to
assess baseline variables as predictors for each out-
come. Variables that were significant at p < 0.05 in the
univariate analysis were considered as candidates in a
prediction model.
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For each outcome, multivariable logistic regression
models were constructed using a combination of prede-
fined core variables, and additional variables selected using
a forward stepwise selection method. Since the predictive
ability of the models is assessed using cross-validation, the
conventional limitations related to the screening of a large
number of covariates in multivariable models are evaded
[21]. Cross-validation controlled for overfitting of the data
(internal validation), and the degree of overfitting is
reflected in the performance in validation sets.
Clinical characteristics included in the Wallace
provisional criteria for remission were a priori included in
the prediction models; the cumulative active joint count,
erythrocyte sedimentation rate (ESR), CRP, physician’s GA,
and morning stiffness [22]. Uveitis activity applies only to a
minority of the cohort and was therefore not included. The
additional baseline variables were included in a stepwise
fashion if they contributed to the multivariable model with
p < 0.05 when included. Symmetric joint involvement was
not considered a candidate predictor as it correlates
strongly with the specific joint involvement (Fig. 1). To en-
sure model simplicity the total number of variables was not
allowed to exceed 10. Once the set of variables were se-
lected, the model coefficients βi for each predictor variable
xi were estimated using multivariable logistic regression,
and the probability of unfavorable outcome was given as:
P ¼ 1= 1þ e−A
! "
;where A ¼ β0 þ β1x1 þ…þ βnxn:
For each of the four outcomes, cross-validation of the
method was performed by partitioning the cohort ran-
domly in training sets consisting of three quarters of the
patients (N = 317) and validation sets consisting of one
quarter of the patients (N = 106). In each realization of
the random partitioning we constructed prediction
models using the algorithm described above, using only
the training set to select variables and estimate coeffi-
cients. For each of the patients in the corresponding val-
idation set the multivariable logistic model provides a
probability of the unfavorable outcome. By comparing
the predicted probability of unfavorable outcome with
the actual outcome at the final study visit, the receiver
operating characteristic (ROC) curve was computed, and
the area under the curve (AUC) was estimated. The me-
dian AUC with interquartile range (IQR) was estimated
from 100 realizations of the random partitioning of the
cohort. For each step in the cross-validation we omitted
any patients where the outcome or the required pre-
dictor variables were not available.
Finally, in our cohort we tested the prediction model
for severe disease course developed by Guzman et al.
[10]. We tested Guzman’s model using the 4 outcome
measures described above, i.e. not the outcomes for
which their model was constructed. The analysis was
performed using the software packages STATA version
14, and Wolfram Mathematica version 11.1.1.0.
Ethical considerations
Approvals from medical research ethical committees and
data protection authorities were granted according to the
regulations of each participating country. Written in-
formed consent was obtained from parents of children
aged < 16 years, and from the children themselves if aged
≥ 16 years of age.
Results
The main finding is that in the Nordic cohort, long-term
outcome in JIA can be predicted, with acceptable sensi-
tivity and specificity, using only a handful of readily
available clinical variables.
Study cohort
Characteristics of the 440 patients in the cohort have
previously been published [11]. The study cohort consti-
tuted 423 children, after 17 patients with systemic JIA
were excluded. The median time between disease onset
and the baseline study visit was 7 (IQR 6–8) months,
Fig. 1 Correlations between baseline variables. Lines are drawn
only between pairs of baseline variables for which the sample
Spearman correlation coefficient is ≥ 0.50. Baseline variables
without correlation ≥0.50 are not included in the figure. RF,
rheumatoid factor; VAS, visual analogue scale; GA, global
assessment; CHAQ, Childhood Health Assessment Questionnaire
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Not in remissionb OR
(95% CI)
p
Gender female, n (%) 410 106 (38.8) 167 (61.2) 0.8 (0.5–1.2) 0.334
Age at disease onset, years 410 6.3 (2.5–10.0) 5.2 (2.5–9.6) 0.9 (0.9–1.0) 0.401
Time from onset to diagnosis, months 388 1.5 (0.5–2.9) 1.7 (0.5–3.6) 1.0 (1.0–1.1) 0.152
Cumulative active joint count 410 2 (1–4) 4 (2–7) 1.1 (1.1–1.2) < 0.001
Physician’s global assessment VAS 227 0.8 (0.0–1.3) 2.0 (1.0–3.8) 3.5 (1.9–6.2) < 0.001
Polyarticular RF-positive, n (%) 410 1 (25.0) 3 (75.0) 2.1 (0.2–20.0) 0.535
Polyarticular RF-negative, n (%) 410 25 (26.9) 68 (73.1) 2.2 (1.3–3.6) 0.003
Oligoarticular, n (%) 410 107 (49.1) 111 (50.9) 0.5 (0.3–0.7) < 0.001
Psoriatic arthritis, n (%) 410 3 (50.0) 3 (50.0) 0.7 (0.1–3.4) 0.635
Enthesitis-related arthritis (ERA), n (%) 410 11 (32.4) 23 (67.6) 1.5 (0.7–3.1) 0.315
Undifferentiated arthritis, n (%) 410 19 (34.5) 36 (65.5) 1.3 (0.7–2.4) 0.336
ANA-positive, ≤ 6 years, n (%)c 397 22 (31.4) 48 (68.6) 1.6 (0.9–2.7) 0.107
Specific joint involvement, n (%)
Hip joint 409 18 (32.1) 38 (67.9) 1.5 (0.8–2.8) 0.168
Ankle joint 409 57 (31.0) 127 (69.0) 2.1 (1.4–3.1) < 0.001
Tarsal joint 409 6 (16.7) 30 (83.3) 3.8 (1.5–9.2) 0.004
Subtalar joint 409 14 (26.9) 38 (73.1) 2.0 (1.1–3.8) 0.034
Wrist joint 409 33 (30.6) 75 (69.4) 1.8 (1.1–2.9) 0.014
Finger joint 409 36 (27.7) 94 (72.3) 2.3 (1.5–3.6) < 0.001
Neck 409 9 (26.5) 25 (73.5) 2.0 (0.9–4.4) 0.085
Upper limb joints 410 67 (32.7) 138 (67.3) 1.9 (1.3–2.9) 0.001
Lower limb joints 410 144 (39.0) 225 (61.0) 1.8 (0.9–3.5) 0.073
Symmetric involvement, n (%)
Hip joints 409 5 (21.7) 18 (78.3) 2.6 (0.9–7.1) 0.067
Ankle joints 409 27 (28.4) 68 (71.6) 2.0 (1.2–3.3) 0.006
Wrist joints 409 22 (34.4) 42 (65.6) 1.4 (0.8–2.4) 0.272
Finger joints 409 13 (22.0) 46 (78.0) 2.7 (1.4–5.3) 0.002
Patient-reported outcomes
Patient’s/parent’s global assessment VAS 250 0.5 (0.0–2.2) 1.7 (0.5–3.5) 2.2 (1.4–3.4) 0.001
CHAQ score 257 0.1 (0.0–0.6) 0.5 (0.0–1.1) 2.0 (1.3–3.0) 0.002
Pain VAS 246 0.4 (0.0–3.0) 2.3 (0.5–4.2) 1.9 (1.3–2.8) 0.002
Morning stiffness for > 15 min, n (%) 314 25 (22.1) 88 (77.9) 3.6 (2.1–6.0) < 0.001
Laboratory tests
ESR mm/h 332 11.0 (6.0–18.0) 17.0 (9.5–34.0) 1.4 (1.2–1.7) < 0.001
CRP >10 mg/L, n (%) 329 12 (16.7) 60 (83.3) 3.9 (2.0–7.5) < 0.001
ANA-positive, n (%) 397 37 (33.0) 75 (67.0) 1.5 (1.0–2.4) 0.075
RF-positive, n (%) 221 5 (50.0) 5 (50.0) 0.6 (0.2–2.0) 0.376
HLA-B27 positive, n (%) 382 21 (25.9) 60 (74.1) 2.1 (1.2–3.6) 0.010
Values are the median (interquartile range, IQR), or number (percentage)
OR odds ratio, CI confidence interval, VAS visual analogue scale, CHAQ Childhood Health Assessment Questionnaire, ESR erythrocyte sedimentation rate for an
increase in 10 mm/h, CRP C-reactive protein, ANA antinuclear antibody, RF rheumatoid factor, HLA-B27 human leucocyte antigen
aInactive disease off medication for 12 months according to the preliminary Wallace criteria
bNot in remission equals non-achievement of remission off medication
cANA-positive patients ≤6 years at disease onset, with oligoarticular, polyarticular RF negative, psoriatic or undifferentiated arthritis
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and between disease onset and the final study visit it was
98 (IQR 95–102) months. The median time from disease
onset to diagnosis was 1.6 (IQR 0.5–3.3) months. A total
of 280 patients (66.2%) were female, and the median age
of disease onset in the cohort was 5.5 (IQR 2.5–9.7)
years (Additional file 1: Table S1).
At the baseline study visit, 227/423 patients (53.7%)
had oligoarthritis, 94/423 (22.2%) had rheumatoid fac-
tor (RF)-negative polyarthritis, and 4/423 (1.0%) had
RF-positive polyarthritis (Additional file 1: Table S1).
The median cumulative number of active joints within
the first visit was 3 (IQR 1–6), and 381/423 patients
(90.1%) had one or more affected lower limb joints
at the baseline visit. Antinuclear antibodies (ANA)
were present in 115/410 patients (28.1%), and HLA-
B27 in 85/393 patients (21.6%) [23], presented in
Additional file 1: Table S1. None of the children had
started biologic agents before the baseline study visit,
and early medications are shown in Additional file 2:
Table S2. A total of 410/423 (96.9% of the total co-
hort) had baseline assessments and data on remission
8 years after disease onset. The corresponding numbers
were 340/423 (80.4%) for CHAQ, 199/423 (47.0%) for PhS
and 216/423 (51.1%) for JADI-A.
Correlation between baseline variables
The clinical predictor variables were analyzed with re-
spect to correlation. There was significantly positive,
moderate to strong correlation between several variables,
especially between cumulative number of active joints,
the joint-specific variables, and the polyarthritis RF-
negative category. Physician’s GA and the patient-
reported outcomes also correlated positively with each
other. The correlation structure between the predictor
variables is illustrated in Fig. 1.
Prediction of non-achievement of remission off
medication
Remission status at the final study visit was available for
410 patients. There were 166 (40.5%) children in remis-
sion without medication, while 38 (9.3%) were in remis-
sion on medication, and 206 (50.2%) were not in
remission: 244/410 children (59.5%) did not achieve re-
mission off medication. The baseline predictors of not
achieving remission off medication were analyzed by uni-
variate logistic regression and are presented in Table 1.
The following predictor variables were included in the
multivariable prediction model for non-achievement of
remission: Cumulative active joint count, ESR, CRP,
morning stiffness, physician’s GA, ANA, HLA-B27, and
ankle joint arthritis. The first five variables were chosen
a priori, and ANA, HLA-B27, and ankle joint arthritis
were the variables included through the stepwise selec-
tion method (Table 2). The model has an AUC of 0.84
in the total cohort. Cross-validation yielded a median
AUC = 0.78 (IQR 0.72–0.82) in the validation sets
(Table 3). The corresponding ROC curves are shown
in Figs. 2 and 3.
Table 2 Prediction of unfavorable outcome by multivariable
modeling of baseline clinical characteristics
Coef. Std.Err
Not in remissiona N = 156
β0=-1.58 0.44
Cumulative active joint count β1=0.04 0.05
ESR mm/h β2=0.03 0.02
CRP >10 mg/L β3=-0.07 0.69
Morning stiffness > 15 min β4=1.16 0.45
Physician’s global assessment VAS β5=0.16 0.46
ANA-positive β6=1.25 0.50
HLA-B27-positive β7=1.37 0.54
Ankle joint arthritis β8=1.10 0.49
Functional disability (CHAQ), N = 141
β0=-1.68 0.35
Cumulative active joint count β1=-0.02 0.03
ESR mm/h β2=0.01 0.01
CRP > 10 mg/L β3=-0.20 0.63
Morning stiffness > 15 min β4=1.03 0.42
Physician’s global assessment VAS β5=-0.40 0.56
Finger joint arthritis β6=1.21 0.54
Pain VAS β7 = 0.77 0.40
Functional disability (PhS), N = 92
β0=-3.40 0.75
Cumulative active joint count β1=0.10 0.05
ESR mm/h β2=0.01 0.02
CRP > 10 mg/L β3=-2.06 1.28
Morning stiffness > 15 min β4=1.68 0.80
Physician’s global assessment VAS β5=-0.71 0.88
Pain VAS β6=1.30 0.64
Joint damage (JADI-A), N = 141
β0=-3.84 0.76
Cumulative active joint count β1=0.02 0.04
ESR mm/h β2=0.01 0.02
CRP > 10 mg/l β3= -0.11 0.83
Morning stiffness > 15 min β4=-0.59 0.61
Physician’s global assessment VAS β5=0.28 0.52
Finger joint arthritis β6=1.84 0.68
Older age at disease onset (years) β7= 0.16 0.07
Coef. coefficients in the logistic regression, Std.Err. standard error in the
coefficients, VAS visual analogue scale, ESR erythrocyte sedimentation rate for
an increase in 10 mm/h, CRP C-reactive protein, ANA antinuclear antibody,
HLA-B27 human leucocyte antigen
aNot in remission equals non-achievement of remission off medication
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We also developed a prediction model without the
blood samples (ESR, CRP, ANA, and HLA-B27). This
model yielded an AUC = 0.76 (IQR 0.72–0.80) for
non-achievement of remission in the validation sets
(Additional file 3: Figure S1).
Prediction of functional disability and joint damage
The CHAQ score at the final study visit was available in
340 children, and 111 (32.7%) had a CHAQ score >0.
Three of the four patients with RF-positive polyarthritis
reported functional disability. For univariate logistic re-
gression results see Additional file 4: Table S3.
The prediction model for CHAQ score >0 uses cumu-
lative active joint count, ESR, CRP, morning stiffness,
physician’s GA, finger joint arthritis, and pain VAS as
variables (Table 2). The AUC of this model was 0.79 in
the total cohort, and cross validation gave a median
AUC of 0.73 (IQR 0.67–0.76) in the validation sets
(Table 3). The ROC curve for the total cohort, and valid-
ation sets are shown in Figs. 2 and 3, respectively. The
AUC for the model without blood samples was 0.72
(IQR 0.67–0.76) in the validation sets (Additional file 3:
Figure S1).
Of the 199 patients with a physical summary score, 40
(20.1%) had a score <40. Results of the univariate ana-
lysis with PhS <40 as the outcome variable are shown in
Additional file 5: Table S4. Variables included in the pre-
diction model for PhS were cumulative active joint
count, ESR, CRP, morning stiffness, Physician’s GA, and
pain VAS (Table 2). The AUC was 0.90 in the total
cohort, and cross-validation gave a median AUC = 0.74
(IQR 0.65–0.80) in the validation sets (Table 3, Figs. 2
and 3). The AUC for the model without blood
samples was 0.73 (0.66–0.79) in the validation sets
(Additional file 3: Figure S1).
The JADI-A was collected for 216 patients at the final
study visit, and 29 patients (13.4%) had joint damage
registered 8 years after disease onset. The baseline pre-
dictors of joint damage are presented in Additional file 6:
Table S5. In the prediction model, older age at disease
onset and finger joint arthritis were included in addition
to the five previously included variables (Table 2). The
AUC was 0.84 in the cohort, and the median AUC was
0.73 (IQR 0.63–0.76) in the validation sets. The results
are summarized in Table 3 and Figs. 2 and 3. Without
blood tests the median AUC in the validation sets
was 0.73 (IQR 0.63–0.80) (Additional file 3: Figure S1).
Other prediction models
The prediction model developed by Guzman et al. [10]
was tested in our cohort by testing the ability of their
model to predict the four outcomes described above.
The model yielded an AUC = 0.69 for prediction of not
achieving remission. For CHAQ >0, PhS <40, and JADI-
A >0 the AUCs were 0.68, 0.69, and 0.71, respectively
(Additional file 7: Figure S2).
Discussion
In the Nordic JIA cohort, we have developed and evaluated
prediction models for long-term unfavorable outcome with
acceptable sensitivity and specificity based on variables eas-
ily available at baseline, which may guide individually tai-
lored treatment. Prediction of long-term unfavorable
outcome early in the disease course may be useful in decid-
ing when to start aggressive treatment in JIA.
To our knowledge, this is the first study on long-term
prediction of well-established disease outcomes in a
prospective population-based JIA cohort. Cross-validation
analysis of model performance yielded AUCs of 0.78, 0.73,
0.74, and 0.73, for non-achievement of remission, CHAQ
>0, PhS <40, and JADI-A >0, respectively.
An important step in developing applicable prediction
models for JIA was carried out by Guzman et al. in a
Canadian JIA cohort [10]. The authors recommended
that their results should be tested in other JIA cohorts.
We were not able to reproduce the predictive ability of
their model in the Nordic JIA cohort (Additional file 7:
Figure S2). One obvious reason for the discrepancy
could be that Guzman’s model is constructed to predict
severe disease course, and not per se, any of the four
pre-established, validated adverse outcomes that we
assessed. Other reasons may be differences in the
population-based approach, cohort composition, or eth-
nicity, or overfitting of models to the cohort.
The primary goal in the treatment of children with JIA
is to achieve remission off medication, and the main im-
plication of the current study is that prediction models
may be useful in guiding decisions about treatment.
Previous studies have indicated that the disease course
may be modified by starting appropriate treatment early
Table 3 Cross-validation of the four prediction models of unfavorable long-term outcome in the Nordic JIA cohort
Not in remissiona Functional disability (CHAQ) Functional disability (PhS) Joint damage (JADI-A)
AUC total cohort 0.84 0.79 0.90 0.84
AUC validation setsb 0.78 (0.72–0.82) 0.73 (0.67–0.76) 0.74 (0.65–0.80) 0.73 (0.63–0.76)
AUC area under the receiver operating characteristic curve, CHAQ Childhood Health Assessment Questionnaire, PhS Physical Summary Score, JADI-A Juvenile
Arthritis Damage Index-Articular
aNot in remission equals non-achievement of remission off medication
bThe AUCs in the validation sets are the median AUCs with the interquartile range of the 100 constructed models
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[9, 24, 25]. To reach the goal of early inactive disease, a
treat-to-target strategy including shared decision-making
with well-informed children and parents is currently rec-
ommended [6, 9]. Even with promising advances in
using gene expression profiles and biomarkers as predic-
tors of treatment response and flare risk [26–29], the
practical value of prediction based on a handful of read-
ily available clinical variables cannot be understated.
The main strengths of our study are the use of validated
outcome measures, the simplicity of the models, and the
strict cross-validations. The use of validated outcomes is
called for in reports on prognosis in JIA [3, 30, 31]. Model
simplicity is ensured through the model construction
method, where the main variables in the preliminary
Wallace criteria of remission are included in the models a
priori [15, 22]. The additional variables that were included
in our models have independently been associated with
adverse outcomes in previous studies [4, 23, 32–36].
The model performance was assessed using cross-
validations, where predictions were performed on valid-
ation sets that were completely separate from the data used
to construct the models. The 100 repeated model construc-
tions and evaluations prevent overfitting the data. Despite
Fig. 2 Receiver operating characteristic (ROC) curves for the four
unfavorable clinical outcomes in the total cohort. Non-achievement
of remission off medication; CHAQ, Childhood Health Assessment
Questionnaire; PhS, Physical Summary Score; JADI-A, Juvenile
Arthritis Damage Index-Articular
Fig. 3 Receiver operating characteristic (ROC) curves for the four unfavorable clinical outcomes in the validation sets. The colored lines are the
mean ROC curves for the 100 different realizations of the partitioning of the cohort into training sets and validation sets (thin gray curves). a Not
in remission. b Childhood Health Assessment Questionnaire (CHAQ) >0. c Physical Summary Score (PhS) <40. d Juvenile Arthritis Damage
Index-Articular (JADI-A) >0
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the strictness of the model-developing procedure, we still
obtained acceptable predictive ability. The robustness and
applicability of the prediction rules are emphasized by the
fact that when the analyses were repeated without any
blood tests, the performance was similar. An online calcula-
tor based on our models is available at the web-page http://
predictions.no. An iOS app is also designed, and the test
versions are available on request.
One of the limitations of our study is that for some of
the patients, the baseline study visit scheduled 6 months
after disease onset was not the first clinical visit. Some
children had therefore already started treatment, mostly
with nonsteroidal anti-inflammatory drugs (NSAIDs) or
intraarticular corticosteroids, and were not treatment
naïve when the predictor variables were assessed. This
baseline time point, however, allowed use of the cumula-
tive active joint count during the first 6 months of the dis-
ease, which is an important measure of early disease
severity in line with the International League of Associa-
tions for Rheumatology (ILAR) criteria. A limitation is
also that the primary outcome, non-achievement of remis-
sion off medication, is defined as inactive disease for more
than 1 year, and this outcome does not necessarily reflect
the disease course during the whole 8-year period. In
addition, JADI-A is a rather crude measure of joint dam-
age, and future predictive studies should therefore include
imaging in joint damage assessment. Finally, the treatment
given during the disease course may have altered the dis-
ease outcome, even though biologic medications were not
generally available in the beginning of the study period in
1997. The natural history of JIA disease course without
treatment is clearly impossible and unethical to study.
Conclusion
We have developed statistical models for predicting non-
achievement of remission off medication, functional dis-
ability, and joint damage in children with JIA. The models
are easy to use, and may provide a valuable tool to aid
early treatment decisions on the need for DMARDs in-
cluding biologic agents if validation in other JIA cohorts
and across ethnicities can confirm our results [37]. We en-
courage further testing of our models before the applic-
ability can be generalized and recommended.
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Abstract
Background: Models to predict disease course and long-term outcome based on clinical characteristics at disease
onset may guide early treatment strategies in juvenile idiopathic arthritis (JIA). Before a prediction model can be
recommended for use in clinical practice, it needs to be validated in a different cohort than the one used for
building the model. The aim of the current study was to validate the predictive performance of the Canadian
prediction model developed by Guzman et al. and the Nordic model derived from Rypdal et al. to predict severe
disease course and non-achievement of remission in Nordic patients with JIA.
Methods: The Canadian and Nordic multivariable logistic regression models were evaluated in the Nordic JIA
cohort for prediction of non-achievement of remission, and the data-driven outcome denoted severe disease
course. A total of 440 patients in the Nordic cohort with a baseline visit and an 8-year visit were included. The
Canadian prediction model was first externally validated exactly as published. Both the Nordic and Canadian
models were subsequently evaluated with repeated fine-tuning of model coefficients in training sets and testing in
disjoint validation sets. The predictive performances of the models were assessed with receiver operating
characteristic curves and C-indices. A model with a C-index above 0.7 was considered useful for clinical prediction.
Results: The Canadian prediction model had excellent predictive ability and was comparable in performance to the
Nordic model in predicting severe disease course in the Nordic JIA cohort. The Canadian model yielded a C-index
of 0.85 (IQR 0.83–0.87) for prediction of severe disease course and a C-index of 0.66 (0.63–0.68) for prediction of
non-achievement of remission when applied directly. The median C-indices after fine-tuning were 0.85 (0.80–0.89)
and 0.69 (0.65–0.73), respectively. Internal validation of the Nordic model for prediction of severe disease course
resulted in a median C-index of 0.90 (0.86–0.92).
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Conclusions: External validation of the Canadian model and internal validation of the Nordic model with severe
disease course as outcome confirm their predictive abilities. Our findings suggest that predicting long-term
remission is more challenging than predicting severe disease course.
Keywords: Juvenile idiopathic arthritis, Prediction, Validation, Outcome research, Remission
Background
Population-based studies show that juvenile idiopathic
arthritis (JIA) is a chronic childhood rheumatic disease
with diverse disease manifestations, courses, and progno-
ses [1–4]. Prognostic prediction models are increasingly
important tools for informed decision-making in medi-
cine [5, 6]. In a newly diagnosed patient with JIA, it can
be challenging to decide if a potent treatment with pos-
sible serious side effects should be started early in the
disease course. A well-performing prediction model can
help assess the risk of severe disease and hence guide de-
cisions on starting or stepping up disease-modifying an-
tirheumatic drugs, including biologic treatments. This
may facilitate individually tailored treatment strategies
within the so-called window of opportunity [7–10]. Be-
fore such prediction models can be recommended for
general use in clinical practice, we need to ensure they
have good predictive performance across different JIA
populations. Unfortunately, studies on development of
prediction models in pediatrics [11] and in JIA are
scarce [12–18]. As far as we know, no study has previ-
ously reported a quantitative external validation of pre-
diction models in JIA in a different population.
To address this knowledge gap, a collaboration has
been initiated between two prospective and well-defined
longitudinal cohort studies: the Research in Arthritis in
Canadian Children Emphasizing Outcomes (ReACCh-
Out) Cohort and the Nordic JIA cohort. The first results
of the collaboration are presented here and in the twin
study by Henrey et al. (part 2). These studies analyze
prediction models recently proposed by Guzman et al.
[17] and Rypdal et al. [19]. Guzman et al. constructed a
model for predicting severe disease course derived from
the ReACCh-Out study (the Canadian model). The
model had a C-index of 0.85 in internal validation in the
Canadian cohort. Rypdal et al. constructed a model for
prediction of non-achievement of remission (the Nordic
model), and this model had a C-index of 0.78 in internal
validation in the Nordic cohort.
In the present study, our aims were to validate the pre-
dictive ability of the Canadian model in the Nordic JIA
cohort and to internally validate the performance of the
Nordic model to predict severe disease course, an out-
come originally constructed from data in the Canadian
cohort [17, 20]. Conversely, the Nordic prediction model
was tested for these outcomes in the Canadian cohort,
with results presented in the twin paper by Henrey et al.
(part 2). The validated prediction models may in the fu-
ture be updated, harmonized, and eventually used as
clinical tools in decision-making regarding early individ-
ualized treatment in JIA.
Patients and methods
The Nordic JIA study is a prospective, longitudinal, mul-
ticenter cohort [2, 21]. Measures were taken to ensure a
population-based approach; all consecutive newly diag-
nosed JIA patients from 12 pediatric rheumatology cen-
ters in defined geographical areas of Denmark, Finland,
Norway, and Sweden were included if disease onset was
between January 1, 1997, and June 30, 2000, and the
International League of Associations for Rheumatology
criteria for JIA [2] were fulfilled. The aim was to have a
baseline visit 6 months after disease onset, and the pa-
tients were followed at regular visits with 1-to-3-year in-
tervals up to 8-years after disease onset.
The ReACCh-Out study is also a multicenter prospect-
ive study. A total of 16 pediatric rheumatology centers
across Canada participated, and consecutive patients with
newly diagnosed JIA were recruited between January 2005
and December 2010. The first visit occurred as soon as
possible after diagnosis, but the time from diagnosis to the
first visit could be up to 1 year. The inclusion criterion in
the Canadian prediction study was attendance in at least 6
of 8 study visits, which were scheduled every 6months for
2 years, and then yearly up to 5 years. It was also required
that information was available at least at one visit, for each
of the 5 clinical variables used to construct the severe dis-
ease course outcome [17].
Both studies collected extensive clinical and laboratory
data at the study visits as previously reported [17, 19].
Characteristics of the two study populations are pre-
sented in Table 1.
The current study is reported according to the TRIPOD
guideline (Transparent reporting of a multivariable predic-
tion model for individual prognosis or diagnosis) [4, 22].
Patients
The present study includes all patients from the Nordic
cohort with data available from at least a baseline and an
8-year visit. This includes 440 (88%) of the 500 patients
originally included at baseline. In contrast to the previ-
ous work on prediction models in the Nordic cohort
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[19], patients with systemic JIA are included in the
current study.
Outcomes
The main outcome predicted in the previous Nordic
study was non-achievement of remission at the 8-year
visit, which included patients with active disease, inactive
disease on medications, or inactive disease off medica-
tions for less than 12months. Inactive disease was de-
fined by the Wallace 2004 criteria, the current criteria at
the time the 8-year study was conducted [23, 24].
The main outcome in the Canadian study was severe
disease course. The method used to develop and define
this outcome was previously reported [17]. In summary,
the clinical JIA course was described according to five
variables: participant-defined quality of life and pain re-
ports, both assessed on 10-cm visual analogue scales
(VAS); active joint count; medication requirements; and
medication side effects. Based on this information, four
different clinical courses were identified by a clustering
algorithm. The main outcome, severe disease course, was
the union of the two worst groups, severe controlled
course and severe persistent course, as defined by
Guzman et al. [17].
In the present study, a version of the Canadian outcome
was constructed in the Nordic cohort using information
on four variables collected at the 8-year study visit. This
outcome is also denoted severe disease course, but the
construct variables in the Nordic cohort were the cumula-
tive active joint count, the remission status, the Childhood
Health Assessment Questionnaire disability index
(CHAQ), and the Physical Summary Score (PhS) derived
from the Child Health Questionnaire Parent form (CHQ-
PF50) [25]. The aim was to construct a severe disease
course group corresponding as closely as possible to the
outcome used in the ReACCh-Out prediction study. Ac-
cordingly, we used these four variables and a clustering al-
gorithm to divide the Nordic cohort in four disease course
groups. The two most severe courses were defined to have
a severe disease course. Characteristics of the four disease
course clusters in the Nordic JIA cohort are presented in
Additional file 1: Table S1.
We also constructed an alternative definition of the
outcome using five variables, the four described above in
addition to the pain-VAS report at the 8-year follow-up.
Both constructions corresponded reasonably well with
the construction in the ReACCh-Out study, and the re-
sults of the external validation of the Canadian model
were similar in the two cases. In both cases, we made a
series of choices and essentially tuned the construction
to obtain clusters that corresponded in relative size to
those found in the Canadian study. We used linear di-
mensionality reduction and then the K-means or the K-
medoids clustering algorithm [26] to construct clusters.
Predictors in the Nordic and the Canadian model
The baseline predictors that we considered as candidates for
the Nordic multivariable logistic regression model are previ-
ously published [19]. The following eight predictors consti-
tuted the final multivariable model: cumulative active joint
count; erythrocyte sedimentation rate (ESR) mm/hour, mea-
sured as a continuous variable; C-reactive protein (CRP) mg/
l, with values < 10mg/l considered to be normal; morning
stiffness > 15min; physician’s global assessment of disease
activity on a 10-cm VAS; presence of antinuclear antibodies
(ANA) analyzed by immunofluorescence on Hep-2cells and
tested at least twice with a minimum of 3months apart;
presence of human leucocyte antigen (HLA)-B27; and ankle
joint arthritis. The first five variables were included a priori
based on a clinical judgment and justified on the basis that
these variables are central in the American College of
Rheumatology (ACR) for clinical active disease [27].
The Canadian multivariable logistic regression model
used 16 variables: active joint count, psoriatic arthritis,
oligoarthritis, RF-negative polyarthritis, upper limb joint
involvement, symmetric joint involvement, RF positivity,
Table 1 JIA-study population in the Canadian ReACCh-Out and the Nordic JIA cohort
Characteristics Canadian development cohort Nordic validation cohort
Study design Prospective multicenter Prospective multicenter
Patient recruitment perioda January 2005–December 2010 January 1997–June 2000
Total participants, n 1497 500
Time from onset to baseline study visit, monthsb 5.8 (3.0–11.0) 7.0 (6.0–8.0)
Time from onset to outcome assessment, monthsb 49 (38–59)c 98 (95–102)
Participants in the current study, n 609 440
Inclusion criteria 6 of 8 study visitsd Baseline and 8-year study visit
Main outcome Severe disease course Non-achievement of remission
aNewly diagnosed JIA patients
bMedian interquartile range (IQR)
cSevere disease course outcome was assessed over time, not at a single point
dAdditionally, at least one value available for each of the five patient-relevant variables
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subtalar joint involvement, finger joint involvement, cer-
vical spine involvement, ankle joint involvement, pres-
ence of morning stiffness, hip joint involvement,
temporomandibular joint involvement, mid-foot involve-
ment, and the presence of enthesitis. Details regarding
measurement and assessment of these variables were
previously reported [17].
Model validation
This study presents external validation of the Canadian
model and internal validation of the Nordic model. The Can-
adian model was tested for its ability to predict severe disease
course and non-achievement of remission in a separate cohort
from the one used to build the model. The Canadian model
was first tested exactly as published by Guzman et al., and
also after fine-tuning, i.e., with re-estimated coefficients. The
Nordic model was tested for its ability to predict severe dis-
ease course by internal validation, involving repeated parti-
tioning of the cohort in multiple training sets for model
building and validation sets for model testing.
Statistical analyses
Rypdal et al. constructed multivariable logistic regression
models using a set of 5 pre-defined variables and a step-
wise forward selection method to obtain additional vari-
ables from a set of 29 candidate variables. Variables with
a P value > 0.05 were removed. Selections of variables
were performed in training sets, and no more than 10
predictor variables were allowed in each of the models.
The final model included 8 predictors, as previously de-
scribed [19].
Guzman et al. constructed their model through a ver-
sion of backwards elimination starting with a full model
of 52 predictors and retaining 16 predictor variables in
their multivariable logistic regression model. Both the
Nordic and the Canadian models underwent internal
validation with the repeated random split-sample tech-
nique and cross-validation in their respective cohorts.
External validation of the Canadian model
The model [17] is tested by computing the probability of
severe disease course and non-achievement of remission
according to the formula:
p ¼ 1
1þ e−A
where A = β0 + β1x1 +… + β16x16 is a linear combin-
ation of predictors. Apart from the active joint count, all
variables are dichotomous. In external validation, we
used the coefficients βi from the ReACCh-Out cohort
exactly as published [17]. A probability of severe disease
course and non-achievement of remission was computed for
each patient in the Nordic cohort, and these probabilities
were compared to the outcomes described above. By varying
the probability threshold, pairs of corresponding sensitivity
and specificity values were obtained, and consequently a re-
ceiver operating characteristic (ROC) curve. The area under
the curve (AUC), or C-statistic, was computed from the
ROC curve for each outcome. This is reported as the C-
index. For each outcome, the uncertainty in the C-statistic
was quantified by a standard bootstrapping (resampling)
method and reported as interquartile range (IQR).
Testing of the Canadian model after fine-tuning
This involved re-estimating the coefficients βi in subsets (train-
ing sets) of the Nordic cohort and evaluating the correspond-
ing models (using the same method) as described above on
disjoint validation sets. We used 500 repeated random splits
into training and validation sets, and the median C-statistics
with IQRs were computed. For each random split, we used
75% of available patients for training, and 25% for testing.
Internal validation of the Nordic model
The Nordic model was validated by constructing and
training models on training sets and tested on disjoint val-
idation sets as described above. For the Nordic model, the
training involved not only the estimation of coefficients βi,
but also the variable selection as reported [19]. The results
for prediction of non-achievement of remission have been
previously reported, but in the present study, we extended
this analysis to prediction of severe disease course. For
comparison, we also carried out this analysis for a univari-
ate logistic regression model with cumulative active joint
count at baseline as the only predictor. The sample size
was determined by the number of patients with available
data for analyses in the Nordic JIA cohort.
For the construction of the severe disease course outcome,
there were 1 or more missing values for 248 of the 440 pa-
tients. Since severe disease course is a data-driven outcome, it
was necessary to impute these missing values. For this pur-
pose, we used the linear dimension-reduction algorithm in
the Wolfram Mathematica software. The results presented
in this study are without imputation of missing data for the
predictor variables; thus, patients with 1 or more missing
predictor variables were omitted from the testing of that par-
ticular model. For the external validation of the Canadian
model, we lost 222 of 440 patients due to missing data in 1
or more of the 16 predictors. Most of these were missing
tests of RF positivity (repeated twice at least 3 months apart).
To test the effect of the missing predictor data on the main
result, we performed a sensitivity analysis where we imputed
missing data in predictor variables and re-tested the
Canadian model. Results did not change significantly.
The statistical analyses in the current study were per-
formed using Stata/MP version 15 and Wolfram Mathe-
matica version 11.3.0.0.
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Results
Among the 440 patients in the Nordic cohort, 98/440
(22%) were identified with a severe disease course. This
ratio is similar to the 125 (21%) of 609 patients identified
with a severe disease course in the ReACCh-Out study.
Altogether, 246/427 (58%) were not in remission off
medication at the 8-year visit. The general characteristics
of the 2 study populations are presented in Table 1, and
Table 2 Baseline clinical characteristics for patients in the ReACCh-Out and the Nordic JIA cohort according to severe disease course
or non-severe disease course
Characteristics ReACCh-Out development cohort Nordic validation cohort
Severe disease (n = 125) Non-severe (n = 484) Severe disease (n = 98) Non-severe (n = 342)
Age at onset, years 9.9 (5.4–12.0), n = 123 6.9 (2.5–10.7), n = 474 8.1 (2.9–11.0) 5.2 (2.3–9.0)
Female, n (%) 88 (70.4) 325 (67.1) 78 (79.6) 213 (62.3)
Disease onset to diagnosis, months 5.6 (2.4–13.9) 3.3 (1.6–6.4) 2.4 (1.4–5.1), n = 94 1.4 (1.4–2.8), n = 321
Disease onset to enrollment, months 8.8 (4.9–17.0) 5.5 (2.8–9.9) 6.0 (6.0–9.0) 7.0 (6.0–8.0)
JIA category, n (%)
Oligoarthritis 9 (7.2) 214 (44.2) 27 (27.6) 200 (58.5)
RF-neg. polyarthritis 44 (35.2) 85 (17.6) 37 (37.8) 57 (16.7)
RF-pos. polyarthritis 20 (16.0) 6 (1.2) 3 (3.1) 1 (0.3)
Systemic 10 (8.0) 37 (7.6) 2 (2.0) 15 (4.4)
Enthesitis-related 24 (19.2) 57 (11.8) 9 (9.2) 25 (7.3)
Psoriatic 4 (3.2) 32 (6.6) 1 (1.0) 5 (1.5)
Undifferentiated 14 (11.2) 53 (11.0) 19 (19.4) 39 (11.4)
Active joints, n (%)
Cervical arthritis 21 (16.8) 8 (1.7) 22 (22.7) 16 (4.7)
Finger arthritis 86 (68.8) 122 (25.2) 63 (65.0) 72 (21.1)
Ankle arthritis 78 (62.4) 140 (28.9) 61 (62.9) 137 (40.1)
Hip arthritis 35 (28.0) 34 (7.0) 19 (19.6) 45 (13.2)
Cumulative active joint counta 13 (4–26) 2 (1–4) 9 (5–14) 2 (1–5)
Physician global assessment VAS 5.3 (3.2–7.2) 2.3 (1.0–4.6) 2.4 (1.0–4.7), n = 75 1.0 (0.3–2.1), n = 173
Parents’ global assessment VAS 3.6 (1.8–5.7), n = 114 1.3 (0.3–3.5), n = 440 2.3 (1.0–5.0), n = 76 0.9 (0.0–2.5), n = 195
Pain VAS 5.0 (2.7–6.8), n = 114 2.0 (0.5–5.0), n = 440 3.4 (1.1–5.0), n = 75 0.8 (0.0–2.8), n = 192
CHAQ 0.9 (0.3–1.4), n = 109 0.3 (0.0–0.8), n = 408 0.9 (0.3–1.4), n = 78 0.1 (0.0–0.7), n = 200
Morning stiffness, n (%) 102/124 (82.3)b 334/447 (74.7)b 60/86 (69.8)c 60/254 (23.6)c
ESR mm/hour 20 (9–45), n = 119 20 (9–36), n = 433 16 (8–39), n = 77 14 (8–25), n = 281
CRP mg/l 5.8 (0.4–34.0), n = 98 2.0 (0.1–10.0), n = 371 0.0 (0.0–22.5), n = 80 0.0 (0.0–10.0), n = 274
ANA positive, n (%) 54 (43.0)d 233 (48.0)d 22/95 (23.2) 93/332 (28.3)
RF positive, n (%) 24 (19.2)d 21 (4.3)d 4/70 (5.7) 6/171 (3.5)
HLA B27 positive, n (%) 18 (14.4)d 46 (9.5)d 23/96 (24.0) 63/314 (20.1)
Treatment by first study visit, n (%)
NSAIDs 115/125 (92.0) 451/484 (93.2) 83/97 (85.6) 290/337 (86.1)
Joint injections 9/125 (7.2) 92/484 (19.0) 46/95 (48.4) 195/334 (58.4)
DMARDs 89/125 (71.2) 114/484 (23.6) 39/94 (41.5) 53/320 (16.6)
Biologics 2/125 (1.6) 0 0 0
Numbers are median interquartile range (IQR) unless otherwise specified
VAS visual analogue scale, CHAQ Childhood Health Assessment Questionnaire, ESR erythrocyte sedimentation rate, CRP C-reactive protein, ANA antinuclear
antibodies, RF rheumatoid factor, HLA B27 Human Leucocyte Antigen B27, NSAID non-steroidal anti-inflammatory drug, DMARD disease modifying
antirheumatic drug
aThe Nordic cohort used the cumulative joint count within 6 months of disease onset, and the ReACCh-Out cohort used the active joint count at baseline
bMorning stiffness > 30min
cMorning stiffness > 15 min
dValues on ANA, RF, and HLA B7 for the Canadian cohort are after imputation
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detailed clinical characteristics of the groups of patients
with severe disease course in the two cohorts are pre-
sented in Table 2.
In the Nordic validation cohort, 66.2% were female.
The baseline visit took place at a median of 7 (IQR 6–8)
months after the first symptom of JIA, and the median
time for assessment of the outcome was 98 (IQR 95–
102) months after disease onset. Time from disease on-
set to JIA diagnosis was 1.6 (IQR 1.4–3.3) months. The
median age at disease onset was 5.5 (IQR 2.5–9.7) years.
In the Canadian development cohort, 67.9% were fe-
male. The median time from disease onset to the base-
line visit was 5.8 (IQR 3–11) months. The outcome was
assessed on patients that attended at least six of eight
planned visits, which correspond to a follow-up of 3 to
5 years. Time from first symptom to diagnosis was 3.7
(IQR 1.8–7.3) months, and the median age at disease on-
set was 8.4 (IQR 3.4–11.9) years.
Model validation
The external validation with severe disease course as out-
come resulted in a C-index of 0.85, and bootstrapping
gave an estimated IQR of 0.83–0.87. For non-achieve-
ment of remission, the C-index was 0.66 (IQR 0.63–0.68)
(Table 3). The corresponding ROC curves for the exter-
nal validation are shown in Fig. 1, and the calibration
plots are shown in the Additional file 2: Figure S1. The
alternative construction of severe disease course, based
on five rather than four variables at the 8-year follow-up,
gave a C-index of 0.84 with an IQR of 0.82–0.87. After
imputation of missing data in predictor variables the C-
index was 0.83.
After fine-tuning in training sets, the Canadian model
had a median C-index of 0.85 (IQR 0.80–0.89) with se-
vere disease course as outcome (Table 3 and Fig. 2a).
The same analysis with non-achievement of remission as
outcome gave a C-index of 0.69 (IQR 0.65–0.73)
(Table 3, Fig. 2b). The model variables and their corre-
sponding βi-coefficients for the original ReACCh-Out
model and the model fine-tuned to the Nordic popula-
tion are presented in Table 4.
We also performed internal validation of our Nordic
model using severe disease course as outcome. This gave a
median C-index of 0.90 (IQR 0.86–0.92) (Table 3, Fig. 2c).
Ultimately, we tested a very simple prediction model with
cumulative active joint count at baseline as the only pre-
dictor. For this model, a C-index of 0.85 (IQR 0.82–0.88)
was estimated. The corresponding ROC curve is presented
in Additional file 3: Figure S2.
Discussion
A clinically useful prediction model for long-term out-
come in JIA should be tested for reliability and accuracy
across cohorts, countries, and ethnicities to avoid over-
estimating the predictive performance of the model. To
our knowledge, the two studies presented in this issue
are the first where prediction models for unfavorable
outcomes in JIA are tested on cohorts completely differ-
ent to those used to construct the models.
The main result of this study is that the external valid-
ation of the Canadian prediction model yielded excellent
predictive performance with a C-index of 0.85 (IQR
Table 3 C-indices for testing of Canadian and Nordic prediction models





Original Canadian model 0.85 (0.83–0.87) 0.66 (0.63–0.68) External validation (bootstrapping)
Canadian model fine-tuned for Nordic
population
0.85 (0.81–0.89) 0.69 (0.65–0.73) Fine-tuning (repeated random splits)
Nordic model 0.90 (0.86–0.92) 0.78 (0.72–0.82)a Internal validation (repeated random
splits)
C-indices with median interquartile range (IQR)
C-index presented includes patients with systemic JIA, except for athe C-index for the Nordic model and the outcome non-achievement of remission previously
published by Rypdal et al. [19]
Fig. 1 Receiver operating characteristic (ROC) curves showing
external validation of the Canadian prediction model in the Nordic
JIA cohort. Blue curve: using severe disease course as outcome. C-
index with IQR = 0.85 (0.83–0.87). Red curve: using non-achievement
of remission as outcome. C-index with IQR = 0.66 (0.63–0.68)
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0.83–0.87) for severe disease course in the Nordic cohort.
The result is consistent with the internal validation in
the Canadian cohort, where a C-index of 0.85 was ob-
tained [17]. The Canadian model was also tested after
fine-tuning on repeated random splits, giving a similar
result to the ones in external validation. Internal valid-
ation of the Nordic model also indicated excellent per-
formance (C-index of 0.90) for predicting a severe
disease course.
In all comparisons, C-indices for prediction of severe
disease course were higher than for prediction of non-
achievement of remission.
Recently, several prediction models in JIA have been
published, but predictive abilities are suboptimal, and
none of them have been externally validated in an en-
tirely different population [14–16, 18, 19]. The current
study highlights two key points: (1) The choice of out-
come to be predicted is essential for predictive perform-
ance and perhaps more important than model design.
(2) Prediction models based on a few key variables may
have similar predictive ability to more complex models,
at least for the outcomes examined in this study.
The first point is supported by the comparison of non-
achievement of remission and severe disease course. It seems
the latter defines a narrower and more homogeneous group
of patients that is easier to identify and predict. In our opin-
ion, severe disease course is clinically relevant because it
captures a group of JIA patients most severely affected by
the disease. This adverse outcome may correspond better
with the threshold in many countries for initiating biologic
treatment and therefore be a better prediction target to
guide early aggressive treatment [8–10, 28].
The second point is supported by observing that in
this study, the predictive abilities of the most complex
models are not much better than those of simpler
models. The Nordic model for prediction of non-
achievement of remission was designed with specific
conditions in place to ensure model simplicity. It is com-
parable to the Canadian model in performance. How-
ever, the Canadian model is based on 16 variables and
may be more difficult to use in clinical practice, even
though an available online calculator is easy to use. Be-
sides its predictive performance, one of the key features
of a good clinical prediction rule is simplicity [29].
To further investigate the potential of very simple pre-
diction models, we also assessed a univariate logistic
Fig. 2 Receiver operating characteristic (ROC) curves showing results
of fine-tuned models in the Nordic JIA cohort for different
outcomes. a Fine-tuned Canadian prediction model using severe
disease course as outcome. b Fine-tuned Canadian prediction model
using non-achievement of remission as outcome. c Internal
validation of Nordic prediction model using severe disease course
as outcome
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regression model using cumulative active joint count
during the first 6 months after disease onset as the only
predictor. The model achieved high predictive perform-
ance for severe disease course, and we take this as an in-
dication that model simplification is feasible. However,
the high predictive ability of this very simple model may
be explained by the dependence between cumulative ac-
tive joint count at baseline and the cumulative active
joint count later in the disease.
Simple prediction models may perform well for a large
group of JIA patients, where the total number of joints
affected explains much of the disease burden, but they
may be of little use for patients with, for example, sys-
temic JIA or enthesitis-related arthritis, where the sever-
ity of the disease may be strongly associated with other
clinical features [30]. The heterogeneity of JIA is there-
fore an argument against oversimplified prediction
models, and multivariable models may have greater ap-
plicability across the whole spectrum of JIA. While sep-
arate models for different JIA categories may be more
accurate [15], they may add complexity to prediction.
Study strengths and limitations
The main strength of this work is that we validate a model
constructed in the Canadian cohort in the completely sep-
arate Nordic cohort. Both studies were multicenter, pro-
spective, longitudinal studies and collected extensive
clinical information. However, both the Canadian and
Nordic models were constructed starting from a large
number of clinical variables, which may have increased
the risk of retaining uninformative predictors in the
models and overfitting. A weakness of our study is missing
data in predictor and outcome variables, which is a com-
mon problem in prediction studies [31]. We have tried to
address this issue by imputing the values for the variables
used in the data-driven outcome and by not omitting
patients who lack information on predictor variables.
Selecting only patients with complete data may lead to
biased results.
In conclusion, we found excellent predictive perform-
ance of both the Canadian and Nordic prediction models
for predicting a severe disease course in children with
JIA. Severe disease course was identified using an impli-
cit, data-driven clustering method. Identifying an object-
ive definition of a severe disease course was beyond the
scope of this paper, but a clinical definition of severe dis-
ease course in JIA is clearly needed. Future studies on
prediction models in JIA are necessary, focusing not only
on constructing simplified prediction models, but also
on determining improved disease-outcome definitions in
JIA. Once objective outcome definitions are in place, we
can use the knowledge gained from the Nordic-
Canadian collaboration to develop new models that can
be tested in a third and independent cohort. The ultim-
ate step will be testing the model in a randomized con-
trolled trial to verify if it can significantly improve
patient outcomes. The aim is to develop models that can
be used in every day clinical practice. We have
Table 4 Canadian prediction model with respective βi coefficients before and after fine-tuning in the Nordic JIA cohort
Predictor variables in the Canadian model Original ReACCh-Out cohorta Fine-tuned in the Nordic cohortb
Constant Intercept = − 2.92 Intercept = 2.76
Active joint count, n = 440 0.18 0.21
Psoriatic arthritis, n = 440 − 1.23 − 1.40
Oligoarthritis, n = 440 − 1.14 − 0.72
RF-negative polyarthritis, n = 440 − 0.49 − 0.68
Upper limb joint involvement, n = 440 0.75 − 1.11
Symmetric joint involvement, n = 439 − 0.88 0.68
RF positivity, n = 241 1.31 − 1.06
Subtalar joint involvement, n = 439 − 1.42 − 2.81
Finger joint involvement, n = 439 − 0.31 1.31
Cervical spine involvement, n = 439 0.84 0.38
Ankle joint involvement, n = 439 0.48 − 0.25
Presence of morning stiffness, n = 340 0.56 1.64
Hip involvement, n = 439 0.06 − 0.50
TMJ-involvement, n = 439 1.50 0.09
Mid foot involvement, n = 439 0.54 0.39
Presence of enthesitis, n = 437 0.86 1.26
aCoefficients found by logistic regression in the Canadian cohort, previously reported [17]
bThe changes in coefficients after fine-tuning in the Nordic JIA cohort
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developed a smartphone application for the Nordic
model, and online web-based calculators exist for both
the Nordic (http://predictions.no) and the Canadian
(https://shiny.rcg.sfu.ca/jia-sdcc/) models [17, 19]. These
tools can easily be extended to new models. As we better
understand the accuracies and limitations of the models,
physicians may incorporate them in their overall assess-
ments to improve outcome in JIA.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13075-019-2060-2.
Additional file 1: Table S1. Characteristics of the four clusters
identified in the Nordic JIA cohort. Cluster 3 and 4 correspond to the
severe disease course outcome defined in the ReACCh-Out cohort.
Additional file 2: Figure S1. Calibration curves for the Canadian model
in the Nordic JIA cohort. Each point represents one tenth of the patient
sample, arranged from lowest to highest probability of the outcome. A:
For predicting severe disease course. B: For predicting non-achievement
of remission.
Additional file 3: Figure S2. Receiver operating characteristic (ROC)
curve showing the result of the univariate logistic regression model with
cumulative active joint count as the predictor variable and severe disease
course as the outcome. C-index of 0.85 (IQR 0.82–0.88).
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Abstract
Background: Validated clinical prediction models to identify children with poor prognosis at the time of juvenile
idiopathic arthritis (JIA) diagnosis would be very helpful for tailoring treatments, and avoiding under- or over-
treatment. Our objective was to externally validate Nordic clinical prediction models in Canadian patients with JIA.
Methods: We used data from 513 subjects at the 3-year follow-up from the Research in Arthritis in Canadian
Children emphasizing Outcomes (ReACCh-Out) cohort. The predicted outcomes were non-achievement of
remission, severe disease course, and functional disability. The Nordic models were evaluated exactly as published
and after fine-tuning the logistic regression coefficients using multiple data splits of the Canadian cohort. Missing
data was handled with multiple imputation, and prediction ability was assessed with C-indices. C-index values > 0.7
were deemed to reflect helpful prediction.
Results: Overall, 81% of evaluable patients did not achieve remission off medications, 15% experienced a severe
disease course, and 38% reported disability (CHAQ score > 0). The Nordic model for predicting non-achievement of
remission had a C-index of 0.68 (95% CI 0.62–0.74), and 0.74 (0.67–0.80) after fine-tuning. For prediction of severe
disease course, it had a C-index of 0.69 (0.61–0.78), and 0.79 (0.68–0.91) after fine-tuning. The fine-tuned Nordic
model identified 85% of the cohort as low risk for a severe disease course (< 20% chance) and 7% as high risk (>
60% chance). The Nordic model to predict functional disability had a C-index of 0.57 (0.50–0.63), and 0.51 (0.39–
0.63) after fine-tuning.
Conclusions: Fine-tuned Nordic models, combining active joint count, physician global assessment of disease
activity, morning stiffness, and ankle involvement, predicted well non-achievement of remission and severe disease
course in Canadian patients with JIA. The Nordic model for predicting disability could not predict functional
disability in Canadian patients.
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Background
Juvenile idiopathic arthritis (JIA) is a heterogeneous
group of conditions characterized by chronic arthritis of
unknown cause with onset before the age of 16 years [1].
Validated clinical prediction models to identify children
with poor prognosis at diagnosis would be very helpful
for tailoring aggressive treatments, such as synthetic
and/or biologic DMARDS prescribed shortly after diag-
nosis, to patients with poor prognosis and prevent
under- or over-treatment.
Clinical prediction models are relatively recent devel-
opments in JIA, but they are widely used to tailor treat-
ments in practice guidelines, e.g., in cardiovascular
disease [2] or osteoporosis [3]. Good practices for devel-
opment of clinical prediction models and consensus
statements for reporting these studies are available [4,
5]. Their discrimination accuracy is often assessed with
the C-index, equivalent to the area under the Receiver
Operating Characteristic curve (AUC), where 1.0 reflects
perfect prediction and 0.5 reflects chance alone. In the
cardiovascular literature, prediction models with C-
index values > 0.7 are considered helpful and those with
values > 0.8 are considered excellent [6].
Using data from the Research in Arthritis in Canadian
Children Emphasizing Outcomes (ReACCh-Out)
Cohort, Guzman et al. developed a clinical prediction
model to predict a severe disease course that had a C-
index of 0.85 in internal validation in that cohort [7].
Using data from the Nordic Study Group of Pediatric
Rheumatology (NoSPeR) cohort, Rypdal et al. developed
models to predict non-achievement of remission, func-
tional disability, and articular damage 8 years after dis-
ease onset. For prediction of non-achievement of
remission and functional disability, the C-indices in split
validation sets were 0.78 and 0.73, respectively [8]. The
mathematical models for Canadian and Nordic predic-
tion tools are shown in Table 1, and user-friendly online
calculators are available at https://shiny.rcg.sfu.ca/jia-
sdcc/ and http://predictions.no.
Although they aimed to predict different outcomes,
there are similarities between the Canadian model to
predict a severe disease course and the Nordic model to
predict non-achievement of remission. Both are multi-
variable logistic regression models that combine routine
clinical and laboratory variables available early in the
disease and both include the active joint count, ankle in-
volvement, and presence of morning stiffness. The main
differences are that the Canadian model uses twice as
many variables (16 vs 8), including JIA category, pres-
ence of enthesitis, and involvement of joints other than
Table 1 The original Canadian and Nordic prediction models for juvenile idiopathic arthritis
Source Outcome predicted Calculate A Use A to calculate chance
of outcome (%)
Guzman et al., Canada
2017 [7]
Severe disease course, defined by
trajectory of quality of life, pain,
active joint count, medication
requirements, and medication
side effects over the 5 years
after diagnosis
A = − 2.92 + 0.18 × (active joint count at
baseline) − 1.23 × (psoriatic arthritis) − 1.14 ×
(oligoarthritis) − 0.49 × (RF-negative
polyarthritis) + 0.75 × (upper limb
joint involvement) − 0.88 × (symmetric
joint involvement) + 1.31 × (RF positivity)
− 1.42 × (subtalar joint involvement)
− 0.31 × (finger joint involvement) + 0.84
× (cervical spine involvement) + 0.48 ×
(ankle joint involvement) + 0.56 ×
(presence of morning stiffness) + 0.06
× (hip involvement) + 1.50 × (temporal
mandibular joint involvement) + 0.54
× (mid-foot involvement) + 0.86 ×
(presence of enthesitis)
[eA/(1 + eA)] × 100
where eA is the natural
antilogarithm of A
Rypdal et al., Norway
2018 [8]
Non-achievement of remission
8 years after onset
A = − 1.58 + 0.04 × (cumulative joint
count within 6 months of onset) + 0.03
× (ESR in mm/h) − 0.07 × (CRP > 10 mg/L)
+ 1.16 × (morning stiffness > 15 min)
+ 0.16 × (physician global assessment)
+ 1.25 × (ANA positive) + 1.37 ×
(B27 positive) + 1.10 × (ankle joint arthritis)
[eA/(1 + eA)] × 100
where eA is the natural
antilogarithm of A
Rypdal et al., Norway
2018 [8]
Functional disability (CHAQ > 0)
8 years after onset
A = − 1.68 − 0.02 × (cumulative joint
count within 6 months of onset)
+ 0.01 × (ESR in mm/h) − 0.20 ×
(CRP > 10 mg/L) + 1.03 × (morning stiffness >
15 min) − 0.40 × (physician global assessment
VAS) + 1.21 × (finger joint arthritis) + 0.77 ×
(pain VAS)
[eA/(1 + eA)] × 100
where eA is the natural
antilogarithm of A
RF rheumatoid factor, ESR erythrocyte sedimentation rate, CRP C-reactive protein, ANA antinuclear antibody test, B27 human leucocyte antigen B27, VAS visual
analogue scale from 0 to 10 with 10 indicating worse values
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the ankles, and that the Canadian model uses active joint
count at presentation, while the Nordic model uses cu-
mulative joint count 6 months after onset.
External validation of clinical prediction models in
populations different than those in which they were de-
veloped is essential before general adoption can be rec-
ommended [5]. The goal of this collaboration between
ReACCh-Out and NoSPeR researchers was to determine
if clinical prediction models developed in one cohort
could be externally validated in the other cohort. The
aim of the present study was to externally validate the
Nordic models in Canadian patients. A twin study by
Rypdal et al. externally validated the Canadian model in
Nordic patients [9].
Patients and methods
The ReACCh-Out cohort has been previously described
in detail [10, 11]. In brief, 1497 patients newly diagnosed
with JIA were recruited at 16 pediatric rheumatology
centers across Canada from January 2005 to December
2010. The first visit occurred as soon as possible after
diagnosis, but the time from diagnosis to the first visit
could be as long as 1 year. Follow-up visits were sched-
uled every 6 months for 2 years and then yearly up to 5
years, or until May 2012. At each official study visit, full
clinical information was collected, including the Ameri-
can College of Rheumatology (ACR) core variables [12],
treatment information, and patient-reported outcomes.
Erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) levels were only measured if clinically in-
dicated. At interim clinic visits between study visits, a re-
duced dataset was collected, including the number of
active joints, limited joints or enthesitis sites, treatment
information, and ESR and CRP levels if measured.
ReACCh-Out was approved by Research Ethics Boards
at all participating institutions and performed in accord-
ance with the Declaration of Helsinki, including in-
formed written consent.
The Nordic Cohort recruited 500 patients newly diag-
nosed with JIA in defined geographical locations of
Norway, Sweden, Finland, and Denmark in 1997–2000.
First visit occurred approximately 6 months after disease
onset, then at 12 months, and then every 1–3 years with
an obligatory visit at approximately 8 years after disease
onset (available for 440 subjects) [13].
Patients
For the current study, the goal was to select patients re-
cruited in ReACCh-Out who were as similar as possible
to the population used for development of the original
Nordic prediction models. We considered including only
patients with information at the 5-year follow-up, but
this would have reduced our sample size considerably.
Moreover, since ReACCh-Out did not follow patients
into adulthood, many children who entered the cohort
as teenagers would have been excluded, resulting in
under-representation of JIA categories commonly seen
in teenagers. We chose instead to include data of pa-
tients recruited within 3 months of diagnosis who had
enough information at the 3-year visit to ascertain the
outcomes of interest.
Outcomes
Our primary outcome was non-achievement of remis-
sion at the 3-year visit. We were not able to use the
exact same outcome definition as in the original Nordic
study, since the schedule of visits and other features dif-
fered between the two cohorts. We designated a primary
definition and examined several alternative definitions.
The primary definition of remission was clinical inactive
disease for at least 12 months while off treatment [14].
We also examined the model’s ability to predict a severe
disease course as defined by Guzman et al. [7], based on
cluster analysis of changes in pain, health related quality
of life, number of active joints, medication requirements,
and medication side effects over 5 years.
Clinical inactive disease was defined as no active joints,
no active extra-articular manifestations (no enthesitis,
uveitis, or systemic manifestations), and a physician glo-
bal assessment of disease activity (PGA) of < 1 cm in a
10-cm visual analogue scale (VAS). This definition was
based on the 2004 Wallace criteria [14] and has been
previously used by our group [11, 15]. The main differ-
ences relative to the current American College of
Rheumatology (ACR) provisional criteria [16] are that a
morning stiffness of 15 min or less and normal acute
phase reactants were not required.
We defined functional disability as a Childhood
Health Assessment Questionnaire (CHAQ) disability
index [17] greater than 0 at the 3-year visit. This is the
same instrument and cutoff used in the Nordic study,
but at a different follow-up time. The Nordic study also
developed a model to predict functional disability de-
fined by the Child Health Questionnaire physical sum-
mary score [18], but the Canadian cohort did not use
that instrument.
Model validation
For each subject in the Canadian cohort, we first com-
puted the probabilities of non-achievement of remission
and functional disability, using the Nordic models
exactly as published (i.e., with the same intercept and
coefficients). We compared this prediction to the ob-
served outcome to assess prediction accuracy (C-index
and confidence intervals, details below). If the resulting
value was substantially lower than the value originally
published in the Nordic cohort, we proceeded to fine-
tune the models. Fine-tuning means re-estimation of the
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model’s intercept and coefficients to better fit a new
population, while keeping the same predictors and same
logistic regression methods to combine predictors. Inter-
cept and coefficients were re-estimated using multiple
splits of the Canadian cohort.
In pre-specified sensitivity analyses, we assessed the
ability of the Nordic model to predict alternative defini-
tions of remission, including inactive disease while off
treatment (i.e., without requiring 12months) and in-
active disease for > 6months irrespective of treatment.
We also looked at the model’s ability to predict a severe
disease course, as defined by Guzman et al [7]. This ana-
lysis was not pre-specified. Similar to what was reported
in the Nordic cohort [8], we looked at the performance
of prediction models that excluded the laboratory vari-
ables from the prediction model. Additional post hoc
analyses assessed the models’ performance after exclud-
ing patients with systemic JIA and in a subsample of pa-
tients who attended the 5-year follow-up. Lastly, we
examined the prediction ability of a model that included
only the active joint count at baseline.
Statistical analysis
All analyses were conducted using R software. The Can-
adian cohort had an overall 10% missing rate of baseline
data. Missing data were imputed in 20 datasets using the
method of multiple imputation by chained equations
(MICE) [19]. Outcome data was not imputed. Our re-
ported average C-indices and average coefficient esti-
mates are unweighted means across all 20 imputed
datasets. We followed Rubin’s rules [20] to compute
standard errors (SEs) for all quantities across the 20 im-
puted datasets.
To validate the original un-tuned Nordic models in
Canadian children, we fit each model to 100% of the
data within each of 20 imputed datasets. From each
dataset, we computed the C-index and the SE of the C-
index. We then combined these individual SEs to pro-
duce the overall C-index SE.
For the fine-tuned models, we needed to ensure that
the model-evaluation statistics were computed on data
not used to estimate the coefficients. We followed the
procedure published by Jiang et al. [21] and modified it
to compute the C-index. For a given imputed dataset,
we estimated the average C-index using their recom-
mendation of the Leave-One-Out Cross-Validation
(LOOCV) error. To estimate the within-dataset standard
error, we used their recommendation of a nested cross-
validation within a bootstrap (the BCCV algorithm). We
created B = 25 bootstrap samples on an imputed dataset.
Within each bootstrap sample, we removed one original
observation (if it occurred multiple times in the imputed
data, we removed all cases) and predicted this observa-
tion using the fitted model. We repeated this process for
each observation in turn to obtain predictions on each
case. We then computed a C-index on all predicted
values of that bootstrap sample. We then computed the
standard deviation (SD) of the B = 25 bootstrap sample
C-indices as an estimate of the within-dataset SD of the
C-index. The between-dataset and within-dataset SDs
were combined to produce the overall multiple imput-
ation SE using Rubin’s rules [20].
To obtain SE of coefficients, we fitted the model on
each of B = 25 bootstrap samples from each imputed
dataset (a total of 500 fits). For each imputed dataset,
we estimated the within-dataset SE of the coefficients
using the SD of the coefficient estimates from the glm
package in R across the 25 bootstrap samples. Again,
we combined this with the between-dataset SD to get
the overall SE.
Results
A total of 513 subjects fulfilled our inclusion criteria at
the 3-year visit, which occurred on average 3.75 years
after JIA onset. The patient flow chart is shown in Fig. 1.
The figure also shows the corresponding patient flow
chart used to select subjects for the original Nordic
study.
Baseline patient characteristics in the validation cohort
are compared with the reported characteristics in the
original development cohort in Table 2. Overall, the co-
horts are similar to each other and to other inception
cohorts of JIA reported in western populations. The ori-
ginal Nordic study excluded patients with systemic JIA
from model development and had only four patients
with RF-positive polyarthritis [8].
In total, 408 of 506 evaluable Canadian patients (81%)
were not in remission at the 3-year visit. Applying the
Nordic model for prediction of non-achievement of re-
mission exactly as published resulted on a C-index of
0.68 (95% CI 0.62–0.74). As this was lower than the pub-
lished value (median AUC 0.78, IQR 0.72, 0.82), we pro-
ceeded with fine-tuning of coefficients. After fine-tuning,
the C-index tested in multiple splits of the Canadian co-
hort was 0.74 (0.67–0.80). Figure 2 shows the corre-
sponding Receiver Operating Characteristic (ROC)
curves (panels a and b). The coefficients for original and
fine-tuned models are shown in Table 3. Excluding pa-
tients with systemic JIA had a small impact on model
performance, with a C-index of 0.73 (0.66–0.80) for the
original model and 0.76 (0.69–0.83) for the fine-tuned
model.
In secondary analyses, the C-index values calculated
when using alternative definitions of remission were
nominally lower than when using our primary definition
of remission. For inactive disease while off treatment, it
was 0.66 (0.60–0.71), and after fine-tuning, it was 0.69
(0.63–0.75). For inactive disease > 6months irrespective
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of treatment, it was 0.62 (0.53–0.71), and after fine-
tuning, it was 0.63 (0.50–0.75). We also calculated the
C-index for a subsample of patients assessed at the 5-
year follow-up in the ReACCh-Out cohort; the C-index
was 0.57 (0.35–0.79), but this subsample was no longer
representative of all patients with JIA since patients diag-
nosed as teenagers were not followed into adulthood,
and the subsample was small, resulting in wide confi-
dence intervals.
A severe disease course was observed in 53 of 354 (15%)
evaluable patients. Prediction with the Nordic model had
a C-index of 0.69 (CI 0.61–0.78), and after fine-tuning, it
was 0.79 (0.68–0.91). The corresponding ROC curves are
shown in Fig. 2c, d. The calibration curves for the fine-
tuned Nordic models are shown in Fig. 3. The Nordic
model fine-tuned for severe disease course identified 85%
of the cohort as low risk for severe disease (< 20% chance)
and 7% of the cohort as high risk (> 60% chance).
We also examined the predictive ability of the model
after exclusion of laboratory variables as it was done in
the original publication. Fine-tuned versions with no la-
boratory values had a C-index of 0.74 (CI 0.67–0.81)
when predicting non-achievement of remission and 0.79
(CI 0.69–0.89) when predicting a severe disease course,
virtually the same values as models including laboratory
variables. Lastly, a model using the baseline active joint
count alone had a C-index of 0.66 (0.61–0.71) to predict
non-achievement of remission and 0.76 (0.66–0.86) to
predict a severe disease course.
Functional disability defined as a CHAQ > 0 was re-
ported by 137 of 361 (38%) evaluable patients. Prediction
with the Nordic model for functional disability had a C-
index of 0.57 (0.50–0.63), and fine-tuning of coefficients
was not able to improve accuracy, with a C-index of 0.51
(0.39–0.63). The corresponding ROC curves are shown
in Additional file 1: Figure S1.
We note that the Nordic model for functional disabil-
ity differed from the model for non-achievement of re-
mission not only by the value of its coefficients, but also
by the set of predictor variables. In the study of Rypdal
et al., there was no model for prediction of severe
disease course [8], and we used the model for non-
achievement of remission when we tested for ability to
predict severe disease course.
Discussion
The aim of this study was to externally validate predic-
tion models for poor prognosis in JIA developed in the
Nordic cohort by assessing their performance in Canad-
ian patients enrolled in the ReACCh-Out cohort. We
found that after fine-tuning of coefficients, the Nordic
model for predicting non-achievement of remission 8
years after disease onset had good accuracy to predict
non-achievement of remission 3.75 years after onset (C-
index 0.74) and a severe disease course over 5 years (C-
index 0.79) in Canadian patients, even after laboratory
variables were excluded. As shown in Table 3, fine-
tuning of the model to predict non-achievement of re-
mission increased the relative contribution of active joint
count (beta coefficient changed from 0.04 to 0.16) and
decreased the relative contribution of morning stiffness,
ankle joint arthritis, and laboratory test results. The
Fig. 1 Patient flow charts for the development and validation cohorts
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contribution of the physician global assessment was vir-
tually the same (from 0.16 to 0.15). In contrast, the
model to predict functional disability had a low C-index
of 0.57 and fine-tuning did not improve accuracy (C-
index 0.51).
For decades, prognostic research in JIA has concen-
trated on identifying features of poor prognosis [22], but
the last decade has seen publication of several models
that combine prognostic features to estimate the likeli-
hood of an outcome for each patient. In 2012, Bulatovic
Table 2 Baseline characteristics for patients in the development and validation cohorts according to non-achievement of remission
q Nordic development cohort (N = 427) ReACCh-Out validation cohort (N = 506)
Remission (n = 181) Non-remission (n = 246) Remission (n = 98) Non-remission (n = 408)
Characteristics
Age at onset, years 5.9 (2.5, 10.0)* 5.2 (2.5, 9.5) 8.0 (3.6, 11.5) 7.2 (2.6, 11.1)
Female, n (%) 115 (63.5) 169 (68.7) 62 (63.3) 285 (70.4)
Onset to enrolment, months 7 (6, 8) 6.5 (6, 8) 3.9 (2.4, 6.0) 5.1 (2.7, 9.7)
JIA category, n (%)**
Oligoarthritis 107 (59.1) 111 (45.1) 55 (56.1) 137 (33.6)
RF-neg. polyarthritis 25 (13.8) 68 (27.6) 4 (4.1) 113 (27.7)
RF-pos. polyarthritis 1 (0.6) 3 (1.2) 0 (0.0) 17 (4.2)
Systemic 15 (8.3) 2 (0.8) 13 (13.3) 28 (6.9)
Enthesitis-related 11 (6.1) 23 (9.3) 8 (8.2) 50 (12.3)
Psoriatic 3 (1.7) 3 (1.2) 8 (8.2) 20 (4.9)
Undifferentiated 19 (10.5) 36 (14.6) 10 (10.2) 43 (10.5)
Assessments and laboratory tests
Active joints, n (%)
Cervical arthritis 13 (7.2) 25 (10.2) 0 (0.0) 26 (7.0)
Finger arthritis 40 (22.1) 94 (38.2) 16 (19.3) 167 (44.7)
Ankle arthritis 65 (35.9) 129 (52.4) 17 (20.5) 186 (49.7)
Hip arthritis 24 (13.3) 38 (15.4) 7 (8.4) 50 (13.4)
Active joint count*** 2 (1, 4) 4 (2, 7) 1 (1, 2) 3 (1, 9)
Physician global assessment 0.8 (0.0, 1.3) 2.0 (1.0, 3.8) 1.9 (1.0, 3.2) 3.8 (2.0, 6.0)
Parent global assessment 0.6 (0.0, 2.0) 1.7 (0.5, 3.5) 0.7 (0.2, 2.4) 2.3 (0.7, 4.9)
Pain 0.4 (0.0, 3.0) 2.3 (0.5, 4.2) 1.0 (0.2, 3.0) 3.9 (1.0, 6.1)
CHAQ DI 0.1 (0.0, 0.6) 0.5 (0.0, 1.1) 0.1 (0.0, 0.5) 0.5 (0.1, 1.1)
Stiffness > 15min (%) 30 (16.6) 90 (36.6) 45 (55.6) 184 (65.0)
ESR**** 11.5 (6, 20) 17.5 (10, 31) 20 (9, 34) 21 (9, 40)
CRP**** 0.0 (0, 0) 0.0 (0, 15) 2.0 (0.2, 10) 3.0 (0.3, 17)
ANA 37 (20.4) 76 (30.9) 49 (50.0) 182 (50.7)
RF 5 (2.8) 5 (2.0) 5 (5.1) 23 (6.4)
HLA B27 22 (12.2) 60 (24.4) 5 (5.1) 36 (10.0)
Treatment by first study visit (%)
NSAIDs 152 (84.0) 215 (87.4) 88 (89.8) 390 (95.6)
Joint injections 84 (46.4) 152 (61.8) 24 (24.5) 88 (21.6)
DMARDs 20 (11.0) 71 (28.9) 9 (9.2) 137 (33.6)
Biologics 0 0 1 (1) 1 (0.2)
*Numbers are median (25th centile, 75th centile) or number of patients (%)
**Patients with systemic JIA were excluded from the Nordic prediction model development study. They are included in the validation cohort and in this table
***The Nordic development cohort used the cumulative active joint count within 6months of disease onset, and the ReACCh-Out validation cohort used the
active joint count at baseline
****Erythrocyte sedimentation rate measurements were available for 322 of 427 patients (75.4%) in the Nordic cohort and for 458 of 506 patients (90.5%) in the
ReACCh-Out cohort. C-reactive protein measurements were available for 345 of 427 patients (80.8%) in the Nordic cohort and 404 of 506 patients (79.8%) in the
ReACCh-Out cohort
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Fig. 2 Receiver Operating Characteristic (ROC) curves for the Nordic model to predict non-achievement of remission when applied to Canadian
data. a Original model predicting non-remission. b Fine-tuned model predicting non-remission. c Original model predicting a severe disease
course. d Fine-tuned model predicting a severe disease course
Table 3 Changes to model coefficients for the Nordic model to predict non-achievement of remission made during the fine-tuning
process
Variable Original Nordic Fine-tuned Canada to predict non-achievement of
remission
Fine-tuned Canada to predict severe disease
course
With lab tests No lab tests With lab tests No lab tests
Constant (intercept) - 1.58 (- 0.70, -2.46)* 0.24 0.17 − 2.9 − 2.8
Active joint count** 0.04 (- 0.06, 0.14) 0.16 0.15 0.22 0.21
ESR in mm/h 0.03 (- 0.01, 0.07) - 0.01 – − 0.01 –
CRP > 10 mg/L - 0.07 (- 1.45, 1.31) 0.12 – 0.08 –
Morning stiffness > 15 min 1.16 (0.26, 2.06) 0.42 0.38 0.23 − 0.03
Physician global assessment 0.16 (- 0.76, 1.08) 0.15 0.14 − 0.05 − 0.06
ANA positive 1.25 (0.25, 2.25) 0.03 – − 0.56 –
HLA-B27 positive 1.37 (0.29, 2.45) 1.07 – 0.85 –
Ankle joint arthritis 1.10 (0.12, 2.08) 0.52 0.53 − 0.70 − 0.70
C-index (95% CI) 0.68 (0.62, 0.74) 0.74 (0.67, 0.80) 0.74 (0.67, 0.81) 0.79 (0.68, 0.91) 0.79 (0.69, 0.89)
*Numbers in parentheses are the 95% confidence interval
**The Nordic cohort used the cumulative active joint count within 6months of disease onset, while the ReACCh-Out cohort used the active joint count at baseline
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et al. reported a model to predict non-response to
methotrexate with an AUC of 0.65 [23], and in 2015,
van Dijkhuizen et al. reported a model to predict metho-
trexate intolerance with C-index of 0.77 in internal val-
idation [24]. More recently, van Dijkhuizen et al.
combined clinical characteristics, Luminex biomarkers,
and microbiota information to predict attainment of in-
active disease within 2 years of diagnosis, but the result-
ing overall model was deemed not satisfactory with a
AUC-like statistic of 0.65 [25]. Also recently, Guzman
et al. used routine clinical and laboratory data at the
time of diagnosis to predict early remission on medica-
tion (within 1 year of diagnosis) and the resulting model
had a C-index of 0.69 in internal validation, just short of
the conventional threshold of > 0.7 to consider a predic-
tion model helpful [26].
In the context of these studies, our current findings
raise four important questions: (1) Does the timing of
outcome measurement influence our ability to predict
inactive disease or remission? (2) Is the overall course of
JIA a better prediction target than remission at a single
point in time? (3) Should we eliminate laboratory values
from the Nordic model altogether? (4) Is the fine-tuned
Nordic model a better model to predict JIA disease
course than the Canadian model?
In our opinion, the timing of assessment of inactive
disease and remission will indeed influence the accuracy
of a prediction model, particularly since it is well known
that early in the course of JIA patients often transition
in and out of inactive disease with subsequent visits [27,
28]. Later in the disease course, remission off medica-
tions may be a relatively stable target. This may be one
reason why the Nordic model performed slightly better
when predicting remission at 8 years in the original co-
hort than when predicting remission at 3.75 years in the
current study. In addition to shorter follow-up, there
were some differences in cohort composition, in ascer-
tainment of predictors, and in the definition of inactive
disease.
Whether the overall disease course is a better predic-
tion target than remission is open to discussion. It is
somewhat surprising that the Nordic model developed
for predicting non-achievement of remission performed
better at predicting a severe disease course than non-
achievement of remission, since the severe-disease-
course outcome is constructed very differently from
non-achievement of remission. The results suggest that
there are strong dependencies between outcome vari-
ables that are not fully understood, and that data-driven
outcome measures, such as severe disease course, may
be more valuable than previously assumed. The defin-
ition of a severe disease course is based on the overall
trajectory of variables that are meaningful for families
and clinicians, instead of accepted JIA core variables
measured at a single point in time [7]. That said, remis-
sion is a well-accepted and easy to comprehend concept,
although using ACR criteria for inactive disease [16]
identifies a different patient population than using
JADAS criteria [29, 30]. In the context of prediction
studies, a targeted outcome needs to be useful for
Fig. 3 Calibration curves for the Nordic model to predict non-achievement of remission fine-tuned to Canadian data. a When predicting non-
achievement of remission. b When predicting a severe disease course. Each point represents one tenth of the testing patient sample, arranged
from lowest to highest probability of the outcome
Henrey et al. Arthritis Research & Therapy           (2020) 22:10 Page 8 of 11
clinical decision-making but also well-suited for pre-
diction. Future work should focus on rigorous clinical
definitions of predicted outcomes. Such definitions
will facilitate more accurate validation studies across
cohorts.
It is remarkable that the exclusion of laboratory values
(ESR, CRP, ANA, B27) had negligible impact on model
accuracy, replicating the original findings in the Nordic
cohort [8]. This means that a simple combination of ac-
tive joint count, physician global assessment of disease
activity, morning stiffness > 15min, and presence of
ankle involvement at baseline predicts well non-
achievement of remission 3 or 8 years later, as well as a
severe disease course during the first 5 years after diag-
nosis. Now that this has been demonstrated in both co-
horts, it is hard to think of a good reason to keep
laboratory values in the Nordic model.
The final question, which model is preferable, is also
open to discussion. Although the Nordic model is simple
and a simpler model is generally preferable, our results
suggest that the accuracy of the fine-tuned Nordic
model is somewhat lower than that of the Canadian
model (C-index of 0.79 vs 0.85), but this could be
simply due to the fact that the latter model was de-
veloped in the same Canadian cohort used in this
study. A definitive answer to this question may re-
quire testing both models side by side in a third sep-
arate independent cohort.
Study strengths and limitations
The main strength of our study is that it provides exter-
nal validation of the Nordic prediction model in an en-
tirely independent inception cohort with prospectively
determined outcome measures. Study limitations include
that our definition of remission is not exactly the same
and the timeline for assessment is shorter than in the
original study. A second limitation is the 10% rate of
missing data on predictors, but we used multiple imput-
ation by chained equations, which is a well-established
method. A third limitation is that we used the baseline
active joint count, instead of the cumulative active joint
count within 6 months of disease onset used in the ori-
ginal Nordic model, yet we suspect they would be very
similar, given that the baseline active joint count was ob-
tained around the time of diagnosis and the start of
treatment. Lastly, the observed improvements in accur-
acy with fine-tuning of coefficients suggest that for opti-
mal accuracy, the Nordic model should be fine-tuned to
the population in which it will be used. This may be
problematic as the necessary cohorts for fine-tuning are
only available in a few countries. Alternatively, this could
indicate slight overfitting during model development in
the Nordic cohort.
Conclusions
The Nordic model developed to predict non-achievement
of remission 8 years after JIA onset accurately predicted
non-achievement of remission 3.75 years after onset and
the overall disease course over 5 years after diagnosis in a
Canadian cohort after the model coefficients were fine-
tuned. The model is simple (active joint count, physician
global assessment, morning stiffness, and ankle involve-
ment with or without routine laboratory results), and it
should be tested in clinical care to assess whether it im-
proves the tailoring of treatment, i.e., more aggressive
treatments for patients at high risk of non-achievement of
remission, and whether this actually changes the subse-
quent disease course and prognosis. This should in turn
lead to increased cost-effectiveness of care and, most im-
portantly, improved patient outcomes.
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Purpose: To assess the long-term outcome of uveitis in juvenile idiopathic arthritis (JIA).
Design: Population-based, multicenter, prospective JIA cohort, with a cross-sectional assessment of JIA-
associated uveitis (JIA-U) 18 years after the onset of JIA.
Participants: A total of 434 patients with JIA, of whom 96 had uveitis, from defined geographic areas of
Denmark, Finland, Norway, and Sweden.
Methods: Patients with onset of JIA between January 1997 and June 2000 were prospectively followed for
18 years. Pediatric rheumatologists and ophthalmologists collected clinical and laboratory data.
Main Outcome Measures: Cumulative incidence of uveitis and clinical characteristics, JIA and uveitis
disease activity, ocular complications, visual outcome, and risk factors associated with the development of
uveitis-related complications.
Results: Uveitis developed in 96 (22.1%) of 434 patients with JIA. In 12 patients (2.8%), uveitis was diag-
nosed between 8 and 18 years of follow-up. Systemic immunosuppressive medication was more common among
patients with uveitis (47/96 [49.0%]) compared with patients without uveitis (78/338 [23.1%]). Active uveitis was
present in 19 of 78 patients (24.4%) at the 18-year visit. Ocular complications occurred in 31 of 80 patients
(38.8%). Short duration between the onset of JIA and the diagnosis of uveitis was a risk factor for developing
ocular complications (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.1e1.8). Patients with a diagnosis of
uveitis before the onset of JIA all developed cataract and had an OR for development of glaucoma of 31.5 (95%
CI, 3.6e274). Presence of antinuclear antibodies (ANAs) was also a risk factor for developing 1 or more ocular
complications (OR, 3.0; 95% CI, 1.2e7.7). Decreased visual acuity (VA) <6/12 was found in 12 of 135 eyes (8.9%)
with uveitis, and 4 of 80 patients (5.0%) with JIA-U had binocular decreased VA <6/12.
Conclusions: Our results suggest that uveitis screening should start immediately when the diagnosis of JIA
is suspected or confirmed and be continued for more than 8 years after the diagnosis of JIA. Timely systemic
immunosuppressive treatment in patients with a high risk of developing ocular complications must be considered
early in the disease course to gain rapid control of ocular inflammation. Ophthalmology 2020;-:1e11 ª 2020 by
the American Academy of Ophthalmology. This is an open access article under the CC BY license (http://creative
commons.org/licenses/by/4.0/).
Supplemental material available at www.aaojournal.org.
Juvenile idiopathic arthritis (JIA) is a chronic rheumatic
disease of unknown etiology that develops in children and
adolescents before the age of 16 years. Uveitis, inflamma-
tion of the uvea, is the most common extra-articular
manifestation in JIA.1,2 The reported occurrence of uveitis
in JIA varies considerably between different studies.3-5
Point prevalence is commonly reported between 10% and
15%.3,5,6 In a Finnish JIA cohort, the cumulative incidence
was 24% during the first 7 years of JIA,4 and in a Canadian
cohort, 13% developed uveitis during a mean follow-up
time of 6.9 years.5 Both lower and higher occurrences of
uveitis in JIA are reported in other studies.7,8 Chronic
anterior uveitis is the most frequent type of uveitis
associated with JIA. Because of the asymptomatic nature
of JIA-associated uveitis (JIA-U), all children with JIA
should be routinely screened by an ophthalmologist.9 Early
identification and timely treatment of uveitis are crucial to
prevent complications that may lead to visual impairment
1ª 2020 by the American Academy of Ophthalmology
This is an open access article under the CC BY license (http://creativecommons.o
rg/licenses/by/4.0/). Published by Elsevier Inc.
https://doi.org/10.1016/j.ophtha.2020.08.024
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and, in some cases, blindness.10,11 Recently, evidence has
emerged for a treatment strategy for JIA-U, where early
introduction of immunomodulating treatment and rapid
control of the uveal inflammation aim to reduce the risk of
developing ocular complications and visual loss.12,13
There are few long-term prospective studies on uveitis in
JIA.4,14,15 Studies have shown that the majority of patients
with JIA-U develop uveitis within the first 4 years after
the onset of JIA5,16,17 and that high-grade uveitis and active
uveal inflammation are associated with higher complication
rates.11,13,18,19 At diagnosis, ocular complications are seen
in up to 21% to 76% of eyes with JIA-U,11,13 and further
complications are reported to occur during the course with
a complication rate of 0.33 per eye per year.18 However,
our knowledge is limited regarding long-term complica-
tions and complications in patients who develop uveitis late
in the course of JIA.14,16
Previous studies have reported that female gender, young
age at onset of JIA, oligoarticular JIA, and the presence of
antinuclear antibodies (ANAs) and human leukocyte antigen
(HLA)-B27 are risk factors for the development of uveitis in
JIA.3,5,20 Reported risk factors for ocular complications in
established uveitis are male gender, the onset of uveitis
before arthritis, short interval between the onsets of JIA and
uveitis, and the presence of ocular complications early in
the disease course.6,21 However, there are inconsistencies
between studies concerning risk factors of ocular
complications in JIA-U.
Our study describes the long-term clinical outcome in
JIA-U in terms of cumulative incidence, the use of immu-
nosuppressive treatment, visual outcome, ocular complica-




The Nordic JIA cohort is a prospective multicenter population-
based study with 12 participating centers from specific geographic
areas of Denmark, Finland, Norway, and Sweden. We included 510
consecutive patients with onset of JIA between January 1, 1997, and
June 30, 2000. Onset of JIA was defined as the first episode of
arthritis. Juvenile idiopathic arthritis was classified according to the
International League of Associations for Rheumatology criteria.22
To reflect a population-based sample, the study included all
referred children from defined catchment areas in each country.
During the inclusion period, letters were repeatedly sent to primary
healthcare providers, child health centers, and orthopedic, pediatric,
and rheumatology specialists in the catchment areas to ensure the
referral of all eligible patients.23 The healthcare systems in the
Nordic countries are mostly free of charge for children aged less
than 16 years, making it feasible to conduct a population-based
study. The baseline study visit took place at a median of 7
months (interquartile range [IQR], 6e8 months) after the onset of
JIA. Thereafter, at a median of 98 months, the 8-year follow-up
study took place, with 440 participants at this follow-up. All pa-
tients with a baseline visit were invited to the 18-year follow-up.
Among the 510 patients with a baseline inclusion, 434 were fol-
lowed for 18 years and 329 (75.8%) attended a study visit at a
department of pediatrics; of these, 273 (62.9%) attended a study
visit at a department of ophthalmology. The remaining 105 patients
(24.2%) participated in the 18-year follow-up study through a
standardized telephone interview where we used the same
questionnaires as for the patients who attended the visit in person
(Fig 1). During the observation period, the patients were screened
for uveitis. For the first 2 years, the interval between the
ophthalmologic examinations was scheduled every 2 to 3 months;
thereafter, the intervals were longer depending on the time since
onset of JIA and JIA category. The screening followed local
programs based on international recommendations.9,10,24
Data Collection
Demographics, JIA and uveitis disease characteristics, and blood
samples were collected. Laboratory tests analyzed in this study
included HLA-B27, rheumatoid factor (RF), and immunofluores-
cence ANAs. Because no universal screening dilutions have been
established, ANA was considered positive according to the cutoff
value developed at the local laboratory related to the specific ANA
kits used. The cutoff value was !1/320 in Finland; !1/160 in
Copenhagen, Aarhus, and some parts of Sweden; and !1/80 in
Tromsø, Trondheim, and other parts of Sweden. Laboratory values
from disease onset were used but supplemented from the 18-year
visit in case of missing values.
For assessment of clinical remission in JIA, we applied Wallace
et al’s25,26 provisional criteria for inactive disease, requiring no
active arthritis, absence of systemic features due to JIA, normal
erythrocyte sedimentation rate or C-reactive protein, normal
global assessment on a visual analog scale from 0 to 10, absence
of active uveitis, and morning stiffness lasting "15 minutes. The
criterion for remission on medication is inactive disease on
medication for 6 successive months, and the criterion for
remission off medication is inactive disease for at least 12
months without treatment for JIA.
Characteristics of uveitis were recorded following the
Standardization of Uveitis Nomenclature (SUN) Working Group
criteria.27 The uveitis was recorded as an anterior, intermediate,
Figure 1. Flowchart of the study population throughout the observation
period of 18 years. Total number of patients with juvenile idiopathic
arthritis (JIA) and JIA-associated uveitis (JIA-U) at baseline, 8-year, and
18-year follow-up visits.
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posterior, or pan uveitis, and as symptomatic or asymptomatic
disease. The course of uveitis was defined as acute, recurrent, or
chronic, as limited or persistent in duration, and as having a
sudden or insidious onset.27 The activity of uveitis in SUN
grades and intraocular complications were recorded at the 18-
year follow-up visit. Systemic medication was registered as pre-
vious if used in the period up to the 18-year follow-up and present
if used at the 18-year visit. Systemic medication included synthetic
disease-modifying antirheumatic drugs (sDMARDs) and biologic
disease-modifying antirheumatic drugs (bDMARDs).
Ophthalmologic Assessment
The 18-year ophthalmologic examination included measurement of
best-corrected visual acuities (BCVAs) monocular and binocular in
Snellen fraction with a Snellen chart or a letter or number chart. We
used the definition of visual impairment defined by the World
Health Organization:28 mild visual impairment as visual acuity
(VA) <6/12, moderate visual impairment as VA <6/18, severe
visual impairment as VA <6/60, and blindness as VA <3/60.
Slit-lamp examination was performed for assessment of uveitis
activity, which was defined as the presence of cells/mm2 field in
the anterior chamber, following the criteria of the SUN Working
Group.27 We defined uveitis course as acute if there was less than 3
months with uveitis activity and treatment, recurrent if there were
recurrent episodes and at least 3 months without uveitis activity
and treatment, and chronic if there was less than 3 months
without uveitis activity and treatment. Information on ocular
complications and ocular surgery was collected. We defined
glaucoma as pathologic cupping of the optic disc or visual field
defects in the presence of intraocular pressure >21 mmHg or
history of glaucoma surgery. In the case of missing information
in any variable, we excluded the patient from that particular
assessment.
Statistical Analysis
We used medians and IQRs to describe demographics and clin-
ical characteristics, and univariate logistic regression analysis
with odds ratios (ORs) to assess baseline variables as risk factors
of ocular complications in JIA-associated uveitis. Differences
between groups were analyzed using Pearson’s chi-square test
and 2-proportion z-test for dichotomized variables, and contin-
uous variables were analyzed using the ManneWhitney U test.
P < 0.05 was considered as significant. We performed a
KaplaneMeier analysis for the time interval between the onset of
JIA and the diagnosis of uveitis, where the dates of uveitis
diagnoses were obtained from the local screening programs.
Separate KaplaneMeier curves were constructed for patients
who had uveitis-associated ocular complications at 18 years and
patients without ocular complications at 18 years.
We constructed 2 heat maps. In the first, clinical characteristics
were plotted in rows and eyes in columns. By using hierarchical
clustering, rows and columns were ordered so that similar variables
appeared next to each other, and afterward the heat map was an-
notated in the lower panel with ocular complications. In the second
heat map, complications were plotted in rows and patients in col-
umns. After applying hierarchical clustering, the map was anno-
tated with previously reported risk factors for ocular complications
(Fig S1).6,21
We did not perform imputation for missing data, and we
included only patients with information on the assessed variable.
Statistical analyses were performed with Stata/MP version 15
(StataCorp LP, College Station, TX) and Wolfram (Champaign,
IL) Mathematica version 11.1.1.0.
Ethical Approval and Consent to Participate
Written informed consent was obtained from all patients. The
medical research ethics committees and data protection authorities
in the respective participating countries approved the study. The
study was conducted according to the guidelines of the Declaration
of Helsinki.
Results
At the 18-year follow-up, 96 (22.1%) of the 434 patients with
JIA had uveitis. The cumulative incidence of JIA-U was 44 of
143 (30.8%) in Finland, 22 of 111 (19.8%) in Denmark, 19 of
103 (18.4%) in Norway, and 11 of 77 (14.3%) in Sweden.
Finland had significantly more patients with JIA-U compared
with the other countries in the cohort (P ¼ 0.002, Pearson’s
chi-square).
Uveitis was detected in 89 of 440 patients (20.2%) during the
first 8 years of follow-up. Additionally, 12 patients (2.8%) were
diagnosed with uveitis between the 8-year20 and 18-year follow-
ups. Five patients with uveitis were lost to follow-up during this
period. Of the 96 patients with uveitis at the 18-year follow-up, 80
attended the ophthalmology visit (83.3%) (Fig 1). All patients who
were diagnosed with uveitis before JIA and 9 of the 12 patients
diagnosed with uveitis between the 8-year and 18-year follow-
ups were among the 80 patients with JIA-U examined by the
ophthalmologist.
The median age at the diagnosis of uveitis was 5.8 years (IQR,
3.8e11.7 years). The age at onset of JIA was lower for patients
with uveitis compared with those without uveitis (P ¼ 0.006,
ManneWhitney U test). For patients developing uveitis, the me-
dian time from the onset of JIA to the diagnosis of uveitis was 1.6
years (IQR, 0.4e5.0 years). The maximum time from the onset of
JIA to the diagnosis of uveitis was 17.6 years. Uveitis was
diagnosed before arthritis in 8 of 96 patients (8.3%). These 8 were
diagnosed with uveitis at a median of 0.3 years (IQR, 0.2e1.8
years) before the onset of JIA. The majority of patients with
uveitis, 59 of 96 (61.5%), were female (Table 1).
The distribution of uveitis in the different categories of JIA was
as follows: enthesitis-related arthritis in 14 of 45 patients (31.1%),
RF-negative polyarthritis in 21 of 71 patients (29.6%), psoriatic
arthritis in 8 of 28 patients (28.6%), extended oligoarthritis in 19 of
85 patients (22.4%), undifferentiated arthritis in 13 of 66 patients
(19.7%), and persistent oligoarthritis in 21 of 119 patients (17.6%).
We did not detect uveitis in any of the patients with RF-positive
polyarthritis or systemic-onset JIA.
We did not find any significant differences in gender or ANA
positivity among the patients with or without uveitis at the 18-year
visit. Human leukocyte antigen B27 was significantly more com-
mon in patients with uveitis than without (P ¼ 0.005, Pearson’s
chi-square) (Table 1). There was no significant difference in ANA
or HLA-B27 among the patients from Finland compared with the
other Nordic countries.
Clinical Presentation of Uveitis and Disease
Activity
Among the 80 patients with JIA-U who attended the 18-year
ophthalmology visit, 58 of 77 (75.3%) had bilateral uveitis, and
19 of 77 (24.7%) had unilateral uveitis. A total of 135 eyes in 77
patients were affected by uveitis. In 3 of the 80 examined patients,
the information regarding whether the uveitis was unilateral or
bilateral was missing. Anterior uveitis was found in 68 of 71 pa-
tients (95.8%). One patient had intermediate uveitis, and 2 patients
had panuveitis. Thirty-eight of 75 patients (50.7%) had a chronic
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course of uveitis, and 28 of 75 patients (37.3%) had a recurrent
course. Nine of 75 patients (12.0%) had an acute course with
sudden onset and limited duration (<3 months) of the episode of
uveitis activity and treatment (Table 2). Six of the 9 patients with
acute course uveitis were HLA-B27 positive, and 5 patients had a
HLA-B27 positive enthesitis-related arthritis.
At the 18-year follow-up visit, there were no detectable cells in
the anterior chamber (SUN 0) in 59 of 78 (75.6%) of the assessed
patients with uveitis. Standardization of Uveitis Nomenclature
0.5þ to 1þ was found in 18 of 78 (23.1%) and SUN 2þ in 1 of 78
(1.3%) of the examined patients with JIA-U. None of the patients
had >SUN 2þ . Among the 19 patients with anterior chamber cells
at the visit, 13 (68.4%) had at least 1 ocular complication. A faint
flare (1þ ) was found in 14 of 78 (17.9%), and a moderate flare
(2þ ) was found in 4 of 78 (5.1%) of the examined patients with
uveitis (Table 2).
The proportion with active JIA disease according to the pro-
visional criteria reported by Wallace et al25,26 for inactive disease
was significantly higher in patients with JIA-U (45/86 [52.3%])
compared with those without uveitis (86/243 [35.4%]) (P ¼ 0.005,
Pearson’s chi-square). The rate of remission without medication
was lower among patients with uveitis (16/86 [18.6%]) compared
with patients without uveitis (100/243 [41.2%]) (P ¼ 0.005,
Pearson’s chi-square). The rate of remission on medication (inac-
tive disease, including the absence of active uveitis for at least 6
continuous months, while the patient is on medication) was higher
among patients with JIA-U, 14 of 86 (16.3%) compared with 23 of
243 (9.4%) for patients without uveitis, but this was not a signif-
icant difference (P ¼ 0.09, Pearson’s chi-square). Inactive disease
but not yet fulfilling remission criteria was found in 11 of 86
(12.8%) patients with JIA-U and in 34 of 243 (14.0%) of the pa-
tients with JIA without uveitis.
Medication
At the baseline visit (median 7 months after onset of JIA), 25 of 96
(26.0%) of the patients with JIA-U were treated with synthetic
disease-modifying antirheumatic drugs (sDMARDs). sDMARDs
were used in 51 of 96 patients (53.1%) up to the 1-year visit
(median 13 months after onset of JIA) and in 72 of 96 patients
(75.0%) in the period up to the 8-year visit (median 98 months after
onset of JIA). None of the patients with JIA-U were taking
bDMARDs (infliximab or adalimumab) at baseline. Eight were
treated with bDMARDs (infliximab, n ¼ 7, adalimumab, n ¼ 1)
between the baseline and the 1-year visit, and 21 patients used
bDMARDs (infliximab, n ¼ 16, adalimumab, n ¼ 5) within 8 years
after onset of JIA.
Three of 8 patients with uveitis and ocular complications treated
with bDMARDs within the 1-year visit were diagnosed with
uveitis prior to JIA. Twelve of 21 patients treated with bDMARDs
within the 8-year visit were diagnosed with uveitis during the first
year after onset of JIA.
During the 18-year observation period, a total of 76 of 96
patients with uveitis (79.2%, 95% confidence interval [CI],
71.0e87.0) were treated with any sDMARDs compared with 223
of 378 patients without uveitis (59.0%, 95% CI, 54.0e64.0) (P
< 0.001, 2-proportion z-test). Any bDMARDs were given to 52 of
96 patients with uveitis (54.2%, 95% CI, 44.0e64.0) and 76 of 335
patients without uveitis (22.7%, 95% CI, 18.0e27.0) (P < 0.001,
2-proportion z-test). Table S1 (available at www.aaojournal.org)
shows detailed information on the different sDMARDs and
bDMARDs. Among the 19 patients with active uveitis at the 18-
year visit, 17 (89.5%) had been treated with sDMARDs or
bDMARDs at some point during the 18-year observation period.
Of the 59 patients with inactive uveitis (SUN 0) at the 18-year visit,








n [ 96 P Value
Female, n (%) 297/434 (68.4) 238/338 (70.4) 59/96 (61.5) 0.096
Age at JIA onset, yrs 5.7 (2.6e9.8) 6.2 (2.9e10.1) 4.5 (1.9e8.7) 0.006
Age at uveitis diagnosis, yrs e e 5.8 (3.8e11.7)*
Age at 18-yr visit, yrs 23.4 (20.8e27.1) 23.5 (20.4e27.4) 21.6 (19.1e26.1) 0.003
Follow-up time, yrs 17.6 (16.7e18.4) 17.7 (16.8e18.6) 17.4 (16.5e18.2) 0.029
ANA positive, n (%) 142/384 (37.0) 101/291 (35.0) 41/93 (44.1) 0.103
HLA-B27 positive, n (%) 93/433 (21.5) 63/337 (18.7) 30/96 (31.3) 0.005
Cumulative joint count 7.0 (3.0e13.0) 6.5 (2.0e13.0) 8.5 (4.0e14.0) 0.027
Patient PA 0.5 (0.0e3.0)y 1.0 (0.0e3.5)z 1.0 (0.0e4.0)* 0.057
Patient GA 0.5 (0.0e2.5)y 0.5 (0.0e2.0)z 1.0 (0.0e3.0)* 0.013
JADAS27 1.0 (0.0e4.0)y 0.5 (0.0e3.5)z 2.0 (0.0e6.0)* 0.001
JIA categories, n (%)
Systemic JIA 14 (3.2) 14 (3.2) 0 e
Persistent oligoarthritis 119 (27.4) 98 (29.0) 21 (21.8) 0.087
Extended oligoarthritis 85 (19.6) 66 (19.5) 19 (19.9) 0.049
RF-negative polyarthritis 71 (16.4) 50 (14.8) 21 (21.9) 0.019
RF-positive polyarthritis 6 (1.4) 6 (1.4) 0 e
Psoriatic arthritis 28 (6.5) 20 (5.9) 8 (8.3) 0.026
Enthesitis-related arthritis 45 (10.4) 31 (9.2) 14 (14.6) 0.017
Undifferentiated arthritis 66 (15.2) 54 (15.7) 13 (13.5) 0.070
ANA ¼ antinuclear antibody; GA ¼ global assessment; HLA ¼ human leukocyte antigen; JADAS27 ¼ juvenile arthritis disease activity score based on
evaluation of 27 joints; JIA ¼ juvenile idiopathic arthritis; PA ¼ pain assessment; RF ¼ rheumatoid factor.
Values are median interquartile range (IQR) if not otherwise specified. P value for comparison of JIA with and without uveitis, by Pearson’s chi-square for
categoric variables, and ManneWhitney U test for continuous variables. Numbers assessed: *n ¼ 89, yn ¼ 403, and zn ¼ 315.
Self-reported pain on a visual analogue scale (range 0e10). Self-reported global assessment of well-being on a visual analogue scale (range 0e10).
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50 (84.7%) had been treated with sDMARDs or bDMARDs during
the observation period.
At the 18-year visit, 32 of 96 patients (33.3%) with uveitis were
treated with sDMARDs compared with 55 of 338 patients (16.3%)
without uveitis (P < 0.001, Pearson’s chi-square). Biologic
disease-modifying antirheumatic drugs were given to 34 of 96
(35.4%) of the patients with uveitis at the time of the visit and 50 of
338 (14.8%) of the patients without uveitis (P < 0.001, Pearson’s
chi-square). The use of any disease-modifying antirheumatic drugs
(DMARDs) was significantly more common among patients with
uveitis (47/96, 49.0%) at the 18-year visit compared with patients
without uveitis (78/338, 23.1%) (P < 0.001, Pearson’s chi-square)
(Table S1). In 33.7% of the patients with JIA-U uveitis was
reported to be the main reason for ongoing systemic
immunomodulating treatment. Local treatment with any eyedrops
were used by 29 of 92 (31.5%) of patients with JIA-U at the
visit. Among the 19 patients with active uveitis at the visit, 14
(73.7%) were using sDMARDs or bDMARDs. Of the 59 patients
with uveitis without active uveitis (SUN 0) at the 18-year visit, 29
(49.2%) had ongoing treatment with sDMARDs or bDMARDs.
Among the patients who had registered ocular complications at
the 18-year visit, 6 of 31 (19.4%) used bDMARDs within 1 year of
follow-up compared with 1 of 59 (1.7%) of the patients
with uveitis who did not develop complications. This number was
13 of 31 (41.9%) and 5 of 59 (8.5%), respectively, within 8 years
of follow-up. Of the patients who had ocular complications at the
18-year visit, 25 of 31 (80.6%) had used bDMARDs at some point
during the 18-year observation period compared with 27 of 59
(45.8%) of the patients with uveitis who did not develop
complications.
Ocular Complications and Visual Acuity
We found 1 or more ocular complications in 31 of 80 patients
(38.8%) with uveitis attending the 18-year ophthalmology visit.
Forty-two of 135 (31.1%) uveitis eyes were affected by at least 1
complication (Table 3). The most frequent ocular complications
were cataract and glaucoma. Cataract was found in 25 of 80
(31.3%), of whom 21 of 25 (84.0%) had undergone cataract
surgery. Among the patients who had cataract surgery, 16
patients also had glaucoma, 10 had synechiae, 8 had macular
edema, 6 had band keratopathy, and 3 had epiretinal membrane,
hypotony, and phthisis. Glaucoma occurred in 22 of 80 patients
(27.5%), of whom 18 of 22 (82.0%) had undergone glaucoma
surgery. Fifteen patients underwent surgery for both cataract and
glaucoma. Four patients presented with an ocular complication at
the baseline visit, 20 patients developed at least 1 complication
during the first 8 years of follow-up, and 7 of the previously un-
affected patients developed a uveitis-related complication between
the 8-year and 18-year follow-up visits.
Eight patients were diagnosed with uveitis before JIA. All of
them developed a cataract, and 7 were also diagnosed with glau-
coma. In contrast, all patients with uveitis without ocular compli-
cations had their uveitis diagnosed after the onset of JIA. The
timepoint for uveitis diagnosis for patients without complications
was spread throughout the observation period, as presented in the
KaplaneMeier plots (Fig 2). An association was found between
ocular complications and the starting point of uveitis with a
median time of 0.4 years (IQR, 0.1e1.1 years) between the onset
of JIA and the diagnosis of uveitis for the patients who
developed ocular complications and 1.9 years (IQR, 0.5e4.1
years) for the patients who did not develop uveitis-related com-
plications (P < 0.001, ManneWhitney U test). Complications
were most frequent among patients with anterior uveitis (28/68;
41.2%), asymptomatic uveitis (24/55; 43.6%), and a chronic course
(23/38; 60.5%) or insidious onset of uveitis (27/58; 46.6%) (Fig 3).
In our cohort, 87.5% had been diagnosed with uveitis within 8
years after the onset of JIA (Fig 2). Among the 12 patients with
onset of uveitis between the 8-year and 18-year follow-ups, only
1 patient developed uveitis-related complications. The age at
uveitis diagnosis was available for 6 of the 12 patients (median age
22.9 years; IQR, 17.4e26.7 years). Four patients had persistent
oligoarthritis, 2 patients had extended oligoarthritis, 1 patient had
RF-negative polyarthritis, 1 patient had psoriatic arthritis, 1 patient
had enthesitis-related arthritis, and 3 patients had undifferentiated
arthritis. Nine patients were male, and 5 patients were HLA-B27
positive. Information on the clinical presentation of the uveitis
was available for 9 of the 12 patients. Four patients had acute
uveitis, 3 patients had recurrent uveitis, and 2 patients had chronic
uveitis. Five had symptomatic uveitis.
We found worst-eye visual impairment with monocular BCVA
<6/12 in 8 of 80 patients (10.0%) with uveitis examined by the
ophthalmologist at the 18-year follow-up visit. Four of these 8
patients had BCVA >6/12 when tested with both eyes open, and
thus binocular BCVA <6/12 in 4 of 80 patients (5.0%). Two
patients had no light perception in both eyes, and 3 patients had no
Table 2. Clinical Presentation of Juvenile Idiopathic
ArthritiseAssociated Uveitis According to the Standardization of
Uveitis Nomenclature
Clinical presentation Patients, n (%)
Uveitis localization, n ¼ 71
Anterior uveitis 68 (95.8)
Intermediate uveitis 1 (1.4)
Posterior uveitis 0
Pan uveitis 2 (2.8)
Uveitis symptoms, n ¼ 76
Mostly symptomatic 21 (27.6)
Mostly nonsymptomatic 55 (72.4)
Best judgment of onset of uveitis
episodes, n ¼ 72
Sudden onset 14 (19.4)
Insidious onset 58 (80.6)
Best judgment of the duration of uveitis episodes,
n ¼ 71
Limited duration (<3 months) 27 (38.0)
Persistent duration (!3 months) 44 (62.0)
Uveitis course, n ¼ 75
Acute course (<3 mos with uveitis activity
and treatment)
9 (12.0)
Recurrent course (!3 mos without uveitis
activity and treatment)
28 (37.3)
Chronic course (<3 mos without uveitis
activity and treatment)
38 (50.7)
Anterior chamber cells at the 18-yr follow-up,
n ¼ 78
SUN 0 (<1 cell in field) 59 (75.6)
SUN 0.5þ to 1þ (1e15 cells in field)* 18 (23.1)
SUN 2þ (16e25 cells in field) 1 (1.3)
Anterior chamber flare at the 18-yr follow-up,
n ¼ 78y
SUN 0 (none flare) 59 (75.6)
SUN 1þ (faint flare) 14 (17.9)
SUN 2þ (moderate flare) 4 (5.1)
SUN ¼ Standardization of Uveitis Nomenclature.
*Anterior chamber cells SUN 0.5þ to 1þ were grouped together in the
study database; thus, it is not possible to divide into 2 separate groups
(0.5þ and 1þ ).
yNone of the patients had anterior chamber cells or flare SUN 3þ or
SUN 4þ .
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light perception in 1 eye (Table 3). Binocular BCVA <6/12 was
found in 4 of the 21 patients who had undergone cataract
surgery, and 2 of the patients who were blind at the 18-year visit
had both undergone cataract surgery.
Risk Factors Associated with Ocular
Complications
A short time interval between the onset of JIA and diagnosis of
uveitis, including both positive and negative values, was a signif-
icant risk factor for at least 1 complication related to uveitis in
univariate logistic regression (OR, 1.4; 95% CI, 1.1e1.8). Another
significant risk factor for ocular complications was ANA positivity
(OR, 3.0; 95% CI, 1.2e7.7). All 8 patients with a diagnosis of
uveitis before the onset of JIA developed cataract, and the risk of
glaucoma was high when uveitis was diagnosed before JIA (OR,
31.5; 95% CI, 3.6e274). We did not find any significant predictors
of ocular complications in analyses of gender, age at diagnosis of
uveitis, age at onset of JIA, different JIA categories, or uveitis
development 8 to 18 years after onset of JIA. The distribution of
ocular complications relative to these assessed variables is pre-
sented in the heat map in Fig S1 (available at www.aaojournal.org).
Discussion
In our Nordic JIA cohort, enrolled from pediatric rheuma-
tology practices, the cumulative incidence of uveitis was
22.1% during the 18 years of 434 prospectively followed
patients with JIA. Uveitis-related complications occurred in
38.8%, and decreased VA <6/12 occurred in 12 of 135 eyes
(8.9%) with JIA-U.
The reported prevalence of uveitis in JIA varies consider-
ably between different studies and populations.4,6,9,14,15,29-35
Several studies presenting uveitis prevalence are retrospec-
tive or registry-based, with a broad range of follow-up times,
making it difficult to compare results. Other reasons for the
variability in reported uveitis prevalence are differences in
what is actually reported, such as point prevalence or period
prevalence, study design, cohort compositions such as referral
cohorts from which the patients are recruited, and genetic
differences between populations. Some of the highest preva-
lence is reported from the Nordic countries,3,4,20 and it has
been suggested that children with European descent,
especially with Nordic descent, have a higher risk of uveitis
in JIA.3,36 In other population-based studies from Spain,
Czech Republic, Germany, and Estonia, the cumulative inci-
dence of uveitis varied between 4.0% and 12.0%, but the
follow-up period in these studies were shorter than in our
study.31-35
The overall recently reported prevalence of uveitis
appears to be decreasing compared with the 1990s and
2000s.37,38 Kotaniemi et al38 reported a decrease in the
cumulative incidence of uveitis in JIA from 25.0% to
18.0% in 2 separate cohorts collected in 1990 to 1993 and
2000 to 2003. Likewise, Tappeiner et al37 reported a
decrease in uveitis from 33.6% to 23.9% between 2002
and 2013. In their study, the use of DMARDs was more
common in the more recent cohort. In a later publication,
they reported that methotrexate treatment started during
Figure 2. Time for diagnosis of uveitis during the 18-year observation
period in the Nordic juvenile idiopathic arthritis (JIA) cohort for the
patients who developed and did not develop ocular complications. A,
KaplaneMeier curve for the time points for diagnosis of uveitis in the total
JIA cohort (black curve), patients with uveitis who did not develop ocular
complications (blue curve), and patients with uveitis who developed
ocular complications (red curve). Ocular complications were assessed at
the 18-year follow-up, and time points for diagnosis of uveitis were
collected from ophthalmological screening. B, Density histogram for the
onset time points of uveitis among the patients who remain complication
free, with each blue dot representing 1 uveitis case. C, Density histogram
for the onset time points of uveitis with ocular complications, with each
red dot representing 1 uveitis case.
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the first year after the onset of JIA was associated with a
lowered risk of uveitis and that a combination treatment of
methotrexate and anti-tumor necrosis factor was associated
with an even lower risk of JIA-U.39 In our study, the
occurrence of uveitis remains high. This might partly be
explained by the slightly less common sDMARD
treatment in our study at the last study visit compared
with the study by Tappeiner et al37 and by the fact that
our patients had onset of JIA in 1997e2000 when
treatment with biologics was less common. Synthetic
disease-modifying antirheumatic drug treatment was
ongoing at 18 years of follow-up in our study in 25.7% of
patients with JIA with or without uveitis, compared with
47.2% in the study by Tappeiner et al.37 Treatment with
bDMARDs was ongoing at the 18-year visit in our study
in 24.9% of patients, compared with 21.8% of patients in the
study by Tappeiner et al.37 The difference in the rate of
sDMARD treatment may be explained by the longer
follow-up time in our study. Remission of uveitis (in
terms of no detectable cells in the anterior chamber and no
Table 3. Ocular Complications in Juvenile Idiopathic ArthritiseAssociated Uveitis among Patients Examined by an Ophthalmologist at
the 18-Year Follow-up Visit
Patients, n (%)
n [ 80
Uveitis Eyes, n (%)
n [ 135
Ocular complications
At least 1 ocular complication 31 (38.8) 42 (31.1)
Cataract 25 (31.3) 32 (23.7)
Glaucoma 22 (27.5) 30 (22.2)
Synechiae 14 (17.5) 19 (14.1)
Macular edema 8 (10.0) 9 (6.7)
Band keratopathy 7 (8.8) 9 (6.7)
Epiretinal membrane 3 (3.8) 4 (3.0)
Hypotony 3 (3.8) 4 (3.0)
Phthisis 3 (3.8) 4 (3.0)
BCVA, binocular and monocular worst eye
Mild visual impairment 6/18 " BCVA <6/12 1 (1.3),* 2 (2.5)y 3 (2.2)
Moderate visual impairment 6/60 " BCVA <6/18 1 (1.3),* 2 (2.5)y 3 (2.2)
Severe visual impairment 3/60 " BCVA <6/60 0,* 1 (1.3)y 1 (0.7)
Blindness <3/60z 2 (2.5),* 3 (3.8)y 5 (3.7)
BCVA ¼ best-corrected visual acuity.
*Binocular.
yMonocular worst eye.
zOne patient with blindness had trauma to the eye.
Figure 3. Heat map visualization of uveitis clinical characteristics per eye according to ocular complications. Uveitis clinical characteristics (rows) of each
eye (columns) are ordered so that similar variables appear next to each other. The heat map is annotated (lower panel) with ocular complications. Uveitis
characteristics; there is a cluster in orange to the left in the heat map consisting of eyes with persistent, chronic, nonsymptomatic, insidious, and anterior
uveitis. Most complications occur for eyes that belong to this group. The blue color consists of limited, acute, symptomatic, sudden, and nonanterior
(intermediate or pan) localization of the uveitis. The purple color is eyes with recurrent uveitis course. Ocular complications; black square represents each 1
eye with an ocular complication. L ¼ left eye; R ¼ right eye.
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flare) at the 18-year visit was more common among our
patients (75.6%) compared with 42.0% in the study by
Kotaniemi et al38 and 65.3% by Tappeiner et al.37
In our study, the median time from the onset of JIA to the
diagnosis of uveitis was 1.6 years, whereas some previous
studies report a mean time of 1.1 to 1.8 years and a median
time of 5.5 months.4,5,9 Moreover, among study participants
diagnosed with uveitis, 8.3% developed uveitis before JIA,
and 80.0% had uveitis within 4 years after the onset of JIA.
Uveitis reportedly develops before JIA in 3% to 7%3,30 and
during the first 4 years after onset of JIA in up to 91%.4,5,9
These discrepancies with other studies may be explained by
different definitions of the onset date of JIA. In our study,
this was not the date of the physician’s diagnosis of
arthritis, but the date of the first evident clinical sign of
arthritis, such as an obvious swelling or limp, even if
reported the first time by the patients/parents and only
later confirmed by a physician.
In contrast to most recent studies suggesting that uveitis
rarely develops more than 7 years after the onset of JIA,4,5,9
12.5% of the patients with JIA-U in our cohort had onset of
uveitis after the 8-year follow-up. Our results are in line with
those of Zak et al,14 who reported an increase in uveitis
occurrence and complications from 1979 to 1980 to 1996
to 1997. Our study suggests that continuing the uveitis
screening in patients with JIA after 7 to 8 years of
diagnosis might be beneficial because approximately half
of the late uveitis cases were asymptomatic. A lack of
previous long-term prospective cohort studies may have
led to an underestimation of the number of late uveitis cases
and the overall cumulative incidence of uveitis.5,13 Other
prospective, long-term follow-up studies are needed to
better assess the risk of late onset of uveitis in JIA.
In our study, 38.8% of the patients with JIA-U developed
at least 1 ocular complication during the 18 years of
observation. The rate of complications is lower than in
previous reports 2 or more decades ago.15,16,40 However,
complications are more prevalent in our study compared
with other recent studies from Europe.37-39 Kotaniemi
et al38 presented an overall ocular complication rate of
21.0% in 2000e2003. The German prospective study by
Tappeiner et al37 found a decrease in ocular complications
from 33.6% to 23.9% in the period between 2002 and
2013. Our high prevalence of complications might be
explained mainly by the long follow-up because 7 of 31
(22.6%) of the ocular complications occurred in the period
between 8 and 18 years of follow-up.15,16,37,38,40 Earlier
studies have shown that both treatment with synthetic and
biologic DMARDs, and low uveitis activity are associated
with lower occurrence of poor vision and ocular
complications.11,18,19,39 The comparatively high
complication prevalence in our study may be explained
partly by the recruitment period in the era before the early
start of bDMARDs was an established treatment strategy.
In our study, complications are more common in the
group of patients who are diagnosed with uveitis before or
shortly after onset of JIA. For patients who develop
complications, the use of bDMARDs increased from 16%
to 77% from 1 year to 18 years after the onset of JIA.
However, most of our patients (75.6%) had quiescence of
uveitis with no detectable cells in the anterior chamber at
the 18-year visit.
In general, comparisons of studies on uveitis-related
complications are challenging because of selection bias.
Studies with shorter follow-up time may underreport the rate
of complications, whereas studies from retrospective tertiary
centers may report a higher rate of complications because
they include the more severe uveitis cases. Cohorts selected
from tertiary ophthalmology clinics may have more ocular
complications than those collected from pediatric rheuma-
tology centers. On the other hand, in many Nordic countries,
tertiary pediatric rheumatology centers and tertiary
ophthalmology clinics are often located at the same hospital,
meaning that the selection of patients will not differ. In
short, early introduction of DMARDs as a strategy for
treatment of arthritis seems to reduce both the risk of uveitis
and its complications.39 Well-established ophthalmologic
screening programs9,10 may also contribute to the reduced
ocular complications, presumably by earlier diagnosis
before complications have occurred and timely treatment
of the ocular inflammation. We did not find a significant
association between the development of ocular
complications and male gender or young age at the onset
of uveitis.21,41 However, we confirmed that developing
uveitis before JIA, having a short duration between onset
of JIA and diagnosis of uveitis, and having ANA
positivity are risk factors for developing ocular
complications. Notably, all patients who developed uveitis
before JIA had ocular complications.
Long-term poor visual outcome has been associated with
a diagnosis of uveitis before JIA, short interval between the
diagnosis of arthritis and uveitis, high-grade uveal inflam-
mation, and the presence of ocular complications early in
the disease course and history of intraocular surgery.6,11,13,21
Despite a relatively high rate of complications, the
proportion of patients with unfavorable visual outcome in
our study was lower or in line with previous
reports.2,4,17,40 Haasnoot et al17 found in their study from
2016 that 4% had a visual impairment or were legally
blind ("20/200) at the age of 18 years and that 33% had
at least 1 eye with VA "20/50. In our study, 2.5% of the
patients with JIA-U were blind in both eyes and 3.8%
were blind in the worst eye, and 5.0% in our study had a
binocular VA <6/12. Kotaniemi et al4 found that 3 of 104
children (2.9%) with JIA-U had a VA "20/60 after a
mean follow-up time of 4.5 years, whereas we found a
BCVA <6/18 for both eyes in 3 patients (3.8%) and in the
worst eye for 6 patients (7.5%) after a median follow-up
time of 17.6 years.
Study Strengths and Limitations
There are several strengths of this study. To our knowledge,
this is one of few long-term prospective population-based
studies on JIA-associated uveitis. This means that our
results are generalizable to patients in the population with
JIA, not just the patients with more severe JIA-U who are
usually managed at tertiary ophthalmology centers. Despite
the long observation period of 18 years, the proportion of
patients lost to follow-up is relatively small, and we have
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reliable ophthalmologic data for 83% of the patients with
uveitis 18 years after JIA onset. The study is conducted
according to the International League of Association for
Rheumatology classification, the American College of
Rheumatology disease activity criteria, and the SUN
Working Group criteria, enabling comparison with other
studies in the field. A limitation of the study is that we do
not have information on the precise timepoints when
patients started topical corticosteroids, the treatment starting
point, or the indication (arthritis or uveitis) for treatment
with systemic corticosteroids or DMARDs. Also, the
inclusion period of the study was at the beginning of the
biologic era. Thus, it may not reflect the effect of early
implementation of immunomodulating treatment on uveitis
outcomes. At the 18-year visit, 15% were lost to follow-up,
and because patients with more severe disease are likely to
attend follow-ups, this may lead to biases and an over-
estimation of the cumulative uveitis incidence. For instance,
the cumulative incidence of uveitis may be 96 of 510
(18.8%) rather than 96 of 434 (22.1%) if all uveitis cases
attended the 18-year follow-up. On the other hand, we may
also have lost some late diagnosed uveitis cases, which
implies that the true cumulative incidence might be
somewhere between those figures. There is some missing
information for specific uveitis variables, reducing the total
number of assessable patients. The relatively small sample
size in subgroups may limit identification of relevant risk
factors for complications. Future work should focus on
longer follow-up and developing prediction rules for pre-
diction of severe uveitis course to enable targeted screening
and treatment strategies adapted to high-risk subgroups.
In conclusion, this unique long-term prospective
population-based study found that a considerable proportion
of patients with uveitis still develop sight-threatening com-
plications in young adulthood. The patients at highest risk of
complications are those who develop uveitis before JIA or
closely after the onset of JIA. Screening by an ophthalmologist
must start urgently in all children when JIA is suspected and
diagnosed. Our study shows that uveitis may develop up to 18
years after the onset of JIA. We suggest screening to be
extended for a longer period than recommended in most
established screening programs to identify late-onset uve-
itis.9,10,12 The high prevalence of uveitis and ocular
complications emphasizes the need for interdisciplinary care,
with early consideration of systemic immunosuppressive
treatment. Ophthalmologists and pediatric rheumatologists
should collaborate closely to minimize the risk of visual
impairment with potentially severe implications for quality
of life in young adults with JIA.
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